# Patent

## Title
Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG CO-A reductase inhibitors

## Abstract

Provided are novel benzothiepines, derivatives, and analogs thereof; pharmaceutical compositions containing them; and methods of using these compounds and compositions in medicine, particularly in the prophylaxis and treatment of hyperlipidemic conditions such as those associated with atherosclerosis or hypercholesterolemia, in mammals. Also provided are compositions and methods for combination therapy employing ileal bile acid transport inhibitors and HMG Co-A reductase inhibitors for the treatment of hyperlipidemic conditions.

## Background
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation application of U.S. Ser. No. 10/076,091, filed Feb. 15, 2002, now U.S. Pat. No. 6,642,268, which is a divisional application of U.S. Ser. No. 09/676,466, filed Sep. 29, 2000, now U.S. Pat. No. 6,420,417, which is a divisional application of U.S. Ser. No. 09/037,308, filed Mar. 9, 1998, now U.S. Pat. No. 6,268,392, which claims the benefit of priority of U.S. provisional application Ser. No. 60/040,660, filed Mar. 11, 1997, U.S. Ser. No. 09/037,308 is also a continuation-in-part application of U.S. Ser. No. 08/831,284, filed Mar. 31, 1997, now abandoned, which is a continuation application of U.S. Ser. No. 08/517,051, filed Aug. 21, 1995, now abandoned, which is a continuation-in-part application of U.S. Ser. No. 08/305 526, filed Sep. 13, 1994, now abandoned, U.S. Ser. No. 09/037,308 filed Mar. 9, 1998 is a continuation-in-part application of U.S. Ser. No. 08/816,065, filed Mar. 11, 1997, now abandoned which claims priority from U.S. provisional application Ser. No. 60/013,119, filed Mar. 11, 1996.


BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to novel benzothieoines, derivatives and analogs thereof, in combination with HMG Co-A reductase inhibitors, pharmaceutical compositions containing them, and use of these compositions in medicine, particularly in the prophylaxis and treatmenet of hyperlipidemic conditions such as is associated with atherosclerosis or hypercholesterolemia, in mammals.
2. Description of Related Art
It is well-settled that hyperlipidemic conditions associated with elevated concentrations of total cholesterol and low-density lipoprotein cholesterol are major risk factors for coronary heart disease and particularly atherosclerosis. Interfering with the circulation of bile acids within the lumen of the intestinal tract is found to reduce the levels of serum cholesterol in a causal relationship. Epidemiological data has accumulated which indicates such reduction leads to an improvement in the disease state of atherosclerosis. Stedronsky, in “Interaction of bile acids and cholesterol with nonsystemic agents having hypocholesterolemic properties,” Biochimica et Biophysica Acta, 1210 (1994) 255-287 discusses the biochemistry, physiology and known active agents surrounding bile acids and cholesterol.
Pathophysiologic alterations are shown to be consistent with interruption of the enterohepatic circulation of bile acids in humans by Heubi, J. E., et al. See “Primary Bile Acid Malabsorption: Defective in Vitro Ileal Active Bile Acid Transport”, Gastroenterology, 1982:83:804-11.
In fact, cholestyramine binds the bile acids in the intestinal tract, thereby interfering with their normal enterohepatic circulation (Reihnér, E. et al, in “Regulation of hepatic cholesterol metabolism in humans: stimulatory effects of cholestyramine on HMG-CoA reductase activity and low density lipoprotein receptor expression in gallstone patients”, Journal of Lipid Research, Volume 31, 1990, 2219-2226 and Suckling el al, “Cholesterol Lowering and bile acid excretion in the hamster with cholestyramine treatment”, Atherosclerosis, 89(1991) 183-190). This results in an increase in liver bile acid synthesis by the liver using cholesterol as well as an upregulation of the liver LDL receptors which enhances clearance of cholesterol and decreases serum LDL cholesterol levels.
In another approach to the reduction of recirculation of bile acids, the ileal bile acid transport system is a putative pharmaceutical target for the treatment of hypercholesterolemia based on an interruption of the enterohepatic circulation with specific transport inhibitors (Kramer, et al, “Intestinal Bile Acid Absorption” The Journal of Biological Chemistry, Vol. 268, No. 24, Issue of August 25, pp. 18035-18046, 1993).
In a series of patent applications, eg Canadian Patent Application. Nos. 2,025,294; 2,078,588; 2,085,782; and 2,085,830; and EP Application Nos. 0 379 161; 0 549 967; 0 559 064; and 0 563 731, Hoechst Aktiengesellschaft disclosespolymers of various naturally occurring constituents of the enterohepatic circulation system and their derivatives, including bile acid, which inhibit the physiological bile acid transtport with the goal of reducing the LDL cholesterol level sufficiently to be effective as pharmaceuticals and, in particular for use as hypocholesterolemic agents.
In vitro bile acid transportinhibition is disclosed to show hypolipidemic activity in The Wellcome Foundation Limited disclosure of the world patent application number WO 93/16055 for “Hypolipidemic Benzothiazepine Compounds”
Selected benzothiepines are disclosed in world patent application number WO93/321146 for numerous uses including fatty acid metabolism and coronary vascular diseases.
Other selected benzothiepines are known for use as hypolipaemic and hypocholesterolaemic agents, especially for the treatment or prevention of atherosclerosis as disclosed by application Nos. EP 508425, FR 2661676, and WO 92/18462, each of which is limited by an amide bonded to the carbon adjacent the phenyl ring of the fused bicyclo benzothiepine ring.
The above references show continuing efforts to find safe, effective agents for the prophylaxis and treatment of hyperlipidemic diseases and their usefulness as hypocholesterolemic agents.
Additionally selected benzothiepines are disclosed for use in various disease states not within the present invention utility. These are EP 568 898A as abstracted by Derwent Abstract No. 93-351589; WO 89/1477/A as abstracted in Derwent Abstract No. 89-370688; U.S. Pat. No. 3,520,891 abstracted in Derwent 5070R-B; U.S. Pat. No. 3,287,370, U.S. Pat. No. 3,389,144; U.S. Pat. No. 3,694,446 abstracted in Derwent Abstr. No. 65860T-3B and WO 92/18462.
HMG Co-A reductase inhibitors have been used as cholesterol-lowering agents. This class of compounds inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG Co-A) reductase. This enzyme catalyzes the conversion of HMG Co-A to mevalonate, which is an early and rate-limiting step in the biosynthesis of cholesterol.
Benzothiazepine anti-hyperlipidemic agents are disclosed in WO 94/18183, WO 94/18184, WO 96/05188, WO 96/16051, AU-A-30209/92, AU-A-61946/94, AU-A-61948/94, and AU-A-61949/94.
The present invention furthers such efforts by providing novel pharmaceutical compositions and methods for the treatment of hyperlipidemic conditions.
SUMMARY OF THE INVENTION
Accordingly, among its various apects, the present invention provides compounds of formula (I): 




wherein:

q is an integer from 1 to 4;
n is an integer from 0 to 2;
R1 and R2 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, haloalkyl, alkylaryl, arylalkyl, alkoxy, alkoxyalkyl, dialkylamino, alkylthio, (polyalkyl)aryl, and cycloalkyl,
wherein alkyl, alkenyl, alkynyl, haloalkyl, alkylaryl, arylalkyl, alkoxy, alkoxyalkyl, dialkylamino, alkylthio, (polyalkyl)aryl, and cycloalkyl optionally are substituted with one or more substituents selected from the group consisting of OR9, NR9R10, N+R9R10RWA−, SR9, S+R9R10A−, P+R9R10R11A−, S(O)R9, SO2R9, SO3R9, CO2R9, CN, halogen, oxo, and CONR9R10,
wherein alkyl, alkenyl, alkynyl, alkylaryl, alkoxy, alkoxyalkyl, (polyalkyl)aryl, and cycloalkyl optionally have one or more carbons replaced by O, NR9, N+R9R10A−, S, SO, SO2, S+R9A−, P+R9R10A−, or phenylene,
wherein R9, R10, and RW are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, acyl, heterocycle, heteroaryl, ammoniumalkyl, alkylammoniumalkyl, and arylalkyl; or
R1 and R2 taken together with the carbon to which they are attached forn C3-C10 cycloalkylidene;
R3 and R4 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, acyloxy, aryl, heterocycle, heteroaryl, OR9, NR9R10, SR9, S(O)R9, SO2R9, and SO3R9, wherein R9 and R10 are as defined above; or
R3 and R4 together form ═O, ═NOR11, ═S, ═NNR11R12, ═NR9, or ═CR11R12,
wherein R11 and R12 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, arylalkyl, alkenylalkyl, alkynylalkyl, heterocycle, hetreoaryl, carboxyalkyl, carboalkoxyalkyl, cycloalkyl, cyanoalkyl, OR9, NR9R10, SR9, S(O)R9, SO2R9, SO3R9, CO2R9, CN, halogen, oxo, and CONR9R10, wherein R9 and R10 are as defined above, provided that both R3 and R4 cannot be OH, NH2 and SH, or
R11 and R12 together with the nitrogen or carbon atom to which they are attached form a cyclic ring;
R5 and R6 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycle, heteroaryl quaternay heterocycle, quaternary heteroaryl, SR9, S(O)R9, SO2R9, and SO3R9,
wherein alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycle, heteroaryl, quaternary heterocycle, and quaternary heteroaryl can be substituted with one or more substituent groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle, heteroary: arylalkyl, quaternary heterocycle, quaternary heteroaryl, halogen, oxo, OR13, NR13R14, SR13, S(O)R13, SO2R13, SO3R13, NR13OR14, NR13NR14R15, NO2, CO2R13, CN, OM, SO2OM, SO2NR13R14, C(O)NR13R14, C(O)OM, COR13, P(O)R13R14, P+R13R14R15A−, P(OR13)OR14, S+R13R14A−, and N+R9R11R12A−,
wherein:
A− is a pharmaceutically acceptable anion and M is a pharmaceutically acceptable cation,
said alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, hetercycle add heteroar can be further substituted with one or more substituent groups selected from the group consisting of OR7, NR7R8, SR7, S(O)R7, SO2R7, SO3R7, CO2R7, CN, oxo, CONR7R8, N+R7R8R9A−, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycle, heteroaryl, arylalkyl, quaternary heterocycle, quaternary heteroaryl, P(O)R7R8, P+R7R8R9A−, and P(O)(OR7)OR8, and
wherein said alkyl, alkenyl, alkvnyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, hetercycle and heteroaryl can optionally have one or more carbons replaced by O, NR7, N+R7R8A−, S, SO, SO2, S+R7A−, PR7, P(O)R7, P+R7R8A−, or phenylene, and R13, R14, and R15 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, polyalkyl, aryl, arylalkyl, cycloalkyl, heterocycle, heteroaryl quaternary heterocycle, quaternary heteroaryl, and quaternary heteroarylalkyl,
wherein alkyl, alkenyl, alkynyl, arylalkyl, heterocycle, heteroaryl, and polyalkyl optionally have one or more carbons replaced by O, NR9, N+R9R10A−, S, SO, SO2, S+R9A−, PR9, P+R9R10A−, P(O)R9, phenylene, carbohydrate, amino acid, peptide, or polypemtide, and
R13, R14, and R15 are optionally substituted with one or more groups selected from the group consisting of sulfoalkyl, heterocycle, heteroaryl, quaternary heterocycle, quaternary heteroaryl, OR9, NR9R10, N+R9R11R12A−, SR9, S(O)R9, SO2R9, SO3R9, oxo, CO2R9, CN, halogen, CON9R10, SO2OM, SO2NR9R10, PO(OR16OR17, P+R9R10R11A−, S+R9R10A−, and C(O)OM,
wherein R16 and R17 are indepedently selected from the substituents constituting R9 and M; or
R14 and R15, together with the nitrogen atom to which they are attached, form a cyclic ring;
R7 and R8 are independently selected from the group consisting of hydrogen and alkyl; and
one or more RX are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, polyalkyl, acyloxy, aryl, arylalkyl, halogen, haloalkyl, cycloalkyl, heterocycle, heteroaryl, polyether, quaternary heterocycle, quaternary heteroaryl, OR13, NR13R14, SR13, S(O)R13, S(O)2R13, SO3R13, S+R13R14A−, NR13OR14, NR13NR14R15, NO2, CO2R13, CN, OM, SO2OM, SO2NR13R14, NR14C(O)R13, C(O)NR13R14, NR14C(O)R13, C(O)OM, COR13, OR18, S(O)nNR18, N13R18, NR18OR14, N+R9R11R12A−, P+R9R11R12A−, amino acid, peptide, polypeptide, and carbohydrate,
wherein alkyl, alkenyl, alkynyl, cycloalkyl, aryl, polyalkyl, heterocycle, heteroaryl, acyloxy, arylalkyl, haloalkyl, polyether, quaternary heterocycle, and quaternary heteroaryl can be further substituted with OR9, NR9R10, N+R9R11R12A−, SR9, S(O)R9, SO2R9, SO3R9, oxo, CO2R9, CN, halogen, CONR9R10, SO2OM, SO2NR9R10, PO(OR14)OR17, P+R9R11R12A−, S+R9R10A−, or C(O)OM, and
wherein R18 is selected from the group consisting of acyl, arylalkoxycarbonyl, arylalkyl, heterocycle, heteroaryl, alkyl, quaternary heterocycle, and quaternary heteroaryl
wherein acyl, arylalkoxycarbonyl, arylalkyl, heterocycle, heteroaryl, alkyl, quaterray heterocycle, and quaternary heteroaryl optionally are substituted with one or more substituents selected from the group consisting of OR9, NR9R10, N+R9R11R12A−, SR9, S(O)R9, SO2R9, SO3R9, oxo, CO2R9, CN, halogen, CONR9R10, SO3R9, SO2OM, SO2NR9R10, PO(OR16)OR17, and C(O)OM,
wherein in RX, one or more carbons are optionally replaced by O, NR13, N+R13R14A−, S, SO, SO2, S+R13A−, PR13, P(O)R13 P+R13R14A−, phenylene, amino acid, peptide, polypeptide, carbohydrate, polyether, or polyalkyl,
wherein in said polyalkyl, phenylene, amino acid, peptide, polypeptide, and carbohydrate, one or more carbons are optionally replaced by O, NR9, N+R9R10A−, S, SO, SO2, S+R9A−, PR9, P+R9R10A−, or P(O)R9;
wherein quaternary heterocycle and quaternary heteroaryl are optionally substituted with one or more groups selected from the group consisting of alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle, heteroaryl arylalkyl, halogen, oxo, OR13, NR13R14, SR13, S(O)R13, SO2R13, SO3R13, NR13OR14, NR13NR14R15, NO2, CO2R13, C, CM, SO2OM, SO2NR13R14, C(O)NR13R14, C(O)OM, COR13, P(C)R13R14, P+R13R14R15A−, P(OR13)OR14, S+R13R14A−, and N+R9R11R12A−,
provided that both R5 and R6 cannot be hydrogen, OH, or SH, and when R5 is OH, R1, R2, R3, R4, R7 and R8 cannot be all hydrogen;
provided that when R5 or R6is phenyl, only one of R1 or R2 is H;
provided that when q=1 and Rx is styryl, anilido, or anilinocarbonyl, only one of R5 or R6 is alkyl; or
a pharmaceutically acceptable salt, solvate, or prodrug thereof.
Preferably, R5 and R6 can independently be selected from the group consisting of H, aryl, heterocycle, heteroaryl, quaternay heterocycle, and quaternary heteroaryl,
wherein said aryl, heterocycle, heteroaryl, quaternary heterocycle, and quaternary heteroaryl can be substituted with one or more substituent groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle, heteroaryl, arylalkyl, halogen, oxo, OR13, NR13R14, SR13,S (O)R13, SO2R13, SO3R13, NR13OR14, N13NR14R15, NO2, CO2R13, CN, OM, SO2OM, SO2NR13R14, C(O)NR13R14, C(O)OM, COR13, P(O)R13R14, P+R13R14R15A−, P(OR13)OR14, S+R13R14A−, and N+R9R11R12A−,
wherein said alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, hetercycle and heteroaryl can optionally have ore or more carbons replaced by O, NR7, N+R7R8A−, S, SO, SO2, S+R7A−, PR7, P(O)R7 P+R7R8A−, or phenylene,
wherein said alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle and heteroaryl can be further substituted with one or more substituent groups selected from the group consisting of OR7, NR7R8, SR7, S(O)R7, SO2R7, SO3R7, CO2R7, CN, oxo, CONR7R8, N+R7R8R9A−, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycle, heteroaryl, arylalkyl, quaternary heteroaryl, quaternary heteroaryl, P(O)R7R8, P+R7R8R9A−, and P(O)(OR7)OR8.
More preferably, R5 or R4 has the formula:

—Ar—(Ry)c

wherein:
t is an integer from 0 to 5;
Ar is selected from the group consisting of phenyl, thiophenyl, pyridyl, piperazinyl, piperonryl, pyrrolyl, naphthyl, furanyl, anthracenyl, quinolinyl, isoquinolinyl, quinoxalinyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, pyrimidinyl, thiazolyl, triazolyl, isothiazolyl, indolyl, benzoimidazolyl, benzoxazolyl, benzothiazolyl, and benzoisothiazolyl; and
one or more Ry are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycle, heteroaryl, quaternary heterocycle, quaternary heteroaryl OR9, SR9, S(O)R9, SO2R9, and SO3R9,
wherein alkyl, alkenyl, alkynyl, azyl, cycloalkvl, heterocycle, and heteroaryl can be substituted with one or more substituent groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle, heteroaryl, arylalkyl, halogen, oxo, OR13, NR13R14, SR13, S(O)R13, SO2R13, SO3R13, NR13OR14, NR13NR14R15, NO2, CO2R13, CN, OM, SO2OM, SO2NR13R14, C(O)NR13R14, C(O)OM, COR13, P(O)R13R14, P+R13R14R15A−, P(OR13)OR14, S−R3R14A−, and N+R9R11R12A−,
wherein said alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle, and heteroaryl can be further substituted with one or more substituent groups selected from the group consisting of OR7, NR7R8, SR7, S(O)R7, SO2R7, SO3R7, CO2R7, CN, oxo, CONR7R8, N+R7R8R9A−, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycle, heterparyl, arylalkyl, quaternery heterocycle, quaternary heteroaryl, P(O)R7R8, P+R7R8R9A−, and P(O) (OR7)OR8, and
wherein said alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heteroycle, and heteroar can optionally have one or more carbons replaced by O, NR7, N+R7R8A−, S, SO, SO2, S+R7A−, P(O)R7, P+R7R8A−, or phenylene.
Most preferably, R5 or R6 has the formula (II): 




The invention is further directed to a compound selected from among:

R10—R19—R21  (Formula DI)





wherein R19 is selected from the group consisting of alkane diyl, alkene diyl, alkyne diyl, polyalkane diyl, alkoxy diyl, polyether diyl, polyalkoxy diyl, carbohydrate, amino acid, peptide, and polypeptide, wherein alkane diyl, alkene diyl, alkyne diyl, polyalkane diyl, alkoxy diyl, polyether diyl, polyalkoxy diyl, carbohydrate, amino acid, peptide, and polypeptide can optionally have one or more carbon atoms replaced by O, NR7, N+R7R8, S, SO, SO2, S+R7R8, PR7, P+P7R8, phenylene, heterocycle, heteroaryl, quaternary heterocycle, quaternary heteroaryl, or aryl,
wherein alkane diyl, alkene diyl, alkyne diyl, polyalkane diyl, alkoxy diyl, polyether diyl, polyalkoxy diyl, carbohydrate, amino acid, peptide, and polypeptide can be substituted with one or more substituent groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle, heteroaryl, arylalkyl, halogen, oxo, OR13, NR13R14, SR13, S(O)R13, SO2R13, SO3R13, NR13OR14, NR13NR14R15, NO2, CO2R13, CN, OM, SO2OM, SO2NR13R14, C(O)NR13R14, C(O)OCM, COR13, P(O)R13R14, P+R13R14R15A−, P(OR13)OR14, S+R13R14A−, and N+R9R11R12A−;
wherein R19 further conprises functional linkages by which R19 is bonded to R20, R21, or R22 in the ccmpounds of Formulae DII and DIII, and R13 in the compounds of Formula DIII. Each of R20, R21, or R22 and R23 comprises a benzothiepine moiety as described above that is therapeutically effective in inhibiting ileal bile acid transport.
The invention is also directed to a compound selected from amng Formula DI, Formula DII and Formula DIII in which each of R20, R21, R22 and R23 comprises a benzothiepine moiety corresponding to the Formula: 




wherein R1, R2, R3, R4, R5, R6, R7, R8, Rx, q, and n are as defined in Formula I as described above, and R55 is either a covalent bond or arylene.

In compounds of Fromula DIV, it is particularly peferred that each of R20, R21, and R22 in Formulae DII and DIII, and R23 in Formula DIII, be bonded at its 7- or 8-position to R19. In compounds of Formula DIVA, it is particularly preferred that R25 comprise a phenylene moiety bonded at a m- or p-carbon thereof to R19.
Examples of Formula DI include: 




In any of the dimeric or multimeric structures discussed immediately above, benzothiepoine compounds of the present invention can be used alone or in various combinations.
In any of the compounds of the present invention, R1 and R2 can be ethyl/butyl or butyl/butyl.
Other compounds useful in the present invention as ileal bile acid transport inhibitors are shown in Appendix A.
In another aspect, the present invention provides a pharmaceutical composition for the prophylaxis or treatment of a disease or condition for which a bile acid transport inhibitor is indicated, such as a hyperlipidemic condition, for example, atherosclerosis. Such compositions comprise any of the compounds disclosed above, alone or in combination, in an amount effective to reduce bile acid levels in the blood, or to reduce transport thereof across digestive system membranes, and a pharmaceutically acceptable carrier, excipient, or diluent.
In a further aspect, the present invention also provides a method of treating a disease or condition in mammlials, including hum,ans, for which a bile acid transport inhibitor is indicated, comprising acministering to a patient in need thereof a compound ot the present invention in an effective amount in unit dosage form or in divided doses.
In yet a further aspect, the present invention also provides processes for the preparation of compounds of the present invention.
In yet another aspect, the present invention proviaes a combination therapy comprising the use of a first amount of an ileal bile acid transport inhibitor and a second amount of a HMG Co-A reductase inhibitor useful to treat hyperlipidemic disorders, wherein said first and second amounts together comprise an anti-hyperlipidemic condition effective amount of said compounds.
HMG Co-A reductase inhibitor compounds useful in the present invention are shown in Appendix B.
Further scope of the applicability of the present invention will become apparent from the detailed description provided below. However, it should be understood that the following detailed description and examples, while indicating preferred embodiments of the invention, are given by way of illustration only since various changes and modifications within the spirit and scope of the invention will beomce apparent to those skilled in the art from this detailed description.


DETAILED DESCRIPTION OF THE INVENTION
The following detailed description is provided to aid those skilled in the art in practicing the present invention. Even so, this detailed description should not be construed to unduly limit the present invention as modifications and variations in the emobodiments discussed herein can be made by those of ordinary skill in the art without departing from the spirit or scope of the present inventive discovery.
The contents of each of the references cited herein, including the contents of the references cited within these primary references, are herein incorporated by reference in their entirety.
Definitions
In order to aid the reader in understanding the following detailed description, the following definitions are provided:
“Alkyl”, “alkenyl,” and “alkynyl” unless otherwise noted are each straight chain or branched chain hydrocarbons of from one to twenty carbons for alkyl or two to twenty carbons for alkenyl and alkynyl in the present invention and therefore mean, for example, methyl, ethyl, propyl, butyl, pentyl or hexyl and ethenyl, propenyl, butenyl, pentenyl, or hexenyl and ethynyl, propynyl, butynyl, pentynyl, or hexynyl respectively and isomers thereof.
“Arly” means a fully unsaturated mono- or multi-ring carbocyle, including, but not limited to, substituted or unsubstituted phenyl, naphthyl, or anthracenyl.
“Heterocycle” means a saturated or unsaturated mono- or multi-ring carbocycle wherein one or more carbon atoms can be replaced by N, S, P, or O. This includes, for example, the following structures: 




wherein Z, Z′, Z′′ or Z′′′ is C, S, P, O, or N, with the proviso that one of Z, Z′, Z′′, or Z′′′ is other than carbon, but is not O or S when attached to another Z atom by a double bond or when attached to another O or S atom. Furthermore, the optional substituents are understood to be attached to Z, Z′, Z′′ or Z′′′ only when each is C.

The term “heteroaryl” means a fully unsaturated heterocycle.
In either “heterocycle” or “heteroaryl,” the point of attachment to the molecule of interest can be at the heteroatom or elsewhere within the ring.
The term “quaternary heterocycle” means a heterocycle in which one or more of the heteroatoms, for example, O, N, S, or P, has such a number of bonds that it is positively charged. The point of attachment of the quaternary heterocycle to the molecule of interest can be at a heteroatom or elsewhere.
The term “quaternary heteroaryl,” means a heteroaryl in which one or more of the heteroatoms, for example, O, N, S, or P, has such a number of bonds that it is positively charged. The point of attachment of the quaternary heteryaryl to the molecule of interest can be at a heteroatom or elsewhere.
The term “halogen” means a fluoro, chloro, bromo or iodo group.
The term “haloalkyl” means alkyl substitiuted with one or more halogens.
The term “cycloalkyl” means a mono- or multi-ringed carbocycle wherein each ring contains three to ten carbon atoms, and wherein any ring can contain one or more double or triple bonds.
The term “diyl” means a diracdical moiety wherein said moiety has two points of attachment to molecules of interest.
The term “oxo” means a doubly bonded oxygen.
The term “polyalkyl” means a branched or staight hydrocarbon chain having a molecular weight up to about 20,000, more preferably up to about 10,000, most preferably up to about 5,000.
The term “polyether” means a polyalkyl wherein one or more carbons are reolaced by oxygen, wherein the polyether has a molecular weight up to about 20,000, more preferably up to about 10,000, most preferably up to about 5,000.
The term “polyalkoxy” means a polymer of alkylene oxides, wherein the polyalkoxy has a molecular weight up to about 20,000, more preferably up to about 10,000, most preferably up to about 5,000.
The term “cycloaklylidene” means a mono- or multi-ringed carbocycle wherein a carbon within the ring structure is doubly bonded to an atom which is not within the ring structures.
The term “carbohydrate” means a mono-, di-, tri-, or polysaccharide wherein the polysaccharide can have a molecular weight of up to about 20,000, for example, hydroxypropyl-methylcellulose or chitosan.
The term “peptide” means polyamino acid containing up to about 100 amino acid units.
The term “polypeptide” means polyamino acid containing from about 100 amino acid units to about 1000 amino acid units, more preferably from about 100 amino acid units to about 750 amino acid units, most preferably from about 100 amino acid units to about 500 amino acid units.
The term “alkylammoniumalkyl” means a NH2 group or a mono-, di- or tri-substituted amino group, any of which is bonded to an alkyl wherein said alkyl is bonded to the molecule of interest.
The term “triazolyl” includes all positional isomers. In all other heterocycles and heteroaryls which contain more than one ring heteroatom and for which isomers are possible, such isomers are included in the definition of said heterocycles and heteroaryls.
The term “sulfoalkyl” means an alkyl group to which a sulfonate group is bonded, wherein said alkyl is bonded to the molecule of interest.
The term “active compound” means a compound of the present invention which inhibits transport of bile acids.
When used in combination, for examle “alkylaryl” or “arylalkyl,” the individual terms listed above have the meaning indicated above.
The term “a bile acid transport inhibitor” means a compound capable of inhibiting absorption of bile acids from the intestine into the circulatory system of a mammal, such as a human. This includes increasing the fecal excretion of bile acids, as well as reducing the blood plasma or serum concentrations of cholesterol and cholesterol ester, and more specifically, reducing LDL and VLDL cholesterol. Conditions or diseases which benefit from the prophylaxis or treatment by bile acid transport inhibition include, for example, a hyperlipidemic condition such as atherosclerosis.
The phrase “combination therapy” refers to the administration of an ileal bile acid transport inhibitor and a HMG Co-A reductase inhibitor to treat a hyperlipidemic condition, for example atherosclerosis and hypercholesterolemia. Such administration encompasses co-administration of these inhibitors is a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients or in multiple, separate capsules for each inhibitor agent. In addition, such administration also encompasses use of each type of inhibitor in a sequential manner. In either case, the treatment regimen will provide beneficial effects of the drug combination in treating the hyperlipidemic condition.
The phrase “theraputically effective” is intended to qualify the combined amount of inhibitors in the combination therapy. This combined amount will achieve the goal of reducing or eliminating the hyperlipidemic condition.
Compounds
The compounds of the present invention can have at least two asymmetrical carbon atoms, and therefore include racemates and stereoisomers, such as diastereomers and enantiomers, in both pure form and in admixture. Such stereoisomers can be prepared using conventional techniques, either by reacting enantiomeric starting materials, or by separating isomers of compounds of the present invention.
Isomers may include geometric isomers, for example cis isomers or trans isomers across a double bond. All such isomers are contemplated among the compounds of the present invention.
The compounds of the present invention also include tautomers.
The compounds of the present invention as discussed below include their salts, solvates and prodrugs.
Compound Syntheses
The starting materials for use in the premaration the compounds of the invention are known or can be prepared by conventional methods known to a skilled person or in an analogous marlner to processes descried in the art.
Generally, the compounds of the present invention can be prepared by the procedures described below.
For example, as shown in Scheme I, reaction of aldehyde II with formaldehyde and sodium hydroxide yields the hydroxyaldehyde III which is converted to mesylate IV with methanesulfonyl chloride and triethylaine similar to the procedure described in Chem. Ber. 98, 728-734 (1965). Reaction of mesylate IV with thiophenol V, prepared by the procedure described in WO 93/16055, in the presence of triethylamine yields keto-aldehyde VI which can be cyclized with the reagent, prepared from zinc and titanium trichloride in refluxing ethylene glycol dimethyl ether (DME), to give a mixture of 2,3-dihydrobenzothiepine VII and two racemic steroisomers of benzothiepin-(5H)-4-one VIII when R1 and R2 are nonequivalent. Oxidation of VII with 3 equivalents of m-chloro-perbenzoic acid (MCPBA) gives isomeric sulfone-epoxides IX which upon hydrogenation with palladium on carbon as the catalyst yield a mixture of four racemic stereoisomers of 4-hydroxy-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxides X and two racemic stereoisomers of 2,3,4,5-tetrahydrobenzothiepine-1,1-dioxides XI when R1 and R2 are nonequivalent.
Optically active compounds of the present invention can be prepared by using optically active starting material III or by resolution of compounds X with optical resolution agents well known in the art as described in J. Org. Chem., 39, 3904 (1974), ibid., 42, 2781 (1977), and ibid., 44, 4891 (1979). 







Alternatively, keto-aldehyde VI where R1 is H can be prepared by reaction of thiophenol V with a 2-substituted acrolein. 




Benzothiepin-(5H)-4-one VIII can be oxidized with MCPBA to give the benzothiepin-(5H)-4-one-1,1-dioxide XII which can be reduced with sodium borohydride to give four racemic stereoisomers of X. The two stereoisomers of X, Xa and Xb, having the OH group and R5 on the opposite sides of the benzothiepine ring can be converted to the other two isomers of X, Xc and Xd, having the OH group and R5 on the sme side of the benzothiepine ring by reaction in methylene chloride with 40-50% sodium hydroxide in the presence of a phase transfrer catalyst (PTC). The transformation can also be carried out with potassium t-butoxide in THF. 







The compounds of the pesent invention where R5 is OR, NRR′ or S(O)aR and R4 is hydroxy can be prepared by reaction of epoxide IX where R5 is H with thiol, alcohol, or amine in the presence of a base. 




Another route to Xc and Xd of the present invention is shown in Scheme 2. Compound VI is oxidized to compound XIII with two equivalent of m-chloroperbezoic acid. Hydrogenolysis of corrpound XIII with palladium on carbon yields compound XIV which can be cyclized with either potassium t-butoxide or sodium hydroxide under phase transfer conditions to a mixture of Xc and Xd. Separation of Xc and Xd can be accomplished by either HPLC or fractional crystallization.

The thiophenols XVIII and V used in the present invention can also be prepared according to the Scheme 3. Alkylation of phenol XV with an arylmethyl chloride in a nonpolar solvent according to the procedure in J. Chem. Soc., 2431-2432 (1958) gives the ortho substituted phenol XVI. The phenol XVI can be converted to the thiophenol XVIII via the thiocarbamate XVII by the procedure described in J. Org. Chem., 31, 3980 (1966). The phenol XVI is first reacted with dimethyl thiocarbamoyl chloride and triethylamine to give thlocarbamate XVII which is thermally rearranged at 200-300° C., and the rearranged product is hydrolyzed with sodium hydroxide to yield the thiophenol XVIII. Similarly, Thiophenol V can also be prepared from 2-acylphenol XIX via the intermediate thiocarbamate XX. 







Scheme 4 shows another route to benzothiepine-1,1-dioxides Xc and Xd starting from the thiopherol XVIII. Compound XVIII can be reacted with mesylate IV to give the sulfide-aldehyde XXI. Oxidation of XXI with two equivalents of MCPBA yields the sulfone-aldehyde XIV which can be cyclized with potassium t-butoxide to a mixture of Xc and Xd. Cyclyzation of sulfide-aldehyde with potassium t-butoxide also gives a mixture of benzothiepine XXIIc and XXIId. 




Exaples of amine- and hydroxylamine-containing compounds of the present invention can be prepared as shown in Scheme 5 and Scheme 6. 2-Chloro-5-nitrobenzophenone is reduced with triethylsilane triethylsilane and trifluoromethane sulfonic acid to 2-chloro-5-nitrodiphenylymethane 32. Reaction of 32 with lithium sulfide followed by reacting the resulting sulfide with mesylate IV gives sulfide-aldehyde XXIII. Oxidation of XXIII with 2 equivalents of MCPBA yields sulfone-aldehyde XXIV which can be reduced by hydrogenation to the hydroxylamine XXV. Protecting the hydroxylamine XXV with di-t-butyldicarbonate gives the N,O-di-(t-butoxycarbonyl)hydroxylamino derivazive XXVI. Cyclization of XXVI with potassium t-butoxide and removal of the t-butoxycarbonyl protecting group gives a mixture of hydroxylamino derivatives XXVIIc and XXVIId. The primary amine XXXIIIc and XXXIIId derivatives can also be prepared by further hydrogenation of XXIV or XXVIIc and XXVIId. 







In Scheme 6, reduction of the sulfone-aldehyde XXV with hydrogen followed by reductive alkylation of the resulting amino derivative with hydrogen and an aldehyde catalyzed by palladium on carbon in the same reaction vessel yields the substituted amine derivative 




XXVIII. Cyclizatior of XXVIII with potassium t-buoxide yields a mixture of substituted amino derivatives of this invention XXIXC and XXIXd.

Scheme 7 describes one of the methods of introducing a substituent to the aryl ring at the 5-position of benzothiepine. Iodinaton of 5-phenyl derivative XXX with iodine catalyzed by mercuric triflate gives the iodo derivative XXXI, which upon palladiun-catalyzed carbonylation in an alcohol yields the carboxylate XXXII. Hydrolysis of the carboxylate 




and derivatization of the resulting acid to acid derivatives are well known in the art.

Abbreviations used in the foregoing description have the following meanings:
THF—tetrahydrofuran
PTC—phase transfer catalyst
Aliquart 336—methyltricaprylylammonium chloride
MCPBA—m-chloroperbenzoic acid
Celite—a brand of diatomaceous earth filtering aid
DMF—dimethylformamide
DME—ethylene glycol dimethyl ether
BOC—t-butoxycarbonyl group
R1 and R2 can be selected from among substituted and unsubstituted C1 to C10 alkyl wherein the substituent(s) can be selected from among alkylcarbonyl, alkoxy, hydroxy, and nitrogen-containing heterocycles joined to the C1 to C10 alkyl through an ether linkage. Substituents at the 3-carbon can include ethyl, n-propyl, n-butyl, n-pentyl, isobutyl, isopropyl, —CH2C(═O)C2H5, —CH2OC2H5, and —CH2O—(4-picoline). Ethyl, n-propyl, n-butyl, and isobutyl are preferred. In certain particularly preferred compounds of the present invention, substituents R1 and R2 are identical, for example n-butyl/n-butyl, so that the compound is achiral at the 3-carbon. Eliminating optical isomerism at the 3-carbon simplifies the selection, synthesis, separation, and quality control of the compound used as an ileal bile acid transport inhibitor. In both compounds having a chiral 3-carbon and those having an achiral 3-carbon, substituents (Rx) on the benzo-ring can include hydrogen, aryl, alkyl, hydroxy, halo, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, haloalkyl, haloalkoxy, (N)-hydroxy-carbonylalkyl amine, haloalkylthio, haloalkylsulfinyl, haloalkylsufonyl, amino, N-alkylamino, N,N-dialkylamino, (N)-alkoxycarbamoyl, (N)-aryloxycarbamoyl, (N)-aralkyloxycarbamoyl, trialkylammonium (especially with a halide counterion), (N)-amido, (N)-alkylamido, —N-alkylamido, —N,N-dialkylamido, (N)-haloalkylamido, (N)-sulfonamido, (N)-alkylsulfonamido, (N)-haloalkylsulfonamido, carboxyalkylamiro, trialkyl-ammonium salt, (N)-carbamic acid, alkyl or benzyl ester, N-acylamine, hydroxylamine, haloacylamine, carbohydrate, thiophene a trialkyl ammonium salt having a carboxylic acid or hydroxy substituent on one or more of the alkyl substituents, an alkylene bridge having a quaternary ammonium salt substituted thereon, —[O(CH2)w]a—X where x is 2 to 12, w is 2 or 3 and X is a halo or a quaternary ammonium salt, and (N)-nitrogen containing heterocycle wherein the nitrogen of said heterocycle is optionally quaternized. Among the preferred species which may constitute Rx are methyl, ethyl, isopropyl, t-butyl; hydroxy, ethoxy, ethoxy, isopropoxy, methylthio, iodo, bromo, fluoro, metylsulfinyl, methylsulfonyl, ethylthio, amino, hydroxylamine, N-methylamino, N,N-dimethylamino, N,N-diethylamino, (N)-benzyloxycarbamoyl, trimethylammonium, A−, —NHC (═O)CH3, —NHC(═O)C5H11, —NHC(═O)C6H13, carboxyethylamino, (N)-morpholinyl, (N)-azetidinyl, (N)-N-methylazetidinium A−, (N)-pyrrolidinyl, pyrrolyl, (N)-N-methylpyridinium A−, (N)-N-methylmorpholimium A−, and N-N′-methylpiperazinyl, (N)-bromomethylamido, (N)-N-hexylamino, thiophene, —N−(CH3)2CO2H I−, —NCH3CH2CO2H, —(N)—N′dimethylpiperazinium I−, (N)-t-butyloxycarbamoyl, (N)-methylsulfonamido, (N)N′-methylpyrrolidinium, and —(OCH2CH2)3I, where A− is a pharmaceutically acceptable anion. The benzo ring can be mono-substituted at the 6, 7 or 8 position, or disubstituted at the 7- and -8 positions. Also included are the 6, 7, 8-trialkyloxy compounds, for example the 6, 7, 8-trimethoxy compounds. A variety of other substituents can be advantageously present on the 6, 7, 8, and/or 9-positions of the benzo ring, including, for example, guanidinyl, cycloalkyl, carbohydrate (e.g., a 5 or 6 carbon monosaccharcide), peptide, and quaternary ammonium salts linked to the ring via poly(oxyalkylene) linkages, e.g., —(OCH2CH2)x—N−R13R14R15A−, where x is 2 to 10. Exemplary compounds are those set forth below in Table 1.







TABLE 1







Alternative compounds #3 (Family F101.xxx.yyy) *









y 











Prefix
Cpd#





(FFF.xxx.
yyy)
R1═R2
R5
(Rx)q














F101.001
01
n-propyl
Ph—
7-methyl



02
n-propyl
Ph—
7-ethyl



03
n-propyl
Ph—
7-iso-propyl



04
n-propyl
Ph—
7-tert-butyl



05
n-propyl
Ph—
7-OH



06
n-propyl
Ph—
7-OCH3



07
n-propyl
Ph—
7-O(iso-propyl)



08
n-propyl
Ph—
7-SCH3



09
n-propyl
Ph—
7-SOCH3



10
n-propyl
Ph—
7-SO2CH3



11
n-propyl
Ph—
7-SCH2CH3



12
n-propyl
Ph—
7-NH2



13
n-propyl
Ph—
7-NHOH



14
n-propyl
Ph—
7-NHCH3



15
n-propyl
Ph—
7-N(CH3)2



16
n-propyl
Ph—
7-N+(CH3)3, I−



17
n-propyl
Ph—
7-NHC(═O)CH3



18
n-propyl
Ph—
7-N(CH2CH3)2



19
n-propyl
Ph—
7-NMeCH2CO2H



20
n-propyl
Ph—
7-N+(Me)2CH2CO2H, I−



21
n-propyl
Ph—
7-(N)-morpholine



22
n-propyl
Ph—
7-(N)-azetidine



23
n-propyl
Ph—
7-(N)-N-methylazetidinium, I−



24
n-propyl
Ph—
7-(N)-pyrrolidine



25
n-propyl
Ph—
7-(N)-N-methyl-pyrrolidinium, I−



26
n-propyl
Ph—
7-(N)-N-methyl-morpholinium, I−



27
n-propyl
Ph—
7-(N)-N′-methylpiperazine



28
n-propyl
Ph—
7-(N)-N′-dimethylpiperazinium, I−



29
n-propyl
Ph—
7-NH-CBZ



30
n-propyl
Ph—
7-NHC(O)C5H11



31
n-propyl
Ph—
7-NHC(O)CH2Br



32
n-propyl
Ph—
7-NH-C(NH)NH2



33
n-propyl
Ph—
7-(2)-thiophene



34
n-propyl
Ph—
8-methyl



35
n-propyl
Ph—
8-ethyl



36
n-propyl
Ph—
8-iso-propyl



37
n-propyl
Ph—
8-tert-butyl



38
n-propyl
Ph—
8-OH



39
n-propyl
Ph—
8-OCH3



40
n-propyl
Ph—
8-O(iso-propyl)



41
n-propyl
Ph—
8-SCH3



42
n-propyl
Ph—
8-SOCH3



43
n-propyl
Ph—
8-SO2CH3



44
n-propyl
Ph—
8-SCH2CH3



45
n-propyl
Ph—
8-NH2



46
n-propyl
Ph—
8-NHOH



47
n-propyl
Ph—
8-NHCH3



48
n-propyl
Ph—
8-N(CH3)2



49
n-propyl
Ph—
8-N+(CH3)3, I−



50
n-propyl
Ph—
8-NHC(═O)CH3



51
n-propyl
Ph—
8-N(CH2CH3)2



52
n-propyl
Ph—
8-NMeCH2CO2H



53
n-propyl
Ph—
8-N+(Me)2CH2CO2H, I−



54
n-propyl
Ph—
8-(N)-morpholine



55
n-propyl
Ph—
8-(N)-azetidine



56
n-propyl
Ph—
8-(N)-N-methylazetidinium, I−



57
n-propyl
Ph—
8-(N)-pyrrolidine



58
n-propyl
Ph—
8-(N)-N-methyl-pyrrolidinium, I−



59
n-propyl
Ph—
8-(N)-N-methyl-morpholinium, I−



60
n-propyl
Ph—
8-(N)-N′-methylpiperazine



61
n-propyl
Ph—
8-(N)-N′-dimethylpiperazinium, I−



62
n-propyl
Ph—
8-NH-CBZ



63
n-propyl
Ph—
8-NHC(O)C5H11



64
n-propyl
Ph—
8-NHC(O)CH2Br



65
n-propyl
Ph—
8-NH-C(NH)NH2



66
n-propyl
Ph—
8-(2)-thiophene



67
n-propyl
Ph—
9-methyl



68
n-propyl
Ph—
9-ethyl



69
n-propyl
Ph—
9-iso-propyl



70
n-propyl
Ph—
9-tert-butyl



71
n-propyl
Ph—
9-OH



72
n-propyl
Ph—
9-OCH3



73
n-propyl
Ph—
9-O(iso-propyl)



74
n-propyl
Ph—
9-SCH3



75
n-propyl
Ph—
9-SOCH3



76
n-propyl
Ph—
9-SO2CH3



77
n-propyl
Ph—
9-SCH2CH3



78
n-propyl
Ph—
9-NH2



79
n-propyl
Ph—
9-NHOH



80
n-propyl
Ph—
9-NHCH3



81
n-propyl
Ph—
9-N(CH3)2



82
n-propyl
Ph—
9-N+(CH3)3, I−



83
n-propyl
Ph—
9-NHC(═O)CH3



84
n-propyl
Ph—
9-N(CH2CH3)2



85
n-propyl
Ph—
9-NMeCH2CO2H



86
n-propyl
Ph—
9-N+(Me)2CH2CO2H, I−



87
n-propyl
Ph—
9-(N)-morpholine



88
n-propyl
Ph—
9-(N)-azetidine



89
n-propyl
Ph—
9-(N)-N-methylazetidinium, I−



90
n-propyl
Ph—
9-(N)-pyrrolidine



91
n-propyl
Ph—
9-(N)-N-methyl-pyrrolidinium, I−



92
n-propyl
Ph—
9-(N)-N-methyl-morpholinium, I−



93
n-propyl
Ph—
9-(N)-N′-methylpiperazine



94
n-propyl
Ph—
9-(N)-N′-dimethylpiperazinium, I−



95
n-propyl
Ph—
9-NH-CBZ



96
n-propyl
Ph—
9-NHC(O)C5H11



97
n-propyl
Ph—
9-NHC(O)CH2Br



98
n-propyl
Ph—
9-NH-C(NH)NH2



99
n-propyl
Ph—
9-(2)-thiophene



100
n-propyl
Ph—
7-OCH3, 8-OCH3



101
n-propyl
Ph—
7-SCH3, 8-OCH3



102
n-propyl
Ph—
7-SCH3, 8-SCH3



103
n-propyl
Ph—
6-OCH3, 7-OCH3, 8-OCH3





* General Notes 


In the description of the substituents “(N)” indicates that a nitrogen bearing substituent is bonded to the ring structure via the nitrogen atom. 


Similarly, 2-thiophene indicates a bond in the 2 position of the thiophene ring. A similar convention is used for other heterocyclic substituents. 


Abbreviations and Definitions 


NH-CBZ is defined as —HNC(═O)OCH2Ph 




















Prefix
Cpd#





(FFF.xxx.
yyy)
R1═R2
R5
(Rx)q



















F101.002
01
n-butyl
Ph—
7-methyl



02
n-butyl
Ph—
7-ethyl



03
n-butyl
Ph—
7-iso-propyl



04
n-butyl
Ph—
7-tert-butyl



05
n-butyl
Ph—
7-OH



06
n-butyl
Ph—
7-OCH3



07
n-butyl
Ph—
7-O(iso-propyl)



08
n-butyl
Ph—
7-SCH3



09
n-butyl
Ph—
7-SOCH3



10
n-butyl
Ph—
7-SO2CH3



11
n-butyl
Ph—
7-SCH2CH3



12
n-butyl
Ph—
7-NH2



13
n-butyl
Ph—
7-NHOH



14
n-butyl
Ph—
7-NHCH3



15
n-butyl
Ph—
7-N(CH3)2



16
n-butyl
Ph—
7-N+(CH3)3, I−



17
n-butyl
Ph—
7-NHC(═O)CH3



18
n-butyl
Ph—
7-N(CH2CH3)2



19
n-butyl
Ph—
7-NMeCH2CO2H



20
n-butyl
Ph—
7-N−(Me)2CH2CO2H, I−



21
n-butyl
Ph—
7-(N)-morpholine



22
n-butyl
Ph—
7-(N)-azetidine



23
n-butyl
Ph—
7-(N)-N-methylazetidinium, I−



24
n-butyl
Ph—
7-(N)-pyrrolidine



25
n-butyl
Ph—
7-(N)-N-methyl-pyrrolidinium, I−



26
n-butyl
Ph—
7-(N)-N-methyl-morpholinium, I−



27
n-butyl
Ph—
7-(N)-N′-methylpiperazine



28
n-butyl
Ph—
7-(N)-N′-dimethylpiperazinium, I−



29
n-butyl
Ph—
7-NH-CBZ



30
n-butyl
Ph—
7-NHC(O)C5H11



31
n-butyl
Ph—
7-NHC(O)CH2Br



32
n-butyl
Ph—
7-NH—C(NH)NH2



33
n-butyl
Ph—
7-(2)-thiophene



34
n-butyl
Ph—
8-methyl



35
n-butyl
Ph—
8-ethyl



36
n-butyl
Ph—
8-iso-propyl



37
n-butyl
Ph—
8-tert-butyl



38
n-butyl
Ph—
8-OH



39
n-butyl
Ph—
8-OCH3



40
n-butyl
Ph—
8-O(iso-propyl)



41
n-butyl
Ph—
8-SCH3



42
n-butyl
Ph—
8-SOCH3



43
n-butyl
Ph—
8-SO2CH3



44
n-butyl
Ph—
8-SCH2CH3



45
n-butyl
Ph—
8-NH2



46
n-butyl
Ph—
8-NHCH



47
n-butyl
Ph—
8-NHCH3



48
n-butyl
Ph—
8-N(CH3)2



49
n-butyl
Ph—
8-N+(CH3)3, I−



50
n-butyl
Ph—
8-NHC(═O)CH3



51
n-butyl
Ph—
8-N(CH2CH3)2



52
n-butyl
Ph—
8-NMeCH2CO2H



53
n-butyl
Ph—
8-N−(Me)2CH2CO2H, I−



54
n-butyl
Ph—
8-(N)-morpholine



55
n-butyl
Ph—
8-(N)-azetidine



56
n-butyl
Ph—
8-(N)-N-methylazetidinium, I−



57
n-butyl
Ph—
8-(N)-pyrrolidine



58
n-butyl
Ph—
8-(N)-N-methyl-pyrrolidinium, I−



59
n-butyl
Ph—
8-(N)-N-methyl-morpholinium, I−



60
n-butyl
Ph—
8-(N)-N′-methylpiperazine



61
n-butyl
Ph—
8-(N)-N′-dimethylpiperazinium, I−



62
n-butyl
Ph—
8-NH-CBZ



63
n-butyl
Ph—
8-NHC(O)C5H11



64
n-butyl
Ph—
8-NHC(O)CH2Br



65
n-butyl
Ph—
8-NH—C(NH)NH2



66
n-butyl
Ph—
8-(2)-thiophene



67
n-butyl
Ph—
9-methyl



68
n-butyl
Ph—
9-ethyl



69
n-butyl
Ph—
9-iso-propyl



70
n-butyl
Ph—
9-tert-butyl



71
n-butyl
Ph—
9-OH



72
n-butyl
Ph—
9-OCH3



73
n-butyl
Ph—
9-O(iso-propyl)



74
n-butyl
Ph—
9-SCH3



75
n-butyl
Ph—
9-SOCH3



76
n-butyl
Ph—
9-SO2CH3



77
n-butyl
Ph—
9-SCH2CH3



78
n-butyl
Ph—
9-NH2



79
n-butyl
Ph—
9-NHOH



80
n-butyl
Ph—
9-NHCH3



81
n-butyl
Ph—
9-N(CH3)2



82
n-butyl
Ph—
9-N+(CH3)3, I−



83
n-butyl
Ph—
9-NHC(═O)CH3



84
n-butyl
Ph—
9-N(CH2CH3)2



85
n-butyl
Ph—
9-NMeCH2CO2H



86
n-butyl
Ph—
9-N+(Me)2CH2CO2H, I−



87
n-butyl
Ph—
9-(N)-morpholine



88
n-butyl
Ph—
9-(N)-azetidine



89
n-butyl
Ph—
9-(N)-N-methylazetidinium, I−



90
n-butyl
Ph—
9-(N)-pyrrolidine



91
n-butyl
Ph—
9-(N)-N-methyl-pyrrolidinium, I−



92
n-butyl
Ph—
9-(N)-N-methyl-morpholinium, I−



93
n-butyl
Ph—
9-(N)-N′-methylpiperazine



93
n-butyl
Ph—
9-(N)-N′-dimethylpiperazinium, I−



95
n-butyl
Ph—
9-NH-CBZ



96
n-butyl
Ph—
9-NHC(C)C5H11



97
n-butyl
Ph—
9-NHC(O)CH2Br



98
n-butyl
Ph—
9-NH—C(NH)NH2



99
n-butyl
Ph—
9-(2)-thiophene



100
n-butyl
Ph—
7-OCH3, 8-OCH3



101
n-butyl
Ph—
7-SCH3, 8-OCH3



102
n-butyl
Ph—
7-SCH3, 8-SCH3



103
n-butyl
Ph—
6-OCH3, 7-OCH3, 8-OCH3























Prefix
Cpd#





(FFF.xxx.
yyy)
R1═R2
R5
(Rx)q



















F101.003
01
n-pentyl
Ph—
7-methyl



02
n-pentyl
Ph—
7-ethyl



03
n-pentyl
Ph—
7-iso-propyl



04
n-pentyl
Ph—
7-tert-butyl



05
n-pentyl
Ph—
7-OH



06
n-pentyl
Ph—
7-OCH3



07
n-pentyl
Ph—
7-O(iso-propyl)



08
n-pentyl
Ph—
7-SCH3



09
n-pentyl
Ph—
7-SOCH3



10
n-pentyl
Ph—
7-SO2CH3



11
n-pentyl
Ph—
7-SCH2CH3



12
n-pentyl
Ph—
7-NH2



13
n-pentyl
Ph—
7-NHOH



14
n-pentyl
Ph—
7-NHCH3



15
n-pentyl
Ph—
7-N(CH3)2



16
n-pentyl
Ph—
7-N+(CH3)3, I−



17
n-pentyl
Ph—
7-NHC(═O)CH3



18
n-pentyl
Ph—
7-N(CH2CH3)2



19
n-pentyl
Ph—
7-NMeCH2CO2H



20
n-pentyl
Ph—
7-N+(Me)2CH2CO2H, I−



21
n-pentyl
Ph—
7-(N)-morpholine



22
n-pentyl
Ph—
7-(N)-azetidine



23
n-pentyl
Ph—
7-(N)-N-methylazetidinium, I−



24
n-pentyl
Ph—
7-(N)-pyrrolidine



25
n-pentyl
Ph—
7-(N)-N-methyl-pyrrolidinium, I−



26
n-pentyl
Ph—
7-(N)-N-methyl-morpholinium, I−



27
n-pentyl
Ph—
7-(N)-N′-methylpiperazine



28
n-pentyl
Ph—
7-(N)-N′-dimethylpiperazinium, I−



29
n-pentyl
Ph—
7-NH-CBZ



30
n-pentyl
Ph—
7-NHC(O)C5H11



31
n-pentyl
Ph—
7-NHC(O)CH2Br



32
n-pentyl
Ph—
7-NH—C(NH)NH2



33
n-pentyl
Ph—
7-(2)-thiophene



34
n-pentyl
Ph—
8-methyl



35
n-pentyl
Ph—
8-ethyl



36
n-pentyl
Ph—
8-iso-propyl



37
n-pentyl
Ph—
8-tert-butyl



38
n-pentyl
Ph—
8-OH



39
n-pentyl
Ph—
8-OCH3



40
n-pentyl
Ph—
8-O(iso-propyl)



41
n-pentyl
Ph—
8-SCH3



42
n-pentyl
Ph—
8-SOCH3



43
n-pentyl
Ph—
8-SO2CH3



44
n-pentyl
Ph—
8-SCH2CH3



45
n-pentyl
Ph—
8-NH2



46
n-pentyl
Ph—
8-NHOH



47
n-pentyl
Ph—
8-NHCH3



48
n-pentyl
Ph—
8-N(CH3)2



49
n-pentyl
Ph—
8-N+(CH3)3, I−



50
n-pentyl
Ph—
8-NHC(═O)CH3



51
n-pentyl
Ph—
8-N(CH2CH3)2



52
n-pentyl
Ph—
8-NMeCH2CO2H



53
n-pentyl
Ph—
8-N+(Me)2CH2CO2H, I−



54
n-pentyl
Ph—
8-(N)-morpholine



55
n-pentyl
Ph—
8-(N)-azetidine



56
n-pentyl
Ph—
8-(N)-N-methylazetidinium, I−



57
n-pentyl
Ph—
8-(N)-pyrrolidine



58
n-pentyl
Ph—
8-(N)-N-methyl-pyrrolidinium, I−



59
n-pentyl
Ph—
8-(N)-N-methyl-morpholinium, I−



60
n-pentyl
Ph—
8-(N)-N′-methylpiperazine



61
n-pentyl
Ph—
8-(N)-N′-dimethylpiperazinium, I−



62
n-pentyl
Ph—
8-NH-CBZ



63
n-pentyl
Ph—
8-NHC(O)C5H11



64
n-pentyl
Ph—
8-NHC(O)CH2Br



65
n-pentyl
Ph—
8-NH—C(NH)NH2



66
n-pentyl
Ph—
8-(2)-thiophene



67
n-pentyl
Ph—
9-methyl



68
n-pentyl
Ph—
9-ethyl



69
n-pentyl
Ph—
9-iso-propyl



70
n-pentyl
Ph—
9-tert-butyl



71
n-pentyl
Ph—
9-OH



72
n-pentyl
Ph—
9-OCH3



73
n-pentyl
Ph—
9-O(iso-propyl)



74
n-pentyl
Ph—
9-SCH3



75
n-pentyl
Ph—
9-SOCH3



76
n-pentyl
Ph—
9-SO2CH3



77
n-pentyl
Ph—
9-SCH2CH3



78
n-pentyl
Ph—
9-NH2



79
n-pentyl
Ph—
9-NHOH



80
n-pentyl
Ph—
9-NHCH3



81
n-pentyl
Ph—
9-N(CH3)2



82
n-pentyl
Ph—
9-N+(CH3)3, I−



83
n-pentyl
Ph—
9-NHC(═O)CH3



84
n-pentyl
Ph—
9-N(CH2CH3)2



85
n-pentyl
Ph—
9-NMeCH2CO2H



86
n-pentyl
Ph—
9-N+(Me)2CH2CO2H, I−



87
n-pentyl
Ph—
9-(N)-morpholine



88
n-pentyl
Ph—
9-(N)-azetidine



89
n-pentyl
Ph—
9-(N)-N-methylazetidinium, I−



90
n-pentyl
Ph—
9-(N)-pyrrolidine



91
n-pentyl
Ph—
9-(N)-N-methyl-pyrrolidinium, I−



92
n-pentyl
Ph—
9-(N)-N-methyl-morpholinium, I−



93
n-pentyl
Ph—
9-(N)-N′-methylpiperazine



93
n-pentyl
Ph—
9-(N)-N′-dimethylpiperazinium, I−



95
n-pentyl
Ph—
9-NH-CBZ



96
n-pentyl
Ph—
9-NHC(O)C5H11



97
n-pentyl
Ph—
9-NHC(O)CH2Br



98
n-pentyl
Ph—
9-NH—C(NH)NH2



99
n-pentyl
Ph—
9-(2)-thiophene



100
n-pentyl
Ph—
7-OCH3, 8-OCH3



101
n-pentyl
Ph—
7-SCH3, 8-OCH3



102
n-pentyl
Ph—
7-SCH3, 8-SCH3



103
n-pentyl
Ph—
6-OCH3, 7-OCH3, 8-OCH3























Prefix
Cpd#





(FFF.xxx.
yyy)
R1═R2
R5
(Rx)q



















F101.004
01
n-hexyl
Ph—
7-methyl



02
n-hexyl
Ph—
7-ethyl



03
n-hexyl
Ph—
7-iso-propyl



04
n-hexyl
Ph—
7-tert-butyl



05
n-hexyl
Ph—
7-OH



06
n-hexyl
Ph—
7-OCH3



07
n-hexyl
Ph—
7-O-(iso-propyl)



08
n-hexyl
Ph—
7-SCH3



09
n-hexyl
Ph—
7-SOCH3



10
n-hexyl
Ph—
7-SO2CH3



11
n-hexyl
Ph—
7-SCH2CH3



12
n-hexyl
Ph—
7-NH2



13
n-hexyl
Ph—
7-NHOH



14
n-hexyl
Ph—
7-NHCH3



15
n-hexyl
Ph—
7-N(CH3)2



16
n-hexyl
Ph—
7-N+(CH3)3, I−



17
n-hexyl
Ph—
7-NHC(═O)CH3



18
n-hexyl
Ph—
7-N(CH2CH3)2



19
n-hexyl
Ph—
7-NMeCH2CO2H



20
n-hexyl
Ph—
7-N−(Me)2CH2CO2H, I−



21
n-hexyl
Ph—
7-(N)-morpholine



22
n-hexyl
Ph—
7-(N)-azetidine



23
n-hexyl
Ph—
7-(N)-N-methylazetidinium, I−



24
n-hexyl
Ph—
7-(N)-pyrrolidine



25
n-hexyl
Ph—
7-(N)-N-methyl-pyrrolidinium, I−



26
n-hexyl
Ph—
7-(N)-N-methyl-morpholinium, I−



27
n-hexyl
Ph—
7-(N)-N′-methylpiperazine



28
n-hexyl
Ph—
7-(N)-N′-dimethylpiperazinium, I−



29
n-hexyl
Ph—
7-NH-CBZ



30
n-hexyl
Ph—
7-NHC(O)C5H11



31
n-hexyl
Ph—
7-NHC(O)CH2Br



32
n-hexyl
Ph—
7-NH—C(NH)NH2



33
n-hexyl
Ph—
7-(2)-thiophene



34
n-hexyl
Ph—
8-methyl



35
n-hexyl
Ph—
8-ethyl



36
n-hexyl
Ph—
8-iso-propyl



37
n-hexyl
Ph—
8-tert-butyl



38
n-hexyl
Ph—
8-OH



39
n-hexyl
Ph—
8-OCH3



40
n-hexyl
Ph—
8-O(iso-propyl)



41
n-hexyl
Ph—
8-SCH3



42
n-hexyl
Ph—
8-SOCH3



43
n-hexyl
Ph—
8-SO2CH3



44
n-hexyl
Ph—
8-SCH2CH3



45
n-hexyl
Ph—
8-NH2



46
n-hexyl
Ph—
8-NHOH



47
n-hexyl
Ph—
8-NHCH3



48
n-hexyl
Ph—
8-N(CH3)2



49
n-hexyl
Ph—
8-N+(CH3)3,I−



50
n-hexyl
Ph—
8-NHC(═O)CH3



51
n-hexyl
Ph—
8-N(CH2CH3)2



52
n-hexyl
Ph—
8-NMeCH2CO2H



53
n-hexyl
Ph—
8-N−(Me)2CH2CO2H, I−



54
n-hexyl
Ph—
8-(N)-morpholine



55
n-hexyl
Ph—
8-(N)-azetidine



56
n-hexyl
Ph
8-(N)-N-methylazetidinium, I−



57
n-hexyl
Ph—
8-(N)-pyrrolidine



58
n-hexyl
Ph—
8-(N)-N-methyl-pyrrolidinium, I−



59
n-hexyl
Ph—
8-(N)-N-methyl-morpholinium, I−



60
n-hexyl
Ph—
8-(N)-N′-methylpiperazine



61
n-hexyl
Ph—
8-(N)-N′-dimethylpiperazinium, I−



62
n-hexyl
Ph—
8-NH-CBZ



63
n-hexyl
Ph—
8-NHC(O)C5H11



64
n-hexyl
Ph—
8-NHC(O)CH2Br



65
n-hexyl
Ph—
8-NH—C(NH)NH2



66
n-hexyl
Ph—
8-(2)-thiophene



67
n-hexyl
Ph—
9-methyl



68
n-hexyl
Ph—
9-ethyl



69
n-hexyl
Ph—
9-iso-propyl



70
n-hexyl
Ph—
9-tert-butyl



71
n-hexyl
Ph—
9-OH



72
n-hexyl
Ph—
9-OCH3



73
n-hexyl
Ph—
9-O(iso-propyl)



74
n-hexyl
Ph—
9-SCH3



75
n-hexyl
Ph—
9-SOCH3



76
n-hexyl
Ph—
9-SO2CH3



77
n-hexyl
Ph—
9-SCH2CH3



78
n-hexyl
Ph—
9-NH2



79
n-hexyl
Ph—
9-NHOH



80
n-hexyl
Ph—
9-NHCH3



81
n-hexyl
Ph—
9-N(CH3)2



82
n-hexyl
Ph—
9-N+(CH3)3, I−



83
n-hexyl
Ph—
9-NHC(═O)CH3



84
n-hexyl
Ph—
9-N(CH2CH3)2



85
n-hexyl
Ph—
9-NMeCH2CO2H



86
n-hexyl
Ph—
9-N−(Me)2CH2CO2H, I−



87
n-hexyl
Ph—
9-(N)-morpholine



88
n-hexyl
Ph—
9-(N)-azetidine



89
n-hexyl
Ph—
9-(N)-N-methylazetidinium, I−



90
n-hexyl
Ph—
9-(N)-pyrrolidine



91
n-hexyl
Ph—
9-(N)-N-methyl-pyrrolidinium, I−



92
n-hexyl
Ph—
9-(N)-N-methyl-morpholinium, I−



93
n-hexyl
Ph—
9-(N)-N′-methylpiperazine



93
n-hexyl
Ph—
9-(N)-N′-dimethylpiperazinium, I−



95
n-hexyl
Ph—
9-NH-CBZ



96
n-hexyl
Ph—
9-NHC(O)C5H11



97
n-hexyl
Ph—
9-NHC(O)CH2Br



98
n-hexyl
Ph—
9-NH—C(NH)NH2



99
n-hexyl
Ph—
9-(2)-thiophene



100
n-hexyl
Ph—
7-OCH3, 8-OCH3



101
n-hexyl
Ph—
7-SCH3, 8-OCH3



102
n-hexyl
Ph—
7-SCH3, 8-SCH3



103
n-hexyl
Ph—
6-OCH3, 7-OCH3, 8-OCH3























Prefix
Cpd#





(FFF.xxx.
yyy)
R1═R2
R5
(Rx)q



















F101.005
01
iso-propyl
Ph—
7-methyl



02
iso-propyl
Ph—
7-ethyl



03
iso-propyl
Ph—
7-iso-propyl



04
iso-propyl
Ph—
7-tert-butyl



05
iso-propyl
Ph—
7-OH



06
iso-propyl
Ph—
7-OCH3



07
iso-propyl
Ph—
7-O(iso-propyl)



08
iso-propyl
Ph—
7-SCH3



09
iso-propyl
Ph—
7-SOCH3



10
iso-propyl
Ph—
7-SO2CH3



11
iso-propyl
Ph—
7-SCH2CH3



12
iso-propyl
Ph—
7-NH2



13
iso-propyl
Ph—
7-NHOH



14
iso-propyl
Ph—
7-NHCH3



15
iso-propyl
Ph—
7-N(CH3)2



16
iso-propyl
Ph—
7-N+(CH3)3, I−



17
iso-propyl
Ph—
7-NHC(═O)CH3



18
iso-propyl
Ph—
7-N(CH2CH3)2



19
iso-propyl
Ph—
7-NMeCH2CO2H



20
iso-propyl
Ph—
7-N+(Me)2CH2CO2H, I−



21
iso-propyl
Ph—
7-(N)-morpholine



22
iso-propyl
Ph—
7-(N)-azetidine



23
iso-propyl
Ph—
7-(N)-N-methylazetidinium, I−



24
iso-propyl
Ph—
7-(N)-pyrrolidine



25
iso-propyl
Ph—
7-(N)-N-methyl-pyrrolidinium, I−



26
iso-propyl
Ph—
7-(N)-N-methyl-morpholinium, I−



27
iso-propyl
Ph—
7-(N)-N′-methylpiperazine



28
iso-propyl
Ph—
7-(N)-N′-dimethylpiperazinium, I−



29
iso-propyl
Ph—
7-NH-CBZ



30
iso-propyl
Ph—
7-NHC(O)C5H11



31
iso-propyl
Ph—
7-NHC(O)CH2Br



32
iso-propyl
Ph—
7-NH—C(NH)NH2



33
iso-propyl
Ph—
7-(2)-thiophene



34
iso-propyl
Ph—
8-methyl



35
iso-propyl
Ph—
8-ethyl



36
iso-propyl
Ph—
8-iso-propyl



37
iso-propyl
Ph—
8-tert-butyl



38
iso-propyl
Ph—
8-OH



39
iso-propyl
Ph—
8-OCH3



40
iso-propyl
Ph—
8-O(iso-propyl)



41
iso-propyl
Ph—
8-SCH3



42
iso-propyl
Ph—
8-SOCH3



43
iso-propyl
Ph—
8-SO2CH3



44
iso-propyl
Ph—
8-SCH2CH3



45
iso-propyl
Ph—
8-NH2



46
iso-propyl
Ph—
8-NHOH



47
iso-propyl
Ph—
8-NHCH3



48
iso-propyl
Ph—
8-N(CH3)2



49
iso-propyl
Ph—
8-N+(CH3)3, I−



50
iso-propyl
Ph—
8-NHC(═O)CH3



51
iso-propyl
Ph—
8-N(CH2CH3)2



52
iso-propyl
Ph—
8-NMeCH2CO2H



53
iso-propyl
Ph—
8-N+(Me)2CH2CO2H, I−



54
iso-propyl
Ph—
8-(N)-morpholine



55
iso-propyl
Ph—
8-(N)-azetidine



56
iso-propyl
Ph—
8-(N)-N-methylazetidinium, I−



57
iso-propyl
Ph—
8-(N)-pyrrolidine



58
iso-propyl
Ph—
8-(N)-N-methyl-pyrrolidinium, I−



59
iso-propyl
Ph—
8-(N)-N-methyl-morpholinium, I−



60
iso-propyl
Ph—
8-(N)-N′-methylpiperazine



61
iso-propyl
Ph—
8-(N)-N′-dimethylpiperazinium, I−



62
iso-propyl
Ph—
8-NH-CBZ



63
iso-propyl
Ph—
8-NHC(O)C5H11



64
iso-propyl
Ph—
8-NHC(O)CH2Br



65
iso-propyl
Ph—
8-NH—C(NH)NH2



66
iso-propyl
Ph—
8-(2)-thiophene



67
iso-propyl
Ph—
9-methyl



68
iso-propyl
Ph—
9-ethyl



69
iso-propyl
Ph—
9-iso-propyl



70
iso-propyl
Ph—
9-tert-butyl



71
iso-propyl
Ph—
9-OH



72
iso-propyl
Ph—
9-OCH3



73
iso-propyl
Ph—
9-O(iso-propyl)



74
iso-propyl
Ph—
9-SCH3



75
iso-propyl
Ph—
9-SOCH3



76
iso-propyl
Ph—
9-SO2CH3



77
iso-propyl
Ph—
9-SCH2CH3



78
iso-propyl
Ph—
9-NH2



79
iso-propyl
Ph—
9-NHOH



80
iso-propyl
Ph—
9-NHCH3



81
iso-propyl
Ph—
9-N(CH3)2



82
iso-propyl
Ph—
9-N+(CH3)3, I−



83
iso-propyl
Ph—
9-NHC(═O)CH3



84
iso-propyl
Ph—
9-N(CH2CH3)2



85
iso-propyl
Ph—
9-NMeCH2CO2H



86
iso-propyl
Ph—
9-N+(Me)2CH2CO2H, I−



87
iso-propyl
Ph—
9-(N)-morpholine



88
iso-propyl
Ph—
9-(N)-azetidine



89
iso-propyl
Ph—
9-(N)-N-methylazetidinium, I−



90
iso-propyl
Ph—
9-(N)-pyrrolidine



91
iso-propyl
Ph—
9-(N)-N-methyl-pyrrolidinium, I−



92
iso-propyl
Ph—
9-(N)-N-methyl-morpholinium, I−



93
iso-propyl
Ph—
9-(N)-N′-methylpiperazine



93
iso-propyl
Ph—
9-(N)-N′-dimethylpiperazinium, I−



95
iso-propyl
Ph—
9-NH-CBZ



96
iso-propyl
Ph—
9-NHC(O)C5H11



97
iso-propyl
Ph—
9-NHC(O)CH2Br



98
iso-propyl
Ph—
9-NH—C(NH)NH2



99
iso-propyl
Ph—
9-(2)-thiophene



100
iso-propyl
Ph—
7-OCH3, 8-CCH3



101
iso-propyl
Ph—
7-SCH3, 8-CCH3



102
iso-propyl
Ph—
7-SCH3, 8-SCH3



103
iso-propyl
Ph—
6-CCH3, 7-CCH3, 8-CCH3























Prefix
Cpd#





(FFF.xxx.
yyy)
R1═R2
R5
(Rx)q



















F101.006
01
iso-butyl
Ph—
7-methyl



02
iso-butyl
Ph—
7-ethyl



03
iso-butyl
Ph—
7-iso-propyl



04
iso-butyl
Ph—
7-tert-butyl



05
iso-butyl
Ph—
7-OH



06
iso-butyl
Ph—
7-OCH3



07
iso-butyl
Ph—
7-O(iso-propyl)



08
iso-butyl
Ph—
7-SCH3



09
iso-butyl
Ph—
7-SOCH3



10
iso-butyl
Ph—
7-SO2CH3



11
iso-butyl
Ph—
7-SCH2CH3



12
iso-butyl
Ph—
7-NH2



13
iso-butyl
Ph—
7-NHOH



14
iso-butyl
Ph—
7-NHCH3



15
iso-butyl
Ph—
7-N(CH3)2



16
iso-butyl
Ph—
7-N+ (CH3)3, I−



17
iso-butyl
Ph—
7-NHC(═O)CH3



18
iso-butyl
Ph—
7-N(CH2CH3)2



19
iso-butyl
Ph—
7-NMeCH2CO2H



20
iso-butyl
Ph—
7-N− (Me)2CH2CO2H, I−



21
iso-butyl
Ph—
7-(N)-morpholine



22
iso-butyl
Ph—
7-(N)-azetidine



23
iso-butyl
Ph—
7-(N)-N-methylazetidinium, I−



24
iso-butyl
Ph—
7-(N)-pyrrolidine



25
iso-butyl
Ph—
7-(N)-N-methyl-pyrrolidinium, I−



26
iso-butyl
Ph—
7-(N)-N-methyl-morpholinium, I−



27
iso-butyl
Ph—
7-(N)-N′-methylpiperazine



28
iso-butyl
Ph—
7-(N)-N′-dimethylpiperazinium, I−



29
iso-butyl
Ph—
7-NH-CBZ



30
iso-butyl
Ph—
7-NHC(O)C5H11



31
iso-butyl
Ph—
7-NHC(O)CH2Br



32
iso-butyl
Ph—
7-NH—C(NH)NH2



33
iso-butyl
Ph—
7-(2)-thiophene



34
iso-butyl
Ph—
8-methyl



35
iso-butyl
Ph—
8-ethyl



36
iso-butyl
Ph—
8-iso-propyl



37
iso-butyl
Ph—
8-tert-butyl



38
iso-butyl
Ph—
8-OH



39
iso-butyl
Ph—
8-OCH3



40
iso-butyl
Ph—
8-O(iso-propyl)



41
iso-butyl
Ph—
8-SCH3



42
iso-butyl
Ph—
8-SOCH3



43
iso-butyl
Ph—
8-SO2CH3



44
iso-butyl
Ph—
8-SCH2CH3



45
iso-butyl
Ph—
8-NH2



46
iso-butyl
Ph—
8-NHOH



47
iso-butyl
Ph—
8-NHCH3



48
iso-butyl
Ph—
8-N(CH3)2



49
iso-butyl
Ph—
8-N+ (CH3)3, I−



50
iso-butyl
Ph—
8-NHC(═O)CH3



51
iso-butyl
Ph—
8-N(CH2CH3)2



52
iso-butyl
Ph—
8-NMeCH2CO2H



53
iso-butyl
Ph—
8-N− (Me)2CH2CO2H, I−



54
iso-butyl
Ph—
8-(N)-morpholine



55
iso-butyl
Ph—
8-(N)-azetidine



56
iso-butyl
Ph—
8-(N)-N-methylazetidinium, I−



57
iso-butyl
Ph—
8-(N)-pyrrolidine



58
iso-butyl
Ph—
8-(N)-N-methyl-pyrrolidinium, I−



59
iso-butyl
Ph—
8-(N)-N-methyl-morpholinium, I−



60
iso-butyl
Ph—
8-(N)-N′-methylpiperazine



61
iso-butyl
Ph—
8-(N)-N′-dimethylpiperazinium, I−



62
iso-butyl
Ph—
8-NH-CBZ



63
iso-butyl
Ph—
8-NHC(O)C5H11



64
iso-butyl
Ph—
8-NHC(O)CH2Br



65
iso-butyl
Ph—
8-NH—C(NH)NH2



66
iso-butyl
Ph—
8-(2)-thiophene



67
iso-butyl
Ph—
9-methyl



68
iso-butyl
Ph—
9-ethyl



69
iso-butyl
Ph—
9-iso-propyl



70
iso-butyl
Ph—
9-tert-butyl



71
iso-butyl
Ph—
9-OH



72
iso-butyl
Ph—
9-OCH3



73
iso-butyl
Ph—
9-O(iso-propyl)



74
iso-butyl
Ph—
9-SCH3



75
iso-butyl
Ph—
9-SOCH3



76
iso-butyl
Ph—
9-SO2CH3



77
iso-butyl
Ph—
9-SCH2CH3



78
iso-butyl
Ph—
9-NH2



79
iso-butyl
Ph—
9-NHOH



80
iso-butyl
Ph—
9-NHCH3



81
iso-butyl
Ph—
9-N(CH3)2



82
iso-butyl
Ph—
9-N+ (CH3)3, I−



83
iso-butyl
Ph—
9-NHC(═O)CH3



84
iso-butyl
Ph—
9-N(CH2CH3)2



85
iso-butyl
Ph—
9-NMeCH2CO2H



86
iso-butyl
Ph—
9-N− (Me)2CH2CO2H, I−



87
iso-butyl
Ph—
9-(N)-morpholine



88
iso-butyl
Ph—
9-(N)-azetidine



89
iso-butyl
Ph—
9-(N)-N-methylazetidinium, I−



90
iso-butyl
Ph—
9-(N)-pyrrolidine



91
iso-butyl
Ph—
9-(N)-N-methyl-pyrrolidinium, I−



92
iso-butyl
Ph—
9-(N)-N-methyl-morpholinium, I−



93
iso-butyl
Ph—
9-(N)-N′-methylpiperazine



93
iso-butyl
Ph—
9-(N)-N′-dimethylpiperazinium, I−



95
iso-butyl
Ph—
9-NH-CBZ



96
iso-butyl
Ph—
9-NHC(O)C5H11



97
iso-butyl
Ph—
9-NHC(O)CH2Br



98
iso-butyl
Ph—
9-NH—C(NH)NH2



99
iso-butyl
Ph—
9-(2)-thiophene



100
iso-butyl
Ph—
7-OCH3, 8-OCH3



101
iso-butyl
Ph—
7-SCH3, 8-OCH3



102
iso-butyl
Ph—
7-SCH3, 8-SCH3



103
iso-butyl
Ph—
6-OCH3, 7-OCH3, 8-OCH3























Prefix
Cpd#





(FFF.xxx.
yyy)
R1═R2
R5
(Rx)q



















F101.007
01
iso-pentyl
Ph—
7-methyl



02
iso-pentyl
Ph—
7-ethyl



03
iso-pentyl
Ph—
7-iso-propyl



04
iso-pentyl
Ph—
7-tert-butyl



05
iso-pentyl
Ph—
7-OH



06
iso-pentyl
Ph—
7-OCH3



07
iso-pentyl
Ph—
7-O(iso-propyl)



08
iso-pentyl
Ph—
7-SCH3



09
iso-pentyl
Ph—
7-SOCH3



10
iso-pentyl
Ph—
7-SO2CH3



11
iso-pentyl
Ph—
7-SCH2CH3



12
iso-pentyl
Ph—
7-NH2



13
iso-pentyl
Ph—
7-NHOH



14
iso-pentyl
Ph—
7-NHCH3



15
iso-pentyl
Ph—
7-N(CH3)2



16
iso-pentyl
Ph—
7-N+ (CH3)3, I−



17
iso-pentyl
Ph—
7-NHC(═O)CH3



18
iso-pentyl
Ph—
7-N(CH2CH3)2



19
iso-pentyl
Ph—
7-NMeCH2CO2H



20
iso-pentyl
Ph—
7-N− (Me)2CH2CO2H, I−



21
iso-pentyl
Ph—
7-(N)-morpholine



22
iso-pentyl
Ph—
7-(N)-azetidine



23
iso-pentyl
Ph—
7-(N)-N-methylazetidinium, I−



24
iso-pentyl
Ph—
7-(N)-pyrrolidine



25
iso-pentyl
Ph—
7-(N)-N-methyl-pyrrolidinium, I−



26
iso-pentyl
Ph—
7-(N)-methyl-morpholinium, I−



27
iso-pentyl
Ph—
7-(N)-N′-methylpiperazine



28
iso-pentyl
Ph—
7-(N)-N′-dimethylpiperazinium, I−



29
iso-pentyl
Ph—
7-NH-CBZ



30
iso-pentyl
Ph—
7-NHC(O)C5H11



31
iso-pentyl
Ph—
7-NHC(O)CH2Br



32
iso-pentyl
Ph—
7-NH—C(NH)NH2



33
iso-pentyl
Ph—
7-(2)-thiophene



34
iso-pentyl
Ph—
8-methyl



35
iso-pentyl
Ph—
8-ethyl



36
iso-pentyl
Ph—
8-iso-propyl



37
iso-pentyl
Ph—
8-tert-butyl



38
iso-pentyl
Ph—
8-OH



39
iso-pentyl
Ph—
8-OCH3



40
iso-pentyl
Ph—
8-O(iso-propyl)



41
iso-pentyl
Ph—
8-SCH3



42
iso-pentyl
Ph—
8-SOCH3



43
iso-pentyl
Ph—
8-SO2CH3



44
iso-pentyl
Ph—
8-SCH2CH3



45
iso-pentyl
Ph—
8-NH2



46
iso-pentyl
Ph—
8-NHOH



47
iso-pentyl
Ph—
8-NHCH3



48
iso-pentyl
Ph—
8-N(CH3)2



49
iso-pentyl
Ph—
8-N+ (CH3)3, I−



50
iso-pentyl
Ph—
8-NHC(═O)CH3



51
iso-pentyl
Ph—
8-N(CH2CH3)2



52
iso-pentyl
Ph—
8-NMeCH2CO2H



53
iso-pentyl
Ph—
8-N− (Me)2CH2CO2H, I−



54
iso-pentyl
Ph—
8-(N)-morpholine



55
iso-pentyl
Ph—
8-(N)-azetidine



56
iso-pentyl
Ph—
8-(N)-N-methylazetidinium, I−



57
iso-pentyl
Ph—
8-(N)-pyrrolidine



58
iso-pentyl
Ph—
8-(N)-N-methyl-pyrrolidinium, I−



59
iso-pentyl
Ph—
8-(N)-N-methyl-morpholinium, I−



60
iso-pentyl
Ph—
8-(N)-N′-methylpiperazine



61
iso-pentyl
Ph—
8-(N)-N′-dimethylpiperazinium, I−



62
iso-pentyl
Ph—
8-NH-CBZ



63
iso-pentyl
Ph—
8-NHC(O)C5H11



64
iso-pentyl
Ph—
8-NHC(O)CH2Br



65
iso-pentyl
Ph—
8-NH—C(NH)NH2



66
iso-pentyl
Ph—
8-(2)-thiophene



67
iso-pentyl
Ph—
9-methyl



68
iso-pentyl
Ph—
9-ethyl



69
iso-pentyl
Ph—
9-iso-propyl



70
iso-pentyl
Ph—
9-tert-butyl



71
iso-pentyl
Ph—
9-OH



72
iso-pentyl
Ph—
9-OCH3



73
iso-pentyl
Ph—
9-O(iso-propyl)



74
iso-pentyl
Ph—
9-SCH3



75
iso-pentyl
Ph—
9-SOCH3



76
iso-pentyl
Ph—
9-SO2CH3



77
iso-pentyl
Ph—
9-SCH2CH3



78
iso-pentyl
Ph—
9-NH2



79
iso-pentyl
Ph—
9-NHOH



80
iso-pentyl
Ph—
9-NHCH3



81
iso-pentyl
Ph—
9-N(CH3)2



82
iso-pentyl
Ph—
9-N+ (CH3)3, I−



83
iso-pentyl
Ph—
9-NHC(═O)CH3



84
iso-pentyl
Ph—
9-N(CH2CH3)2



85
iso-pentyl
Ph—
9-NMeCH2CO2H



86
iso-pentyl
Ph—
9-N− (Me)2CH2CO2H, I−



87
iso-pentyl
Ph—
9-(N)-morpholine



88
iso-pentyl
Ph—
9-(N)-azetidine



89
iso-pentyl
Ph—
9-(N)-N-methylazetidinium, I−



90
iso-pentyl
Ph—
9-(N)-pyrrolidine



91
iso-pentyl
Ph—
9-(N)-N-methyl-pyrrolidinium, I−



92
iso-pentyl
Ph—
9-(N)-N-methyl-morpholinium, I−



93
iso-pentyl
Ph—
9-(N)-N′-methylpiperazine



93
iso-pentyl
Ph—
9-(N)-N′-dimethylpiperazinium, I−



95
iso-pentyl
Ph—
9-NH-CBZ



96
iso-pentyl
Ph—
9-NHC(O)C5H11



97
iso-pentyl
Ph—
9-NHC(O)CH2Br



98
iso-pentyl
Ph—
9-NH-C(NH)NH2



99
iso-pentyl
Ph—
9-(2)-thiophene



100
iso-pentyl
Ph—
7-OCH3, 8-OCH3



101
iso-pentyl
Ph—
7-SCH3, 8-OCH3



102
iso-pentyl
Ph—
7-SCH3, 8-SCH3



103
iso-pentyl
Ph—
6-OCH3, 7-OCH3, 8-OCH3























Prefix
Cpd#





.xxx.
yyy)
R1═R2
R5
(Rx)q



















F101.008
01
CH2C(═O)C2H5
Ph—
7-methyl



02
CH2C(═O)C2H5
Ph—
7-ethyl



03
CH2C(═O)C2H5
Ph—
7-iso-propyl



04
CH2C(═O)C2H5
Ph—
7-tert-butyl



05
CH2C(═O)C2H5
Ph—
7-OH



06
CH2C(═O)C2H5
Ph—
7-OCH3



07
CH2C(═O)C2H5
Ph—
7-O(iso-propyl)



08
CH2C(═O)C2H5
Ph—
7-SCH3



09
CH2C(═O)C2H5
Ph—
7-SOCH3



10
CH2C(═O)C2H5
Ph—
7-SO2CH3



11
CH2C(═O)C2H5
Ph—
7-SCH2CH3



12
CH2C(═O)C2H5
Ph—
7-NH2



13
CH2C(═O)C2H5
Ph—
7-NHOH



14
CH2C(═O)C2H5
Ph—
7-NHCH3



15
CH2C(═O)C2H5
Ph—
7-N(CH3)2



16
CH2C(═O)C2H5
Ph—
7-N+(CH3)3, I−



17
CH2C(═O)C2H5
Ph—
7-NHC(═O)CH3



18
CH2C(═O)C2H5
Ph—
7-N(CH2CH3)2



19
CH2C(═O)C2H5
Ph—
7-NMeCH2CO2H



20
CH2C(═O)C2H5
Ph—
7-N+(Me)2CH2CO2H, I−



21
CH2C(═O)C2H5
Ph—
7-(N)-morpholine



22
CH2C(═O)C2H5
Ph—
7-(N)-azetidine



23
CH2C(═O)C2H5
Ph—
7-(N)-N-methylazetidinium, I−



24
CH2C(═O)C2H5
Ph—
7-(N)-pyrrolidine



25
CH2C(═O)C2H5
Ph—
7-(N)-N-methyl-pyrrolidinium, I−



26
CH2C(═O)C2H5
Ph—
7-(N)-N-methyl-morpholinium, I−



27
CH2C(═O)C2H5
Ph—
7-(N)-N′-methylpiperazine



28
CH2C(═O)C2H5
Ph—
7-(N)-N′-dimethylpiperazinium, I−



29
CH2C(═O)C2H5
Ph—
7-NH-CBZ



30
CH2C(═O)C2H5
Ph—
7-NHC(O)C5H11



31
CH2C(═O)C2H5
Ph—
7-NHC(O)CH2Br



32
CH2C(═O)C2H5
Ph—
7-NH-C(NH)NH2



33
CH2C(═O)C2H5
Ph—
7-(2)-thiophene



34
CH2C(═O)C2H5
Ph—
8-methyl



35
CH2C(═O)C2H5
Ph—
8-ethyl



36
CH2C(═O)C2H5
Ph—
8-iso-propyl



37
CH2C(═O)C2H5
Ph—
8-tert-butyl



38
CH2C(═O)C2H5
Ph—
8-OH



39
CH2C(═O)C2H5
Ph—
8-OCH3



40
CH2C(═O)C2H5
Ph—
8-O(iso-propyl)



41
CH2C(═O)C2H5
Ph—
8-SCH3



42
CH2C(═O)C2H5
Ph—
8-SOCH3



43
CH2C(═O)C2H5
Ph—
8-SO2CH3



44
CH2C(═O)C2H5
Ph—
8-SCH2CH3



45
CH2C(═O)C2H5
Ph—
8-NH2



46
CH2C(═O)C2H5
Ph—
8-NHOH



47
CH2C(═O)C2H5
Ph—
8-NHCH3



48
CH2C(═O)C2H5
Ph—
8-N(CH3)2



49
CH2C(═O)C2H5
Ph—
8-N+(CH3)3, I−



50
CH2C(═O)C2H5
Ph—
8-NHC(═O)CH3



51
CH2C(═O)C2H5
Ph—
8-N(CH2CH3)2



52
CH2C(═O)C2H5
Ph—
8-NMeCH2CO2H



53
CH2C(═O)C2H5
Ph—
8-N+(Me)2CH2CO2H, I−



54
CH2C(═O)C2H5
Ph—
8-(N)-morpholine



55
CH2C(═O)C2H5
Ph—
8-(N)-azetidine



56
CH2C(═O)C2H5
Ph—
8-(N)-N-methylazetidinium, I−



57
CH2C(═O)C2H5
Ph—
8-(N)-pyrrolidine



58
CH2C(═O)C2H5
Ph—
8-(N)-N-methyl-pyrrolidinium, I−



59
CH2C(═O)C2H5
Ph—
8-(N)-N-methyl-morpholinium, I−



60
CH2C(═O)C2H5
Ph—
8-(N)-N′-methylpiperazine



61
CH2C(═O)C2H5
Ph—
8-(N)-N′-dimethylpiperazinium, I−



62
CH2C(═O)C2H5
Ph—
8-NH-CBZ



63
CH2C(═O)C2H5
Ph—
8-NHC(O)C5H11



64
CH2C(═O)C2H5
Ph—
8-NHC(O)CH2Br



65
CH2C(═O)C2H5
Ph—
8-NH—C(NH)NH2



66
CH2C(═O)C2H5
Ph—
8-(2)-thiophene



67
CH2C(═O)C2H5
Ph—
9-methyl



68
CH2C(═O)C2H5
Ph—
9-ethyl



69
CH2C(═O)C2H5
Ph—
9-iso-propyl



70
CH2C(═O)C2H5
Ph—
9-tert-butyl



71
CH2C(═O)C2H5
Ph—
9-OH



72
CH2C(═O)C2H5
Ph—
9-OCH3



73
CH2C(═O)C2H5
Ph—
9-O(iso-propyl)



74
CH2C(═O)C2H5
Ph—
9-SCH3



75
CH2C(═O)C2H5
Ph—
9-SOCH3



76
CH2C(═O)C2H5
Ph—
9-SO2CH3



77
CH2C(═O)C2H5
Ph—
9-SCH2CH3



78
CH2C(═O)C2H5
Ph—
9-NH2



79
CH2C(═O)C2H5
Ph—
9-NHOH



80
CH2C(═O)C2H5
Ph—
9-NHCH3



81
CH2C(═O)C2H5
Ph—
9-N(CH3)2



82
CH2C(═O)C2H5
Ph—
9-N+(CH3)3, I−



83
CH2C(═O)C2H5
Ph—
9-NHC(═O)CH3



84
CH2C(═O)C2H5
Ph—
9-N(CH2CH3)2



85
CH2C(═O)C2H5
Ph—
9-NMeCH2CO2H



86
CH2C(═O)C2H5
Ph—
9-N+(Me)2CH2CO2H, I−



87
CH2C(═O)C2H5
Ph—
9-(N)-morpholine



88
CH2C(═O)C2H5
Ph—
9-(N)-azetidine



89
CH2C(═O)C2H5
Ph—
9-(N)-N-methylazetidinium, I−



90
CH2C(═O)C2H5
Ph—
9-(N)-pyrrolidine



91
CH2C(═O)C2H5
Ph—
9-(N)-N-methyl-pyrrolidinium, I−



92
CH2C(═O)C2H5
Ph—
9-(N)-N-methyl-morpholinium, I−



93
CH2C(═O)C2H5
Ph—
9-(N)-N′-methylpiperazine



93
CH2C(═O)C2H5
Ph—
9-(N)-N′-dimethylpiperazinium, I−



95
CH2C(═O)C2H5
Ph—
9-NH-CBZ



96
CH2C(═O)C2H5
Ph—
9-NHC(O)C5H11



97
CH2C(═O)C2H5
Ph—
9-NHC(O)CH2Br



98
CH2C(═O)C2H5
Ph—
9-NH—C(NH)NH2



99
CH2C(═O)C2H5
Ph—
9-(2)-thiophene



100
CH2C(═O)C2H5
Ph—
7-OCH3, 8-OCH3



101
CH2C(═O)C2H5
Ph—
7-SCH3, 8-OCH3



102
CH2C(═O)C2H5
Ph—
7-SCH3, 8-SCH3



103
CH2C(═O)C2H5
Ph—
6-OCH3, 7-OCH3, 8-OCH3























Prefix
Cpd#





(FFF.xxx.
yyy)
R1═R2
R5
(Rx)q



















F101.009
01
CH2OC2H5
Ph—
7-methyl



02
CH2OC2H5
Ph—
7-ethyl



03
CH2OC2H5
Ph—
7-iso-propyl



04
CH2OC2H5
Ph—
7-tert-butyl



05
CH2OC2H5
Ph—
7-OH



06
CH2OC2H5
Ph—
7-OCH3



07
CH2OC2H5
Ph—
7-O(iso-propyl)



08
CH2OC2H5
Ph—
7-SCH3



09
CH2OC2H5
Ph—
7-SOCH3



10
CH2OC2H5
Ph—
7-SO2CH3



11
CH2OC2H5
Ph—
7-SCH2CH3



12
CH2OC2H5
Ph—
7-NH2



13
CH2OC2H5
Ph—
7-NHOH



14
CH2OC2H5
Ph—
7-NHCH3



15
CH2OC2H5
Ph—
7-N(CH3)2



16
CH2OC2H5
Ph—
7-N+(CH3)3, I−



17
CH2OC2H5
Ph—
7-NHC(═O)CH3



18
CH2OC2H5
Ph—
7-N(CH2CH3)2



19
CH2OC2H5
Ph—
7-NMeCH2CO2H



20
CH2OC2H5
Ph—
7-N+(Me)2CH2CO2H, I−



21
CH2OC2H5
Ph—
7-(N)-morpholine



22
CH2OC2H5
Ph—
7-(N)-azetidine



23
CH2OC2H5
Ph—
7-(N)-N-methylazetidinium, I−



24
CH2OC2H5
Ph—
7-(N)-pyrrolidine



25
CH2OC2H5
Ph—
7-(N)-N-methyl-pyrrolidinium,






I−



26
CH2OC2H5
Ph—
7-(N)-N-methyl-morpholinium,






I−



27
CH2OC2H5
Ph—
7-(N)-N′-methylpiperazine



28
CH2OC2H5
Ph—
7-(N)-N′-dimethylpiperazinium,






I−



29
CH2OC2H5
Ph—
7-NH-CBZ



30
CH2OC2H5
Ph—
7-NHC(O)C5H11



31
CH2OC2H5
Ph—
7-NHC(O)CH2Br



32
CH2OC2H5
Ph—
7-NH—C(NH)NH2



33
CH2OC2H5
Ph—
7-(2)-thiophene



34
CH2OC2H5
Ph—
8-methyl



35
CH2OC2H5
Ph—
8-ethyl



36
CH2OC2H5
Ph—
8-iso-propyl



37
CH2OC2H5
Ph—
8-tert-butyl



38
CH2OC2H5
Ph—
8-OH



39
CH2OC2H5
Ph—
8-OCH3



40
CH2OC2H5
Ph—
8-O(iso-propyl)



41
CH2OC2H5
Ph—
8-SCH3



42
CH2OC2H5
Ph—
8-SOCH3



43
CH2OC2H5
Ph—
8-SO2CH3



44
CH2OC2H5
Ph—
8-SCH2CH3



45
CH2OC2H5
Ph—
8-NH2



46
CH2OC2H5
Ph—
8-NHOH



47
CH2OC2H5
Ph—
8-NHCH3



48
CH2OC2H5
Ph—
8-N(CH3)2



49
CH2OC2H5
Ph—
8-N+(CH3)3, I−



50
CH2OC2H5
Ph—
8-NHC(═O)CH3



51
CH2OC2H5
Ph—
8-N(CH2CH3)2



52
CH2OC2H5
Ph—
8-NMeCH2CO2H



53
CH2OC2H5
Ph—
8-N+(Me)2CH2CO2H, I−



54
CH2OC2H5
Ph—
8-(N)-morpholine



55
CH2OC2H5
Ph—
8-(N)-azetidine



56
CH2OC2H5
Ph—
8-(N)-N-methylazetidinium, I−



57
CH2OC2H5
Ph—
8-(N)-pyrrolidine



58
CH2OC2H5
Ph—
8-(N)-N-methyl-pyrrolidinium,






I−



59
CH2OC2H5
Ph—
8-(N)-N-methyl-morpholinium,





I−



60
CH2OC2H5
Ph—
8-(N)-N′-methylpiperazine



61
CH2OC2H5
Ph—
8-(N)-N′-dimethylpiperazinium,






I−



62
CH2OC2H5
Ph—
8-NH-CBZ



63
CH2OC2H5
Ph—
8-NHC(O)C5H11



64
CH2OC2H5
Ph—
8-NHC(O)CH2Br



65
CH2OC2H5
Ph—
8-NH—C(NH)NH2



66
CH2OC2H5
Ph—
8-(2)-thiophene



67
CH2OC2H5
Ph—
9-methyl



68
CH2OC2H5
Ph—
9-ethyl



69
CH2OC2H5
Ph—
9-iso-propyl



70
CH2OC2H5
Ph—
9-tert-butyl



71
CH2OC2H5
Ph—
9-OH



72
CH2OC2H5
Ph—
9-OCH3



73
CH2OC2H5
Ph—
9-O(iso-propyl)



74
CH2OC2H5
Ph—
9-SCH3



75
CH2OC2H5
Ph—
9-SOCH3



76
CH2OC2H5
Ph—
9-SO2CH3



77
CH2OC2H5
Ph—
9-SCH2CH3



78
CH2OC2H5
Ph—
9-NH2



79
CH2OC2H5
Ph—
9-NHOH



80
CH2OC2H5
Ph—
9-NHCH3



81
CH2OC2H5
Ph—
9-N(CH3)2



82
CH2OC2H5
Ph—
9-N+(CH3)3, I−



83
CH2OC2H5
Ph—
9-NHC(═O)CH3



84
CH2OC2H5
Ph—
9-N(CH2CH3)2



85
CH2OC2H5
Ph—
9-NMeCH2CO2H



86
CH2OC2H5
Ph—
9-N+(Me)2CH2CO2H, I−



87
CH2OC2H5
Ph—
9-(N)-morpholine



88
CH2OC2H5
Ph—
9-(N)-azetidine



89
CH2OC2H5
Ph—
9-(N)-N-methylazetidinium, I−



90
CH2OC2H5
Ph—
9-(N)-pyrrolidine



91
CH2OC2H5
Ph—
9-(N)-N-methyl-pyrrolidinium,






I−



92
CH2OC2H5
Ph—
9-(N)-N-methyl-morpholinium,






I−



93
CH2OC2H5
Ph—
9-(N)-N′-methylpiperazine



93
CH2OC2H5
Ph—
9-(N)-N′-dimethylpiperazinium,






I−



95
CH2OC2H5
Ph—
9-NH-CBZ



96
CH2OC2H5
Ph—
9-NHC(O)C5H11



97
CH2OC2H5
Ph—
9-NHC(O)CH2Br



98
CH2OC2H5
Ph—
9-NH—C(NH)NH2



99
CH2OC2H5
Ph—
9-(2)-thiophene



100
CH2OC2H5
Ph—
7-OCH3, 8-OCH3



101
CH2OC2H5
Ph—
7-SCH3, 8-OCH3



102
CH2OC2H5
Ph—
7-SCH3, 8-SCH3



103
CH2OC2H5
Ph—
6-OCH3, 7-OCH3, 8-OCH3























Prefix
Cpd#





(FFF.xxx.
yyy)
R1═R2
R5
(Rx)q



















F101.010 01
01
CH2CH(OH)C2H5
Ph—
7-methyl



02
CH2CH(OH)C2H5
Ph—
7-ethyl



03
CH2CH(OH)C2H5
Ph—
7-iso-propyl



04
CH2CH(OH)C2H5
Ph—
7-tert-butyl



05
CH2CH(OH)C2H5
Ph—
7-OH



06
CH2CH(OH)C2H5
Ph—
7-OCH3



07
CH2CH(OH)C2H5
Ph—
7-O(iso-propyl)



08
CH2CH(OH)C2H5
Ph—
7-SCH3



09
CH2CH(OH)C2H5
Ph—
7-SOCH3



10
CH2CH(OH)C2H5
Ph—
7-SO2CH3



11
CH2CH(OH)C2H5
Ph—
7-SCH2CH3



12
CH2CH(OH)C2H5
Ph—
7-NH2



13
CH2CH(OH)C2H5
Ph—
7-NHOH



14
CH2CH(OH)C2H5
Ph—
7-NHCH3



15
CH2CH(OH)C2H5
Ph—
7-N(CH3)2



16
CH2CH(OH)C2H5
Ph—
7-N+(CH3)3, I−



17
CH2CH(OH)C2H5
Ph—
7-NHC(═O)CH3



18
CH2CH(OH)C2H5
Ph—
7-N(CH2CH3)2



19
CH2CH(OH)C2H5
Ph—
7-NMeCH2CO2H



20
CH2CH(OH)C2H5
Ph—
7-N+(Me)2CH2CO2H, I−



21
CH2CH(OH)C2H5
Ph—
7-(N)-morpholine



22
CH2CH(OH)C2H5
Ph—
7-(N)-azetidine



23
CH2CH(OH)C2H5
Ph—
7-(N)-N-methylazetidinium, I−



24
CH2CH(OH)C2H5
Ph—
7-(N)-pyrrolidine



25
CH2CH(OH)C2H5
Ph—
7-(N)-N-methyl-pyrrolidinium, I−



26
CH2CH(OH)C2H5
Ph—
7-(N)-N-methyl-morpholinium, I−



27
CH2CH(OH)C2H5
Ph—
7-(N)-N′-methylpiperazine



28
CH2CH(OH)C2H5
Ph—
7-(N)-N′-dimethylpiperazinium, I−



29
CH2CH(OH)C2H5
Ph—
7-NH-CBZ



30
CH2CH(OH)C2H5
Ph—
7-NHC(O)C5H11



31
CH2CH(OH)C2H5
Ph—
7-NHC(O)CH2Br



32
CH2CH(OH)C2H5
Ph—
7-NH—C(NH)NH2



33
CH2CH(OH)C2H5
Ph—
7-(2)-thiophene



34
CH2CH(OH)C2H5
Ph—
8-methyl



35
CH2CH(OH)C2H5
Ph—
8-ethyl



36
CH2CH(OH)C2H5
Ph—
8-iso-propyl



37
CH2CH(OH)C2H5
Ph—
8-tert-butyl



38
CH2CH(OH)C2H5
Ph—
8-OH



39
CH2CH(OH)C2H5
Ph—
8-OCH3



40
CH2CH(OH)C2H5
Ph—
8-O(iso-propyl)



41
CH2CH(OH)C2H5
Ph—
8-SCH3



42
CH2CH(OH)C2H5
Ph—
8-SOCH3



43
CH2CH(OH)C2H5
Ph—
8-SO2CH3



44
CH2CH(OH)C2H5
Ph—
8-SCH2CH3



45
CH2CH(OH)C2H5
Ph—
8-NH2



46
CH2CH(OH)C2H5
Ph—
8-NHOH



47
CH2CH(OH)C2H5
Ph—
8-NHCH3



48
CH2CH(OH)C2H5
Ph—
8-N(CH3)2



49
CH2CH(OH)C2H5
Ph—
8-N+(CH3)3, I−



50
CH2CH(OH)C2H5
Ph—
8-NHC(═O)CH3



51
CH2CH(OH)C2H5
Ph—
8-N(CH2CH3)2



52
CH2CH(OH)C2H5
Ph—
8-NMeCH2CO2H



53
CH2CH(OH)C2H5
Ph—
8-N+(Me)2CH2CO2H, I−



54
CH2CH(OH)C2H5
Ph—
8-(N)-morpholine



55
CH2CH(OH)C2H5
Ph—
8-(N)-azetidine



56
CH2CH(OH)C2H5
Ph—
8-(N)-N-methylazetidinium, I−



57
CH2CH(OH)C2H5
Ph—
8-(N)-pyrrolidine



58
CH2CH(OH)C2H5
Ph—
8-(N)-N-methyl-pyrrolidinium, I−



59
CH2CH(OH)C2H5
Ph—
8-(N)-N-methyl-morpholinium, I−



60
CH2CH(OH)C2H5
Ph—
8-(N)-N′-methylpiperazine



61
CH2CH(OH)C2H5
Ph—
8-(N)-N′-dimethylpiperazinium, I−



62
CH2CH(OH)C2H5
Ph—
8-NH-CBZ



63
CH2CH(OH)C2H5
Ph—
8-NHC(O)C5H11



64
CH2CH(OH)C2H5
Ph—
8-NHC(O)CH2Br



65
CH2CH(OH)C2H5
Ph—
8-NH—C(NH)NH2



66
CH2CH(OH)C2H5
Ph—
8-(2)-thiophene



67
CH2CH(OH)C2H5
Ph—
9-methyl



68
CH2CH(OH)C2H5
Ph—
9-ethyl



69
CH2CH(OH)C2H5
Ph—
9-iso-propyl



70
CH2CH(OH)C2H5
Ph—
9-tert-butyl



71
CH2CH(OH)C2H5
Ph—
9-OH



72
CH2CH(OH)C2H5
Ph—
9-OCH3



73
CH2CH(OH)C2H5
Ph—
9-O(iso-propyl)



74
CH2CH(OH)C2H5
Ph—
9-SCH3



75
CH2CH(OH)C2H5
Ph—
9-SOCH3



76
CH2CH(OH)C2H5
Ph—
9-SO2CH3



77
CH2CH(OH)C2H5
Ph—
9-SCH2CH3



78
CH2CH(OH)C2H5
Ph—
9-NH2



79
CH2CH(OH)C2H5
Ph—
9-NHOH



80
CH2CH(OH)C2H5
Ph—
9-NHCH3



81
CH2CH(OH)C2H5
Ph—
9-N(CH3)2



82
CH2CH(OH)C2H5
Ph—
9-N+(CH3)3, I−



83
CH2CH(OH)C2H5
Ph—
9-NHC(═O)CH3



84
CH2CH(OH)C2H5
Ph—
9-N(CH2CH3)2



85
CH2CH(OH)C2H5
Ph—
9-NMeCH2CO2H



86
CH2CH(OH)C2H5
Ph—
9-N+(Me)2CH2CO2H, I−



87
CH2CH(OH)C2H5
Ph—
9-(N)-morpholine



88
CH2CH(OH)C2H5
Ph—
9-(N)-azetidine



89
CH2CH(OH)C2H5
Ph—
9-(N)-N-methylazetidinium, I−



90
CH2CH(OH)C2H5
Ph—
9-(N)-pyrrolidine



91
CH2CH(OH)C2H5
Ph—
9-(N)-N-methyl-pyrrolidinium, I−



92
CH2CH(OH)C2H5
Ph—
9-(N)-N-methyl-morpholinium, I−



93
CH2CH(OH)C2H5
Ph—
9-(N)-N′-methylpiperazine



93
CH2CH(OH)C2H5
Ph—
9-(N)-N′-dimethylpiperazinium, I−



95
CH2CH(OH)C2H5
Ph—
9-NH-CBZ



96
CH2CH(OH)C2H5
Ph—
9-NHC(O)C5H11



97
CH2CH(OH)C2H5
Ph—
9-NHC(O)CH2Br



98
CH2CH(OH)C2H5
Ph—
9-NH—C(NH)NH2



99
CH2CH(OH)C2H5
Ph—
9-(2)-thiophene



100
CH2CH(OH)C2H5
Ph—
7-OCH3, 8-OCH3



101
CH2CH(OH)C2H5
Ph—
7-SCH3, 8-OCH3



102
CH2CH(OH)C2H5
Ph—
7-SCH3, 8-SCH3



103
CH2CH(OH)C2H5
Ph—
6-OCH3, 7-OCH3, 8-OCH3























Prefix
Cpd#





(FFF.xxx.
yyy)
R1═R2
R5
(Rx)q



















F101.011
01
CH2O-(4-picoline)
Ph—
7-methyl



02
CH2O-(4-picoline)
Ph—
7-ethyl



03
CH2O-(4-picoline)
Ph—
7-iso-propyl



04
CH2O-(4-picoline)
Ph—
7-tert-butyl



05
CH2O-(4-picoline)
Ph—
7-OH



06
CH2O-(4-picoline)
Ph—
7-OCH3



07
CH2O-(4-picoline)
Ph—
7-O(iso-propyl)



08
CH2O-(4-picoline)
Ph—
7-SCH3



09
CH2O-(4-picoline)
Ph—
7-SOCH3



10
CH2O-(4-picoline)
Ph—
7-SO2CH3



11
CH2O-(4-picoline)
Ph—
7-SCH2CH3



12
CH2O-(4-picoline)
Ph—
7-NH2



13
CH2O-(4-picoline)
Ph—
7-NHOH



14
CH2O-(4-picoline)
Ph—
7-NHCH3



15
CH2O-(4-picoline)
Ph—
7-N(CH3)2



16
CH2O-(4-picoline)
Ph—
7-N+(CH3)3, I−



17
CH2O-(4-picoline)
Ph—
7-NHC(═O)CH3



18
CH2O-(4-picoline)
Ph—
7-N(CH2CH3)2



19
CH2O-(4-picoline)
Ph—
7-NMeCH2CO2H



20
CH2O-(4-picoline)
Ph—
7-N+(Me)2CH2CO2H, I−



21
CH2O-(4-picoline)
Ph—
7-(N)-morpholine



22
CH2O-(4-picoline)
Ph—
7-(N)-azetidine



23
CH2O-(4-picoline)
Ph—
7-(N)-N-methylazetidinium, I−



24
CH2O-(4-picoline)
Ph—
7-(N)-pyrrolidine



25
CH2O-(4-picoline)
Ph—
7-(N)-N-methyl-pyrrolidinium, I−



26
CH2O-(4-picoline)
Ph—
7-(N)-N-methyl-morpholinium, I−



27
CH2O-(4-picoline)
Ph—
7-(N)-N′-methylpiperazine



28
CH2O-(4-picoline)
Ph—
7-(N)-N′-dimethylpiperazinium, I−



29
CH2O-(4-picoline)
Ph—
7-NH-CBZ



30
CH2O-(4-picoline)
Ph—
7-NHC(O)C5H11



31
CH2O-(4-picoline)
Ph—
7-NHC(O)CH2Br



32
CH2O-(4-picoline)
Ph—
7-NH—C(NH)NH2



33
CH2O-(4-picoline)
Ph—
7-(2)-thiophene



34
CH2O-(4-picoline)
Ph—
8-methyl



35
CH2O-(4-picoline)
Ph—
8-ethyl



36
CH2O-(4-picoline)
Ph—
8-iso-propyl



37
CH2O-(4-picoline)
Ph—
8-tert-butyl



38
CH2O-(4-picoline)
Ph—
8-OH



39
CH2O-(4-picoline)
Ph—
8-OCH3



40
CH2O-(4-picoline)
Ph—
8-O(iso-propyl)



41
CH2O-(4-picoline)
Ph—
8-SCH3



42
CH2O-(4-picoline)
Ph—
8-SOCH3



43
CH2O-(4-picoline)
Ph—
8-SO2CH3



44
CH2O-(4-picoline)
Ph—
8-SCH2CH3



45
CH2O-(4-picoline)
Ph—
8-NH2



46
CH2O-(4-picoline)
Ph—
8-NHOH



47
CH2O-(4-picoline)
Ph—
8-NHCH3



48
CH2O-(4-picoline)
Ph—
8-N(CH3)2



49
CH2O-(4-picoline)
Ph—
8-N+(CH3)3, I−



50
CH2O-(4-picoline)
Ph—
8-NHC(═O)CH3



51
CH2O-(4-picoline)
Ph—
8-N(CH2CH3)2



52
CH2O-(4-picoline)
Ph—
8-NMeCH2CO2H



53
CH2O-(4-picoline)
Ph—
8-N+(Me)2CH2CO2H, I−



54
CH2O-(4-picoline)
Ph—
8-(N)-morpholine



55
CH2O-(4-picoline)
Ph—
8-(N)-azetidine



56
CH2O-(4-picoline)
Ph—
8-(N)-N-methylazetidinium, I−



57
CH2O-(4-picoline)
Ph—
8-(N)-pyrrolidine



58
CH2O-(4-picoline)
Ph—
8-(N)-N-methyl-pyrrolidinium, I−



59
CH2O-(4-picoline)
Ph—
8-(N)-N-methyl-morpholinium, I−



60
CH2O-(4-picoline)
Ph—
8-(N)-N′-methylpiperazine



61
CH2O-(4-picoline)
Ph—
8-(N)-N′-dimethylpiperazinium, I−



62
CH2O-(4-picoline)
Ph—
8-NH-CBZ



63
CH2O-(4-picoline)
Ph—
8-NHC(O)C5H11



64
CH2O-(4-picoline)
Ph—
8-NHC(O)CH2Br



65
CH2O-(4-picoline)
Ph—
8-NH—C(NH)NH2



66
CH2O-(4-picoline)
Ph—
8-(2)-thiophene



67
CH2O-(4-picoline)
Ph—
9-methyl



68
CH2O-(4-picoline)
Ph—
9-ethyl



69
CH2O-(4-picoline)
Ph—
9-iso-propyl



70
CH2O-(4-picoline)
Ph—
9-tert-butyl



71
CH2O-(4-picoline)
Ph—
9-OH



72
CH2O-(4-picoline)
Ph—
9-OCH3



73
CH2O-(4-picoline)
Ph—
9-O(iso-propyl)



74
CH2O-(4-picoline)
Ph—
9-SCH3



75
CH2O-(4-picoline)
Ph—
9-SOCH3



76
CH2O-(4-picoline)
Ph—
9-SO2CH3



77
CH2O-(4-picoline)
Ph—
9-SCH2CH3



78
CH2O-(4-picoline)
Ph—
9-NH2



79
CH2O-(4-picoline)
Ph—
9-NHOH



80
CH2O-(4-picoline)
Ph—
9-NHCH3



81
CH2O-(4-picoline)
Ph—
9-N(CH3)2



82
CH2O-(4-picoline)
Ph—
9-N+(CH3)3, I−



83
CH2O-(4-picoline)
Ph—
9-NHC(═O)CH3



84
CH2O-(4-picoline)
Ph—
9-N(CH2CH3)2



85
CH2O-(4-picoline)
Ph—
9-NMeCH2CO2H



86
CH2O-(4-picoline)
Ph—
9-N+(Me)2CH2CO2H, I−



87
CH2O-(4-picoline)
Ph—
9-(N)-morpholine



88
CH2O-(4-picoline)
Ph—
9-(N)-azetidine



89
CH2O-(4-picoline)
Ph—
9-(N)-N-methylazetidinium, I−



90
CH2O-(4-picoline)
Ph—
9-(N)-pyrrolidine



91
CH2O-(4-picoline)
Ph—
9-(N)-N-methyl-pyrrolidinium, I−



92
CH2O-(4-picoline)
Ph—
9-(N)-N-methyl-morpholinium, I−



93
CH2O-(4-picoline)
Ph—
9-(N)-N′-methylpiperazine



94
CH2O-(4-picoline)
Ph—
9-(N)-N′-dimethylpiperazinium, I−



95
CH2O-(4-picoline)
Ph—
9-NH-CBZ



96
CH2O-(4-picoline)
Ph—
9-NHC(O)C5H11



97
CH2O-(4-picoline)
Ph—
9-NHC(O)CH2Br



98
CH2O-(4-picoline)
Ph—
9-NH-C(NH)NH2



99
CH2O-(4-picoline)
Ph—
9-(2)-thiophene



100
CH2O-(4-picoline)
Ph—
7-OCH3, 8-OCH3



101
CH2O-(4-picoline)
Ph—
7-SCH3, 8-OCH3



102
CH2O-(4-picoline)
Ph—
7-SCH3, 8-SCH3



103
CH2O-(4-picoline)
Ph—
6-OCH3, 7-OCH3, 8-OCH3



















Additional Structures of the Present Invention





















Compound









Number
R1
R2
R3
R4
R5
R6
(Rx)q

















101
ethyl
n-butyl
OH
H
phenyl
H














at the 7-position


102
ethyl
n-butyl
OH
H
phenyl
H
7-trimethylammonium iodide


103
n-butyl
ethyl
OH
H
phenyl
H
7-trimethylammonium iodide


104
ethyl
n-butyl
OH
H
phenyl
H
7-dimethylamino


105
ethyl
n-butyl
OH
H
phenyl
H
7-methanesulfonamido


106
ethyl
n-butyl
OH
H
phenyl
H
7-(2′-bromoacetamido)


107
n-butyl
ethyl
OH
H
4-(decyloxy)phenyl
H
7-amino


108
ethyl
n-butyl
OH
H
phenyl
H
7-(hexylamido)


109
ethyl
n-butyl
OH
H
4-(decyloxy)phenyl
H
7-amino


110
ethyl
n-butyl
OH
H
phenyl
H
7-acetamido


111
n-butyl
ethyl
OH
H
4-hydroxyphenyl
H
7-amino


112
ethyl
n-butyl
OH
H





H
7-amino


113
ethyl
n-butyl
OH
H
4-hydroxyphenyl
H
7-amino


114
ethyl
n-butyl
OH
H
4-methoxyphenyl
H
7-amino


115
n-butyl
ethyl
OH
H
4-methoxyphenyl
H
7-(O-benzylcarbamato)


116
ethyl
n-butyl
OH
H
4-methoxyphenyl
H
7-(O-benzylcarbamato)


117
n-butyl
ethyl
OH
H
phenyl
H
7-(O-benzylcarbamato)


118
ethyl
n-butyl
OH
H
phenyl
H
7-(O-benzylcarbamato)


119
ethyl
n-butyl
OH
H
phenyl
H
7-(O-tert-butylcarbamato)


120
n-butyl
ethyl
OH
H
phenyl
H
7-(O-benzylcarbamato)


121
ethyl
n-butyl
OH
H
phenyl
H
7-amino


122
n-butyl
ethyl
OH
H
phenyl
H
7-amino


123
ethyl
n-butyl
OH
H
phenyl
H
7-hexylamino


124
n-butyl
ethyl
OH
H
phenyl
H
7-(hexylamino)


125
ethyl
n-butyl
OH
H
phenyl
H














at the 8-position


126
n-butyl
ethyl
OH
H
4-fluorophenyl
H
7-(O-benzylcarbamato)


127
n-butyl
ethyl
OH
H
4-fluorophenyl
H
7-amino


128
ethyl
n-butyl
OH
H
4-fluorophenyl
H
7-(O-benzylcarbamato)


129
ethyl
n-butyl
OH
H
4-fluorophenyl
H
7-amino


131
ethyl
n-butyl
OH
H
4-fluorophenyl
H














at the 7-position


132
ethyl
n-butyl
OH
H
phenyl
H














at the 8-position


133
ethyl
n-butyl
OH
H
phenyl
H
8-(hexyloxy)


134
ethyl
n-butyl
OH
H
phenyl
H














at the 8-position


135
ethyl
n-butyl
OH
H
phenyl
H














at the 8-position


136
ethyl
n-butyl
OH
H
phenyl
H
8-hydroxy


137
n-butyl
ethyl
OH
H
phenyl
H














at the 7-position


138
n-butyl
ethyl
OH
H
phenyl
H
8-acetoxy


139
n-butyl
ethyl
OH
H
phenyl
H














at the 7-position


142
ethyl
n-butyl
H
OH
H
3-methoxy-
7-methylmercapto








phenyl


143
ethyl
n-butyl
OH
H
3-methoxyphenyl
H
7-methylmercapto


144
ethyl
n-butyl
OH
H
4-fluorophenyl
H
7-(N-azetidinyl)


262
ethyl
n-butyl
OH
H
3-methoxyphenyl
H
7-methoxy


263
ethyl
n-butyl
H
OH
H
3-methoxy-
7-methoxy








phenyl


264
ethyl
n-butyl
OH
H
3-trifluoromethylphenyl
H
7-methoxy


265
ethyl
n-butyl
H
OH
H
3-trifluoro-
7-methoxy








methyl-








phenyl


266
ethyl
n-butyl
OH
H
3-hydroxyphenyl
H
7-hydroxy


267
ethyl
n-butyl
OH
H
3-hydroxyphenyl
H
7-methoxy


268
ethyl
n-butyl
OH
H
4-fluorophenyl
H
7-methoxy


269
ethyl
n-butyl
H
OH
H
4-fluoro-
7-methoxy








phenyl


270
ethyl
n-butyl
OH
H
4-fluorophenyl
H
7-hydroxy


271
ethyl
n-butyl
OH
H
3-methoxyphenyl
H
7-bromo


272
ethyl
n-butyl
H
OH
H
3-methoxy-
7-bromo








phenyl


273
ethyl
n-butyl
H
OH
H
4-fluoro-
7-fluoro








phenyl


274
ethyl
n-butyl
OH
H
4-fluorophenyl
H
7-fluoro


275
ethyl
n-butyl
H
OH
H
3-methoxy-
7-fluoro








phenyl


276
ethyl
n-butyl
OH
H
3-methoxyphenyl
H
7-flluoro


277
ethyl
n-butyl
OH
H
3-fluorophenyl
H
7-methoxy


278
ethyl
n-butyl
H
OH
2-fluorophenyl
H
7-methoxy


279
ethyl
n-butyl
H
OH
3-fluorophenyl
H
7-methoxy


280
ethyl
n-butyl
OH
H
2-fluorophenyl
H
7-methoxy


281
ethyl
n-butyl
OH
H
4-fluorophenyl
H
7-methylmercapto


282
ethyl
n-butyl
OH
H
4-fluorophenyl
H
7-methyl


283
ethyl
n-butyl
H
OH
H
4-fluoro-
7-methyl








phenyl


284
ethyl
n-butyl
OH
H
4-fluorophenyl
H
7-(4′-morpholino)


285




MISSING


286
ethyl
ethyl
OH
H
phenyl
H
7-(O-benzylcarbamato)


287
ethyl
ethyl
OH
H
phenyl
H
7-amino


288
methyl
methyl
OH
H
phenyl
H
7-amino


289
n-butyl
n-butyl
OH
H
phenyl
H
7-amino


290
n-butyl
n-butyl
OH
H
phenyl
H
7-amino


291
n-butyl
n-butyl
OH
H
phenyl
H
7-(O-benzylcarbamato)


292
n-butyl
n-butyl
OH
H
4-fluorophenyl
H
7-amino


293
n-butyl
n-butyl
OH
H
phenyl
H
7-benzylamino


294
n-butyl
n-butyl
OH
H
phenyl
H
7-dimethylamino


295
ethyl
n-butyl
OH
H





H
7-amino


296
ethyl
n-butyl
OH
H





H
7-amino


1000
ethyl
n-butyl
OH
H





H
7-dimethylamino


1001
ethyl
n-butyl
OH
H





H
7-dimethylamino


1002
ethyl
n-butyl
OH
H





H
7-dimethylamino


1003
ethyl
n-butyl
OH
H





H
7-dimethylamino


1004
ethyl
n-butyl
OH
H





H
7-dimethylamino


1005
ethyl
n-butyl
OH
H





H
7-dimethylamino


1006
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1007
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1008
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1009
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1010
n-butyl
n-butyl
OH
H
3-fluoro-4-methoxyphenyl
H
7-dimethylamino


1011
n-butyl
n-butyl
OH
H
3-fluoro-4-(5-triethylammoniumpentyloxy)
H
7-dimethylamino







phenyl, trifluoroacetate salt


1012
n-butyl
n-butyl
OH
H
4-hydroxyphenyl
H
7-dimethylamino;









9-methoxy


1013
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1014
n-butyl
n-butyl
OH
H
4-methoxyphenyl
H
7-dimethylamino;









9-methoxy


1015
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1016
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1017
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1018
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1019
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1020
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1021
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1022
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1023
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1024
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1025
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1026
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1027
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1028
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1029
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1030
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1031
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1032
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1033
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1034
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1035
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1036
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1037
n-butyl
n-butyl
OH
H
4-hydroxyphenyl
H
7-dimethylamino


1038
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1039
n-butyl
n-butyl
OH
H
phenyl
H
7-dimethylamino


1040
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1041
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1042
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1043
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1044
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1045
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1046
n-butyl
n-butyl
OH
H
3-aminophenyl
H
7-dimethylamino


1047
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1048
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1049
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1050
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1051
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1052
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1053
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1054
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1055
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1056
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1057
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1058
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1059
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1060
ethyl
n-butyl
OH
H
3-fluoro-4-methoxyphenyl
H
7-methylamino


1061
n-butyl
n-butyl
OH
H





H
7-methylamino


1062
n-butyl
n-butyl
OH
H





H
7-methylamino


1063
n-butyl
n-butyl
OH
H





H
7-methylamino


1064
n-butyl
n-butyl
OH
H





H
7-methylamino


1065
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1066
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1067
n-butyl
n-butyl
OH
H
thiophen-3-yl
H
9-dimethylamino


1068
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1069
n-butyl
n-butyl
OH
H
phenyl
H
7-dimethylamino;









9-dimethylamino


1070
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1071
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1072
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1073
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1074
ethyl
n-butyl
OH
H
3-fluoro-4-methoxyphenyl
H
7-dimethylamino


1075
n-butyl
n-butyl
OH
H
4-fluorophenyl
H
7-dimethylamino;









9-dimethylamino


1076
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1077
n-butyl
n-butyl
OH
H
3-hydroxymethylphenyl
H
7-dimethylamino


1078
ethyl
n-butyl
OH
H
4-hydroxyphenyl
H
7-dimethylamino


1079
ethyl
n-butyl
OH
H





H
7-dimethylamino


1080
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1081
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1082
n-butyl
n-butyl
OH
H
2-pyridyl
H
7-dimethylamino


1083
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1084
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1085
n-butyl
n-butyl
OH
H
thiophen-3-yl
H
7-dimethylamino


1086
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1087
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1088
ethyl
n-butyl
OH
H
3,4-methylenedioxyphenyl
H
7-dimethylamino


1089
ethyl
n-butyl
OH
H
4-methoxyphenyl
H
7-dimethylamino


1090
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1091
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1092
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1093
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1094
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1095
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1096
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1097
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1098
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1099
ethyl
n-butyl
OH
H
4-methoxyphenyl
H
7-dimethylamino


1100
n-butyl
n-butyl
OH
H
4-methoxyphenyl
H
7-dimethylamino


1101
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1102
n-butyl
n-butyl
OH
H
3-carboxymethylphenyl
H
7-dimethylamino


1103
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1104
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1105
n-butyl
n-butyl
OH
H
5-piperonyl
H
7-dimethylamino


1106
n-butyl
n-butyl
OH
H
3-hydroxyphenyl
H
7-dimethylamino


1107
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1108
n-butyl
n-butyl
OH
H
3-pyridyl
H
7-dimethylamino


1109
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1110
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1111
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1112
n-butyl
n-butyl
OH
H
4-pyridyl
H
7-dimethylamino


1113
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1114
n-butyl
n-butyl
OH
H
3-methoxyphenyl
H
7-methylamino


1115
n-butyl
n-butyl
OH
H
4-fluorophenyl
H
7-dimethylamino


1116
ethyl
n-butyl
OH
H
3-tolyl
H
7-dimethylamino


1117
ethyl
n-butyl
OH
H





H
7-dimethylamino


1118
ethyl
n-butyl
OH
H
3-fluoro-4-hydroxyphenyl
H
7-dimethylamino


1119
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1120
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1121
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1122
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1123
n-butyl
n-butyl
OH
H
phenyl
H
7-dimethylamino


1124
n-butyl
n-butyl
OH
H
3-methoxyphenyl
H
7-dimethylamino


1125
n-butyl
n-butyl
OH
H
3-chloro-4-methoxyphenyl
H
7-dimethylamino


1126
ethyl
n-butyl
OH
H





H
7-dimethylamino


1127
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1128
n-butyl
n-butyl
OH
H
3-fluoro-4-hydroxyphenyl
H
7-dimethylamino


1129
n-butyl
n-butyl
OH
H
4-fluorophenyl
H
7-dimethylamino


1130
n-butyl
n-butyl
OH
H
3-chloro-4-fluorophenyl
H
7-dimethylamino


1131
ethyl
n-butyl
OH
H
4-methoxyphenyl
H
7-dimethylamino


1132
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1133
n-butyl
n-butyl
OH
H
4-cyanomethylphenyl
H
7-dimethylamino


1134
ethyl
n-butyl
OH
H





H
7-dimethylamino


1135
n-butyl
n-butyl
OH
H
3,4-dimethoxyphenyl
H
7-dimethylamino


1136
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1137
n-butyl
n-butyl
OH
H
4-fluorophenyl
H
9-(2′,2′-dimethylhydrazino)


1138
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1139
n-butyl
n-butyl
OH
H
3,4-difluorophenyl
H
7-dimethylamino


1140
n-butyl
n-butyl
OH
H
3-methoxyphenyl
H
7-(2′,2′-dimethylhydrazino)


1141
n-butyl
n-butyl
OH
H
4-fluorophenyl
H
7-ethylmethylamino


1142
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1143
n-butyl
n-butyl
H
OH
H
3-fluoro-4-
7-dimethylamino








methoxy-








phenyl


1144
n-butyl
n-butyl
OH
H
5-piperonyl
H
7-dimethylamino


1145
n-butyl
n-butyl
OH
H
4-methoxyphenyl
H
9-dimethylamino


1146
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1147
n-butyl
n-butyl
OH
H
3-methoxyphenyl
H
7-diethylamino


1148
n-butyl
n-butyl
OH
H
4-fluorophenyl
H
7-dimethylsulfonium, fluoride salt


1149
n-butyl
n-butyl
OH
H
4-fluorophenyl
H
7-ethylamino


1150
n-butyl
n-butyl
OH
H
3-methoxyphenyl
H
7-ethylmethylamino


1151
n-butyl
ethyl
OH
H
3-fluoro-4-methoxyphenyl
H
7-dimethylamino


1152
n-butyl
n-butyl
OH
H
phenyl
H
7-(ethoxymethyl) methylamino


1153
n-butyl
n-butyl
OH
H
4-fluorophenyl
H
7-methylamino


1154
n-butyl
n-butyl
OH
H
3-methoxyphenyl
H
9-methoxy


1155
n-butyl
n-butyl
OH
H
4-fluorophenyl
H
7-methyl


1156
n-butyl
n-butyl
OH
H
4-fluorophenyl
H
7-methylmercapto


1157
n-butyl
n-butyl
OH
H
4-fluorophenyl
H
7-fluoro;









9-dimethylamino


1158
n-butyl
n-butyl
OH
H
4-pyridinyl, hydrochloride salt
H
7-methoxy


1159
n-butyl
ethyl
OH
H
phenyl
H
7-dimethylamino


1160
n-butyl
n-butyl
OH
H
4-fluorophenyl
H
7-diethylamino


1161
n-butyl
n-butyl
OH
H
3,5-dichloro-4-methoxyphenyl
H
7-dimethylamino


1162
n-butyl
n-butyl
OH
H
phenyl
H
7-dimethylamino


1163
n-butyl
n-butyl
OH
H
3-(dimethylamino)phenyl
H
7-methoxy


1164
n-butyl
n-butyl
OH
H
4-pyridinyl
H
7-methoxy


1165
n-butyl
n-butyl
OH
H
3-fluoro-4-methoxyphenyl
H
7-trimethylammonium iodide


1166
n-butyl
n-butyl
OH
H
3-hydroxyphenyl
H
7-trimethylammonium iodide


1167
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1168
n-butyl
n-butyl
OH
H
4-hydroxyphenyl
H
7-trimethylammonium iodide


1169
n-butyl
n-butyl
OH
H
phenyl
H
8-dimethylamino


1170
n-butyl
n-butyl
OH
H
3-methoxyphenyl
H
7-ethylpropylamino


1171
n-butyl
n-butyl
OH
H
4-(trifluoromethylsulfonyloxy)phenyl
H
7-dimethylamino


1172
n-butyl
n-butyl
OH
H
4-pyridinyl
H
7-methoxy


1173
n-butyl
n-butyl
OH
H
4-fluorophenyl
H
7-ethylpropylamino


1174
ethyl
n-butyl
OH
H
3-methoxyphenyl
H
7-phenyl


1175
ethyl
n-butyl
OH
H
3-methoxyphenyl
H
7-methylsulfonyl


1176
n-butyl
n-butyl
OH
H
4-fluorophenyl
H
9-fluoro


1177
n-butyl
n-butyl
OH
H
3-methoxyphenyl
H
7-butylmethylamino


1178
n-butyl
n-butyl
OH
H
3-(trifluoromethylsulfonyloxy)phenyl
H
7-dimethylamino


1179
n-butyl
n-butyl
OH
H
phenyl
H
8-methoxy


1180
n-butyl
n-butyl
OH
H
phenyl
H
7-trimethylammonium iodide


1181
n-butyl
n-butyl
OH
H
4-fluorophenyl
H
7-butylmethylamino


1182
n-butyl
n-butyl
OH
H
4-(dimethylamino)phenyl
H
7-methoxy


1183
n-butyl
n-butyl
OH
H
3-methoxphenyl
H
7-fluoro


1184
n-butyl
n-butyl
OH
H
4-fluorophenyl
H
7-fluoro;









9-fluoro


1185
n-butyl
n-butyl
OH
H
4-fluorophenyl
H
7-fluoro


1186
n-butyl
n-butyl
OH
H
phenyl
H
7-fluoro;









9-fluoro


1187
n-butyl
n-butyl
OH
H
4-fluorophenyl
H
7-methyl


1188
n-butyl
n-butyl
OH
H
4-methoxyphenyl
H
7-trimethylammonium iodide


1189
n-butyl
n-butyl
OH
H
3,4-difluorophenyl
H
7-trimethylammonium iodide


1190
n-butyl
n-butyl
OH
H
2-bromophenyl
H
7-bromo


1191
n-butyl
n-butyl
OH
H
4-(dimethylamino)phenyl
H
7-hydroxy


1192
n-butyl
n-butyl
OH
H
3-(dimethylamino)phenyl
H
7-hydroxy


1193
n-butyl
n-butyl
OH
H
4-(2-(2-methylpropyl)phenyl
H
7-dimethylamino


1194
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1195
n-butyl
n-butyl
OH
H
4-methoxyphenyl
H
7-(4′-methylpiperazin-1-yl)


1196
n-butyl
n-butyl
OH
H





H
7-methoxy


1197
n-butyl
ethyl
R3 +
R3 +
phenyl
H
7-(N-methylformamido)





R4 =
R4 =





oxo
oxo


1198
n-butyl
n-butyl
OH
H
4-(pyridinyl-N-oxide)
H
7-methoxy


1199
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1200
n-butyl
n-butyl
H
OH
H
phenyl
7-dimethylamino


1201
n-butyl
n-butyl
OH
H
H
H
7-methyl


1202
n-butyl
n-butyl
OH
H





H
7-methoxy


1203
n-butyl
n-butyl
OH
H
5-piperazinyl
H
7-(4′-tert-butylphenyl)


1204
n-butyl
n-butyl
OH
H
4-fluorophenyl
H
7-methoxy


1205
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1206
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1207
n-butyl
n-butyl
OH
H
3,5-dichlorophenyl
H
7-dimethylamino


1208
n-butyl
n-butyl
OH
H
4-methoxyphenyl
H
7-dimethylamino


1209
n-butyl
n-butyl
acetoxy
H
phenyl
H
7-dimethylphenyl


1210
n-butyl
n-butyl
OH
H
2-(dimethylamino)phenyl
H
7-dimethylamino


1211
ethyl
n-butyl
OH
H





H
7-dimethylamino


1212
n-butyl
n-butyl
OH
H
4-methoxyphenyl
H
9-(4′-morpholino)


1213
n-butyl
ethyl
H
OH
H
3-fluoro-4-
7-dimethylamino








methoxy-








phenyl


1214
n-butyl
ethyl
OH
H
phenyl
H
7-(N-methylformamido)


1215
n-butyl
n-butyl
OH
H
4-methoxyphenyl
H
9-methylmercapto


1216
ethyl
n-butyl
OH
H
5-piperonyl
H
7-bromo


1217
n-butyl
n-butyl
OH
H
4-carboxyphenyl
H
7-dimethylamino


1218
n-butyl
n-butyl
OH
H
4-methoxyphenyl
H
9-methylsulfonyl


1219
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1220
n-butyl
n-butyl
OH
H
3-methoxyphenyl
H
7-isopropylamino


1221
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1222
n-butyl
n-butyl
OH
H
3-methoxphenyl
H
7-ethylamino


1223
n-butyl
n-butyl
OH
H
phenyl
H
8-bromo;









7-methylamino


1224
n-butyl
n-butyl
OH
H
3-nitrophenyl
H
7-fluoro


1225
n-butyl
ethyl
OH
H
3-methylphenyl
H
7-dimethylamino


1226
ethyl
n-butyl
OH
H
5-piperonyl
H
7-bromo


1227
n-butyl
n-butyl
OH
H
4-fluorophenyl
H
7-(tert-butylamino


1228
n-butyl
n-butyl
OH
H
2-pyrrolyl
H
8-bromo;









7-dimethylamino


1229
n-butyl
n-butyl
OH
H
3-chloro-4-hydroxyphenyl
H
7-dimethylamino


1230
n-butyl
n-butyl
OH
H
phenyl
H
9-dimethylamino;









7-fluoro


1231
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1232
n-butyl
n-butyl
H
OH
3-thiophenyl
H
9-dimethylamino


1233
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1234
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1235
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1236
n-butyl
n-butyl
OH
H
4-(bromomethyl)phenyl
H
7-dimethylamino


1237
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1238
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1239
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1240
n-butyl
n-butyl
OH
H
4-methoxy-3-methylphenyl
H
7-dimethylamino


1241
n-butyl
n-butyl
OH
H
3-(dimethylaminomethyl)phenyl
H
7-dimethylamino


1242
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1243
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1244
n-butyl
n-butyl
OH
H
3-methoxyphenyl
H
7-(1′-methylhydrazido


1245
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1246
n-butyl
n-butyl
OH
H
3-(bromomethyl)phenyl
H
7-dimethylamino


1247
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1248
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1249
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1250
n-butyl
n-butyl
OH
H
3-(dimethylamino)phenyl
H
7-dimethylamino


1251
n-butyl
n-butyl
OH
H
1-naphthyl
H
7-dimethylamino


1252
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1253
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1254
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1255
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1256
n-butyl
n-butyl
OH
H
3-nitrophenyl
H
7-dimethylamino


1257
n-butyl
n-butyl
OH
H
phenyl
H
8-bromo;









7-dimethylamino


1258
n-butyl
n-butyl
OH
H
4-fluorophenyl
H
9-(tert-butylamino)


1259
ethyl
n-butyl
H
OH
H
phenyl
7-dimethylamino


1260
ethyl
n-butyl
OH
H
3-hydroxyphenyl
H
7-dimethylamino


1261
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1262
n-butyl
n-butyl
OH
H
2-thiophenyl
H
7-dimethylamino


1263
n-butyl
n-butyl
OH
H
5-piperonyl
H
7-bromo


1264
n-butyl
n-butyl
OH
H
4-fluorophenyl
H
7-isopropylamino


1265
n-butyl
n-butyl
OH
H
4-fluorophenyl
H
9-isopropylamino


1266
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1267
n-butyl
ethyl
OH
H
5-piperonyl
H
7-carboxy, methyl ester


1268
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1269
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1270
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1271
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1272
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1273
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1274
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1275
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1276
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1277
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1278
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1279
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1280
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1281
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1282
ethyl
n-butyl
OH
H
3-fluoro-4-methoxyphenyl
H
7-trimethylammonium iodide


1283
n-butyl
n-butyl
OH
H
4-hydroxymethylphenyl
H
7-dimethylamino


1284
n-butyl
n-butyl
OH
H
4-fluorophenyl
H
9-ethylamino


1285
n-butyl
ethyl
OH
H
phenyl
H
7-dimethylamino


1286
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1287
n-butyl
ethyl
OH
H
4-hydroxyphenyl
H
7-dimethylamino


1288
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1289
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1290
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1291
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1292
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1293
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1294
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1295
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1296
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1297
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1298
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1299
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1300
n-butyl
ethyl
H
OH
H
phenyl
7-dimethylamino


1301
n-butyl
n-butyl
OH
H
3-methoxyphenyl
H
7-trimethylammonium iodide


1302
n-butyl
n-butyl
OH
H
3-hydroxyphenyl
H
9-hydroxy


1303
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1304
n-butyl
n-butyl
OH
H
3-methoxyphenyl
H
7-tert-butylamino


1305
n-butyl
n-butyl
OH
H
4-fluorophenyl
H
9-methylamino


1306
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1307
n-butyl
n-butyl
OH
H
H
4-methoxy-
9-(4′-morpholino)








phenyl


1308
ethyl
n-butyl
OH
H





H
7-dimethylamino


1309
n-butyl
n-butyl
OH
H
4-methoxyphenyl
H
9-fluoro


1310
ethyl
n-butyl
OH
H
phenyl
H
7-amino


1311
n-butyl
ethyl
OH
H
phenyl
H
7-(hydroxylamino)


1312
n-butyl
ethyl
OH
H
phenyl
H
8-hexyloxy


1313
n-butyl
ethyl
OH
H
phenyl
H
8-ethoxy


1314
ethyl
n-butyl
OH
H
phenyl
H
7-(hydroxylamino)


1315
ethyl
n-butyl
OH
H
phenyl
H
7-(hexyloxy)


1316
n-butyl
ethyl
OH
H
phenyl
H
8-hydroxy


1317
n-butyl
ethyl
OH
H
phenyl
H














at the 8-position


1318
ethyl
n-butyl
OH
H
phenyl
H
7-dimethylamino


1319
ethyl
n-butyl
OH
H
3-methoxyphenyl
H
7-fluoro


1320
ethyl
n-butyl
OH
H
phenyl
H
7-amino


1321
n-butyl
ethyl
OH
H
phenyl
H














at the 8-position


1322
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1323
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1324
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1325
n-butyl
n-butyl
OH
H
4-((diethylamino)methyl)phenyl
H
7-dimethylamino


1326
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1327
n-butyl
n-butyl
OH
H
3-fluoro-4-hydroxy-5-iodophenyl
H
7-dimethylamino


1328
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1329
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1330
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1331
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1332
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1333
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1334
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1335
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1336
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1337
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1338
n-butyl
n-butyl
OH
H
4-methoxyphenyl
H
7-(4′-methylpiperazinyl)


1339
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1340
n-butyl
ethyl
OH
H
5-piperonyl
H
7-methyl


1341
n-butyl
n-butyl
acetoxy
H
3-methoxyphenyl
H
7-dimethylamino


1342
n-butyl
n-butyl
OH
H
5-piperonyl
H
7-(4′-fluorophenyl)


1343
ethyl
n-butyl
OH
H
phenyl
H
7-amino


1344
n-butyl
n-butyl
OH
H
3-fluoro-4-methoxyphenyl
H
7-dimethylamino


1345
ethyl
n-butyl
OH
H
phenyl
H
7-trimethylammonium iodide


1346
ethyl
n-butyl
OH
H
phenyl
H














at the 8-position


1347
n-butyl
n-butyl
OH
H
3-fluoro-4-methoxyphenyl
H
7-dimethylamino


1348
isobutyl
isobutyl
OH
H
phenyl
H
7-dimethylamino


1349
ethyl
n-butyl
OH
H
phenyl
H
7-dimethylamino


1350
n-butyl
n-butyl
OH
H
3-fluoro-4-methoxyphenyl
H
7-trimethylammonium iodide


1351
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1352
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1353
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1354
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1355
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1356
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1357
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1358
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1359
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1360
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1361
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1362
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1363
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1364
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1365
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1366
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1367
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1368
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1369
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1370
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1371
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1372
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1373
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1374
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1375
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1376
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1377
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1378
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1379
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1380
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1381
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1382
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1383
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1384
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1385
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1386
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1387
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1388
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1389
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1390
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1391
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1392
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1393
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1394
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1395
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1396
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1397
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1398
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1399
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1400
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1401
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1402
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1403
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1404
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1405
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1406
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1407
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1408
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1409
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1410
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1411
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1412
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1413
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1414
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1415
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1416
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1417
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1418
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1419
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1420
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1421
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1422
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1423
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1424
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1425
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1426
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1427
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1428
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1429
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1430
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1431
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1432
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1433
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1434
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1435
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1436
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1437
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1438
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1439
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1440
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1441
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1442
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1443
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1444
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1445
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1446
n-butyl
n-butyl
OH
H





H
7-methoxy; 8-methoxy


1447
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1448
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1449
n-butyl
n-butyl
OH
H





H
7-dimethylamino


1450
n-butyl
n-butyl
OH
H
phenyl
H
7-dimethylamino


1451
n-butyl
n-butyl
OH
H





H
7-dimethylamino
































In further compounds of the present invention, R5 and R6 are independently selected from among hydrogen and ring-carbon substituted or unsubscituted aryl, thiophene, pyridine, pyrrole, thiazole, imidazole, pyrazole, pyrimidine, morpholine, N-alkylpyridinium, N-alkyl-piperazinium, N-alkylmorpholinium, or furan in which the substituent(s) are selected from among halo, hydroxyl, trihaloalkyl, alkoxy, amino, N-alkyl amino, N,N-dialkylamino, quaternary ammonium salts, a C1 to C4 alkylene bridge having a quaternary ammonium salt substituted thereon, alkoxycarbonyl, aryloxycarbonyl, alkylcarbonyloxy and arylcarbonyloxy, (O,O)-dioxyalkylene, [O(CH2)w]xX where x is 2 to 12, w is 2 or 3 and X comprises halo or a quaternary ammonium salt, thiophene, pyricine, pyrrole, thiazole, imidazole, pyrazole, or furan. The aryl group of R5 or R6 is preferably phenyl, phenylene, or benzene triyl, i.e., may be unsubstituted, mono-substituted, or di-substituted. Among the species which may constitute the substituents on the aryl ring of R5 or R6 are fluoro, chloro, bromo, methoxy, ethoxy, isopropoxy, trimethylammonium (preferably with an iodide or chloride counterion), methoxycarbonyl, ethoxycarbonyl, formyl, acetyl, propanoyl, (N)-hexyldimethylammonium, hexylenetrimethylammonium, tri(oxyethylene)iodide, and tetra(oxyethylene)trimethylammonium iodide, each substituted at the p-position, the m-position, or both of the aryl ring. Other substituents that can be present on a phenylene, benzene tryl or other aromatic ring include 3,4-dioxmethylene (5-membered ring) and 3,4-dioxyethylene (6-membered ring). Among compounds which have been or can be demonstrated to have desirable ileal bile acid transport inhibiting properties are those in which R5 or R6 is selected from phenyl, p-fluorophenyl, m-fluorophenyl, p-hydroxyphenyl, m-hydroxyphenyl, p-methoxyphenyl, m-methoxyphenyl, p-N,N-dimethylaminophenyl, m-N,N-dimethylaminophenyl, I− p-(CH3)3—N−-phenyl, I− m-(CH2)3—N−-phenyl, I− m-(CH3)3—N−—CH2CH2—(OCH2CH2)2—O-phenyl, I− p-(CH2)3—N−—CH2CH2—(OCH2CH2)2—O-phenyl, I− m-(N,N-dimethyl-piperazinium)—(N′)—CH2—(OCH2CH2)2—O-phenyl, 3-methoxy-4-fluorophenyl, thienyl-2-yl, 5-cholorothienyl-2-yl, 3,4-difluorophenyl, I− p-(N,N-dimethylpiperazinium)-(N′)—CH2—(OCH2CH2)2—O-phenyl, 3-fluoro-4-methoxyphenyl, -4-pyridinyl, 2-pyridinyl, 3-pyridinyl, N-methyl-4-pyridinium, I− N-methyl-3-pyridinium, 3,4-dioxymethylenephenyl, 3,4-dioxyethylenephenyl, and p-methoxycarbonylphenyl. Preferred compounds include 3-ethyl-3-butyl and 3-butyl-3-butyl compounds having each of the above preferred R5 substituents in combination with the Rx substituents shown in Table 1. It is particularly preferred that one but not both of R5 and R6 is hydrogen.
It is especially preferred that R4 and R6 be hydrogen, that R3 and R5 not be hydrogen, and that R3 and R5 be oriented in the same direction relative to the plane of the molecule, i.e., both in ∝- or both in β-configuration. It is further preferred that, where R2 is butyl and R1 is ethyl, then R1 has the same orientation relative to the plane of the molecule as R3 and R5.
Set forth in Table 1A are lists of species of R1/R2, R5/R6 and Rx.







TABLE 1A







Alternative R groups

















R1, R2
R3, R4
R5
(Rx)q





ethyl
HC—
Ph-
7-methyl


n-propyl
H—
p-F-Ph-
7-ethyl


n-butyl

m-F-Ph-
7-iso-propyl


n-pentyl

p-CH3O-Ph-
7-tert-butyl


n-hexyl


7-CH


iso-propl

m-CH3O-Ph-
7-OCH3


iso-butyl

p-(CH3)2N-Ph-
7-O(iso-propyl)


iso-pentyl

m-(CH3)2N-Ph-
7-SCH3


CH2C(═O) C2H5

I−, p-(CH3)3—N+-Ph-
7-SOCH3


CH2CC2H5

I−, m-(CH3)3—N+-Ph-
7-SO2CH3


CH2CH(CH)C2H5

I−, p-(CH3)3—N+—CH2CH2
7-SCH2CH3


CH2O-(4-picoline)

(OCH2CH2)2—C-Ph-
7-NH2




I−, m-(CH3)3—N+—CH2CH2—
7-NHCH




(OCH2CH2)2—O-Ph-
7-NHCH3




I−, p-(N,N-
7-N(CH3)2




dimethylpiperazine)-
7-N+(CH3)3, I−




(N′)-CH2—(CCH2CH2)2—O—
7-NHC(═O)CH3




Ph-
7-N(CH2CH3)2 




I−, m-(N,N-
7-NMeCH2CO2H




dimethylpiperazine)-
7-N+(Me)2CH2CO2H, I−




(N′)-CH2—(OCH2CH2)2—O—
7-(N)-morpholine




Ph-
7-(N)-azetidine




m-F, p-CH3O-Ph-
7-(N)-N-methylazetidinium,  I−




3,4,dioxymethylene-Ph
7-(N)-pyrrolidine




m-CH3O—, p-F-Ph-
7-(N)-N-methyl-pyrrolidinium, I−




4-pyridine
7-(N)-N-methyl-morpholinium, I−




N-methyl-4-pyridinium, I−
7-(N)-N′-methylpiperazine




3-pyridine
7-(N)-N′-dimethylpiperazinium, I−




N-methyl-3-pyridinium, I−
7-NH-CBZ




2-pyridine 
7-NHC(═O)C5H11




p-CH3O2C-Ph-
7-NHC(═O)CH2Br




thienyl-2-yl
7-NH—C(NH)NH2




5-Cl-thienyl-2-yl
7-(2)-thiophene




3,4-difluoro




m-F, P-CH3O-Ph





8-methyl





8-ethyl





8-iso-propyl





8-tert-butyl





8-OH





8-OCH3





8-O(iso-propyl)





8-SCH3





8-SOCH3





8-SO2CH3





8-SCH2CH3





8-NH2





8-NHCH





8-NHCH3





8-N(CH3)2





8-N+(CH3)3, I−





8-NHC(═O)CH3





8-N(CH2CH3)2





8-NMeCH2CO2H





8-N+(Me)2CH2CO2H, I−





8-(N)-morpholine





8-(N)-azetidine





8-(N)-N-methylazetidinium, I−





8-(N)-N-pyrrolidine





8-(N)-N-methyl-pyrrolidinium, I−





8-(N)-N-methyl-morpholinium, I−





8-(N)-N′-methylpiperazine





8-(N)-N′-dimethylpiperadinium, I−





8-NH-CBZ





8-NHC(O)C5H11





8-NHC(O)CH2Br





8-NH—C(NH)NH2





8-(2)-thiophene





9-methyl





9-ethyl





9-iso-propyl





9-tert-butyl





9-OH





9-OCH3





9-O(iso-propyl)





9-SCH3





9-SOCH3





9-SO2CH3





9-SCH2CH3





9-NH2





9-NHCH





9-NHCH3





9-N(CH3)2





9-N+(CH3)3, I−





9-NHC(═O)CH3





9-N(CH2CH3)2





9-NMeCH2CO2H





9-N+(Me)2CH2CO2H, I−





9-(N)-morpholine





9-(N)-azetidine





9-(N)-N-methylazetidinium, I−





9-(N)-N-pyrrolidine





9-(N)-N-methyl-pyrrolidinium, I−





9-(N)-N-methyl-morpholinium, I−





9-(N)-N′-methylpiperazine





9-(N)-N′-dimethylpiperadinium, I−





9-NH-CBZ





9-NHC(O)C5H11





9-NHC(O)CH2Br





9-NH—C(NH)NH2





9-(2)-thiophene





7-OCH3, 8-OCH3





7-SCH3, 8-OCH3





7-SCH3, 8-SCH3





6-OCH3, 7-OCH3, 8-OCH3









Further preferred compounds of the present invention comprise a core structure having two or more pharmaceutically active benzothiepine structures as described above, covalently bonded to the core moiety via functional linkages. Such active benzothiepine structures preferably comprise: 




where R1, R2, R3, R4, R6, R5, R6, R7, R8, X, q and n are as defined above, and R55 is either a covalent bond or arylene.

The core moiety can comprise alkane diyl, alkene diyl, alkyne diyl, polyalkane diyl, alkoxy diyl, polyether diyl, polyalkoxy diyl, carbohydrate, amino acid, and peptide, polypeptide, wherein alkane diyl, alkene diyl, alkyne diyl, polyalkane diyl, alkoxy diyl, polyether diyl, polyalkoxy diyl, carbohydrate, amino acid, and peptide polypeptide, can optionally have one or more carbon replaced by O, NR7, N−R7R8, S, SO, SO2 S+R7R8, PR7, P+R7R8, phenylene, heterocycle, quartarnay heterocycle, quaternary heteroaryl, or aryl,
wherein alkane diyl, alkene diyl, alkyne diyl, polyalkane diyl, alkoxy diyl, polyether diyl, oolyalkoxy diyl, carbohydrate, amino acid, pepticde, and polypeptide can be substituted with one or more substituent groups incependently selected from the group consisting of alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle, arylalkyl, halogen, oxo, OR13, NR13R14, SR13, S(O)R13, SO2R13, SO3R13, NR13OR14, NR13NR14NR15, NO2, CO2R13, CN, OM, SO2OM, SO2NR13R14, C(O)NR13R14, C(O)CM, COR13, P(O)R13R14, P+R13R14R15A−, P(OR13)OR14, S−R13R14A−, and N+R9R11R12A−;
wherein said alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, and heterocycle can be further substituted with one or more substituent groups selected from the group consisting of OR7, NR7R8, SR7, S(O)R7, SO2R7, SO3R7, CO2R7, CN, oxo, CONR7R8, N+R7R8R9A−, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycle, arylalkyl, quaternary heterocycle, quaternary heteroaryl, P(O)R7R8, P+R7R8A−, and P(O) (OR7)OR8, and
wherein said alkyl, alkenyl, alkynyl, polyalkvl, polyether, aryl, haloalkyl, cycloalkyl, and heterocycle can optionally have one or more carbons replaced by O, NR7, N+R7R8A−, S, SO, SO2, S+R7A−, PR7, P(O)R7, P+R7R8A−, or phenylene.
Exemplary core moieties include: 




wherein:

R25 is selected from the group consisting of C and N, and
R26 and R27 are independently selected from the group consisting of: 




wherein R26, R29, R30 and R−are independently selected from alkyl, alkenyl, alkylaryl, aryl, arylalkyl, cycloalkyl, heterocycle, and heterocycloalkyl,
A− is a pharmaceutically acceptable anion, and k=1 to 10.
In compounds of Formula DIV, R20, R21, R22 in Formulae DII and DIII, and R23 in Formula DIII can be bonded at any of their 6-, 7-, 8-, or 9-positions to R19. In compounds of Formula DIVA, it is preferred that R55 comprises a phenylene moiety bonded at a m- or p-position thereof to R19.
In another embodiment, a core moiety backbone, R19, as discussed herein in Formulas DII and DIII can be multiply substituted with more than four pendant active benzothiepine units, i.e., R20, R21, R22, and R23 as discussed above, through multiple functional groups within the core moiety backbone. The core moiety backbone unit, R19, can comprise a single core moiety unit, multimers thereof, and multimeric mixtures of the different core moiety units discussed herein, i.e., alone or in combination. The number of individual core moiety backbone units can range from about one to about 100, preferably about one to about 80, more preferably about one to about 50, and even more preferably about one to about 25. The number of points of attachment of similar or different pendant active benzothiepine units within a single core moiety backbone unit can be in the range from about one to about 100, preferably about one to about 80, more preferably about one to about 50, and even more preferably about one to about 25. Such points of attachment can include bonds to C, S, O, N, or P within any of the groups encompassed by the definition of R19.
The more preferred benzothiepine moieties comprising R20, R21, R22 and/or R23 conform to the preferred structures as outlined above for Formula I. The 3-carbon on each benzothiepine moiety can be achiral, and the substituents R1, R2, R3, R4, R5 and Rx can be selected from the preferred groups and combinations of substituents as discussed above. The core structures can comprise, for example, poly(oxyalkylene) or oligo(oxyalkylene), especially poly- or oligo(oxyethylene) or poly- or oligo(oxypropylene).
Dosages, Formulations, and Routes of Administration
The ileal bile acid transport inhibitor compounds of the present invention can be administered for the prophylaxis and treatment of hyperlipidemic diseases or conditions by any means, preferably oral, that produce contact of these compounds with their site of action in body, for example in the ileum of mammal, e.g., a human.
For the prophylaxis or treatment of the conditions referred to above, the compounds of the present invention can be used as the compound per se.
Pharmaceutically acceptable salts are particularly suitable for medical applications because of their greater aqueous solubility relative to the parent compound. Such salts must clearly have a pharmaceutically acceptable anion or cation. Suitable pharmaceutically acceptable acid addition salts of the compounds of the present invention wnen possible include those derived from inorganic acids, such as hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric, sulfonic, and sulfuric acids, and organic acids such as acetic, benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, gluconic, glycolic, isothionic, lactic, lactobionic, maleic, malic, methanesulfonic, succinic, toluenesulfonic, tartaric, and trifluoroacetic acids. The chloride salt is particularly preferred for medical purposes. Suitable pharmaceutically acceptable base salts include ammonium salts, alkali metal salts such as sodium and potassium salts, and alkaline earth salts such as magnesium and calcium salts.
The anions of the definition of A− in the present invention are, of course, also required to be pharmaceutically acceptable and are also selected from the above list.
The compounds of the present invention can be presented with an acceptable carrier in the form of a pharmaceutical composition. The carrier must, of course, be acceptable in the sense of being comapatible with the other ingredients of the composition and must not be deleterious to the reciDient. The carrier can be a solid or a liquid, or both, and is preferably formulated with the compound as a unit-dose composition, for example, a tablet, which can contain from 0.05% to 95% by weight of the active compound. Other pharmacologically active substances can also be present, including other compounds of the present invention. The pharmaceutical compositions of the invention can be prepared by any of the well known techniques of pharmacy, consisting essentially of admixing the components.
These compounds can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic compounds or as a combination of therapeutic compounds.
The amount of compound which is recuiredto achieve the desired biological effect will, of course, depend on a number of factors such as the specific compound chosen, the use for which it is intended, the mode of administration, and the clinical condition of the recipient.
In general, a daily dose can be in the range of from about 0.3 to about 100 mg/kg bodyweight/day, preferably from about 1 mg to about 50 mg/kg bodyweight/day, more preferably from about 3 to about 10 mg/kg bodyweight/day. This total daily dose can be administered to the patient in a single dose, or in proportionate multiple subdoses. Subdoses can be administered 2 to 6 times per day. Doses can be in sustained release form effective to obtain desired results.
Orally administrable unit dose formulations, such as tablets or capsules, can contain, for example, from about 0.1 to about 100 mg of benzothiepine compound, peferably about 1 to about 75 mg of compound, more preferably from about 10 to about 50 mg of compound. In the case of pharmaceutically acceptable salts, the weights indicated above refer to the weight of the benzothiezine ion derived from the salt.
Oral delivery of an ileal bile acid transport inhibitor of the present invention can include formulations, as are well known in the art, to provide prolonged or sustained delivery of the drug to the gastrointestinal tract by any number of mechanisms. These include, but are not limited to, pH sensitive release from the dosage form based on the changing pH of the small intestine, slow erosion of a tablet or capsule, retention in the stomach based on the physical properties of the formulation, bioadhesion of the dosage form to the mucosal lining of the intestinal tract, or enzymatic release of the active drug from the dosage form. The intended effect is to extend the time period over which the active drug molecule is delivered to the site of action (the ileum) by manipulation of the dosage form. Thus, enteric-coated and enteric-coated controlled release formulations are within the scope of the present invention. Suitable enteric coatings include cellulose acetate phthalate, polyvinylacetate phthalate, hydroxypropylmethylcellulose phthalate and anionic polymers of methacrylic acid and methacrylic acid methyl ester.
When administered intravenously, the dose can, for example, be in the range of from about 0.1 mg/kg body weight to about 1.0 mg/kg body weight, preferably from about 0.25 mg/kg body weight to about 0.75 mg/kg body weight, more preferably from about 0.4 mg/kg body weight to about 0.6 mg/kg body weight. This dose can be conveniently administered as an infusion of from about 10 ng/kg body weight to about 100 ng/kg body weights per minute. Infusion fluids suitable for this purpose can contain, for example, from about 0.1 ng to about 10 mg, preferably from about 1 ng to about 10 mg per milliliter. Unit doses can contain, for example, from about 1 mg to about 10 g of the compound of the present invention. Thus, ampoules for injection can contain, for example, from about 1 mg to about 100 mg.
Pharmaceutical compositions according to the present invention include those suitable for oral, rectal, topical, buccal (e.g., sublingual), and parenteral (e.g., subcutaneous, intramuscular, intradermal, or intravenous) administration, although the most suitable route in any given case will depend on the nature and severity of the condition being treated and on the nature of the particular compound which is being used. In most cases, the preferred route of administration is oral.
Pharmaceutical compositions suitable for oral administration can be presented in discrete units, such as capsules, cachets, lozenges, or tablets, each containing a predetermined amount of at least one compound of the present invention; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion. As indicated, such compositions can be prepared by any suitable method of pharmacy which includes the step of bringing into association the active compound(s) and the carrier (which can constitute one or more accessory ingredients). In general, the compositions are prepared by uniformly and intimately admixing the active compound with a liquid or finely divided solid carrier, or both, and then, if necessary, shaping the product. For example, a tablet can be prepared by compressing or molding a powder or granules of the compound, optionally with one or more assessory ingredients. Compressed tablets can be prepared by compressing, in a suitable machine, the ccmpound in a free-flowing form, such as a powder or granules optionally mixed with a binder, lubricant, inert diluent and/or surface active/dispersing agent(s). Molded tablets can be made by molding, in a suitable machine, the powdered compound moistened with an inert liquid diluent.
Pharmaceutical compositions suitable for buccal (sub-lingual) administration include lozenges comprising a compound of the present invention in a flavored base, usually sucrose, and acacia or tragacanth, and pastilles comprising the compound in an inert base such as gelatin and glycerin or sucrose and acacia.
Pharmaceutical compositions suitable for parenteral administration conveniently comprise sterile aqueous preparations of a compound of the present invention. These preparations are preferably acministered intravenously, although administration can also be effected by means of subcutaneous, intramuscular, or intradermal injection. Such preparations can conveniently be prepared by admixing the compound with water and rendering the resulting solution sterile and isotonic with the blood. Injectable comositions according to the invention will generally contain from 0.1 to 5% w/w of a compound disclosed herein.
Pharmaceutical compositions suitable for rectal administration are preferably presented as unit-dose suppositories. These can be prepared by admixing a compound of the present invention with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.
Pharmaceutical compositions suitable for topical application to the skin preferably take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers wnich can be used include vaseline, lanoline, polyethylene glycols, alcohols, and combinations of two or more thereof. The active compound is generally present at a concentration of from 0.1 to 15% w/w of the composition, for example, from 0.5 to.2%.
Transdermal administration is also possible. Pharmaceutical compositions suitable for transdermal administration can be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. Such patches suitably contain a compound of tne present invention in an optionally buffered, aqueous solution, dissolved and/or disoersed in an adhesive, or dispersed in a polymer. A suitable concentration of the active compound is about 1% to 35%, preferably about 3% to 15%. As one particular possibility, the compound can be delivered from the patch by electrotransport or iontophoresis, for example, as described in Pharmaceutical Research, 3(6), 318 (1986).
In any case, the amount of active ingredient that can be combined with carrier materials to produce a single dosage form to be administered will vary depending upon the host treated and the particular mode of administration.
The solid dosage forms for oral administration including capsules, tablets, pills, powders, and granules noted above comprise one or more compounds of the present invention admixed with at least one inert diluent such as sucrose, lactose, or starch. Such dosage forms may also comprise, as in normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.
Liquid dosage forms for oral administration can include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions may also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.
Injectable preparations, for example, sterile injectable acueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or setting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
Pharmaceutically acceptable carriers encompass all the foregoing and the like.
In combination therapy, administration of the ileal bile acid transport inhibitor and HMG Co-A reductase inhibitor may take place sequentially in separate formulations, or may be accomplished by simultaneous administration in a single formulation or separate formulations. Administration may be accomplished by oral route, or by intravenous, intramuscular, or subcutaneous injections. The formulation may be in the form of a bolus, or in the form of aacueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules having one or more pharmaceutically-acceptable carriers or diluents, or a binder such as gelatin or hydroxypropylmethyl cellulose, together with one or more of a lubricant, preservative, surface active or dispersing agent.
For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension, or liquid. Capsules, tablets, etc., can be prepared by conventional methods well known in the art. The pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient or ingredients. Examples of dosage units are tablets or capsules. These may with advantage contain one or more ileal bile acid transport inhibitors in an amount described above. In the case of HMG Co-A reductase inhibitors, the dose range may be from about 0.01 mg to about 500 mg or any other dose, dependent upon tne specific inhibitor, as is known in the art.
The active ingredients may also be administered by injection as a composition wherein, for example, saline, dextrose, or water may be used as a suitable carrier. A suitable daily dose of each active inhibitor is one that achieves the same blood serum level as produced by oral administration as described above.
The active inhibitors may further be administered by any dual combination of oral/oral, oral/parenteral, or parenteral/parenteral route.
Phamaceutical compositions for use in the treatment methods of the present invention may be administered in oral form or by intravenous administration. Oral administration of the combination therapy is preferred. Dosing for oral administration may be with a regimen calling for single daily dose, or for a single dose every other day, or for multiple, spaced doses throughout the day. The inhibitors which make up the combination therapy may be administered simultaneously, either in a combined dosage form or in separate dosage forms intended for substantially simultaneous oral administration. The inhibitors which make up the combination therapy may also be administered sequentially, with either inhibitor being administered by a regimen calling for two-step ingestion. Thus, a regimen may call for sequential administration of the inhibitors with spaced-apart ingestion of the separate, active agents. The time period between the multiple ingestion steps may range from a few minutes to several hours, depending upon the properties of each inhibitor such as potency, solubility, bioavailability, plasma half-life and kinetic profile of the inhibitor, as well as depending upon the age and condition of the patient. The inhibitors of the combined therapy whether administered simultaneously, substantially simultaneously, or secuentially, may involve a regimen calling for administration of one inhibitor by oral route and the other inhibitor by intravenous route. Whether the inhibitors of the combined therapy are administered by oral or intravenous route, separately or together, each such inhibitor will be contained in a suitable pharmaceutical formulation of pharmaceutically-acceptable excipients, diluents or other formulations components. Examples of suitable pharmaceutically-acceptable formulations containing the inhibitors for oral administration are given above.
Treatment Regimen
The dosage regimen to prevent, give relief from, or ameliorate a disease condition having hyperlipemia as an element of the disease, e.g., atherosclerosis, or to protect against or treat further high cholesterol plasma or blood levels with the compounds and/or compositions of the present invention is selected in accordance with a variety of factors. These include the type, age, weight, sex, diet, and medical condition of the patient, the severity of the disease, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetics and toxicology profiles of the particular compound employed, whether a drug delivery system is utilized, and whether the compound is administered as part of a drug combination. Thus, the dosage regimen actually employed may vary widely and therefore deviate from the preferred dosage regimen set forth above.
Initial treatment of a patient suffering from a hyperlipidemic condition can begin with the dosages indicated above. Treatment should generally be continued as necessary over a period of several weeks to several months or years until the hyperlipidemic disease condition has been controlled or eliminated. Patients undergoing treatment with the compounds or compositions disclosed herein can be routinely monitored by, for example, measuring serum LDL and total cholesterol levels by any of the methods well known in the art, to determine the effectiveness of the combination therapy. Continuous analysis of such data permits modification of the treatment regimen during therapy so that optimal effective amounts of each type of inhibitor are administered at any point in time, and so that the duration of treatment can be determined as well. In this way, the treatment regimen/dosing schedule can be rationally modified over the course of therapy so that the lowest amount of ileal bile acid transport inhibitor and HMG Co-A reductase inhibitor which together exhibit satisfactory effectiveness is administered, and so that administration is continued only so long as is necessary to successfully treat the hyperlipidemic condition.
A potential advantage of the combination therapy disclosed herein may be reduction of the amount of ileal bile acid transport inhibitor, HMG Co-A reductase inhibitor, or both, effective in treating hyperlipidemic conditions such as atherosclerosis and hypercholesterolemia.
The following examples serve to illustrate various aspects of the present invention.
EXAMPLES OF SYNTHETIC PROCEDURES
Preparation 1
2-Ethyl-2-(mesyloxyzethyl)hexanal (1)





To a cold (10° C.) solution of 12.6 g (0.11 mole) of methanesulfonyl chloride and 10.3 g (0.13 mole) of triethylamine was added dropwise 15.8 g of 2-ethyl-2-(hydroxymethyl)hexanal, preparead according to the procedure described in Chem. Ber. 98, 728-734 (1965), while maintaining the reaction temperature below 30° C. The reaction mixture was stirred at room temperature for 18 h, quenched with dilute HCl and extracted with methlyene chloride. The methylene chloride extract was dried over MgSO4 and concentrated in vacuo to give 24.4 g of brown oil.
Preparation 2
2-((2-Benzoylphenylthio)methyl)-2-ethylhexanal





A mixture of 31 g (0.144 mol) of 2-mercaptobenzophenone, prepared according to the procedure described in WO 93/16055, 24.4 g (0.1 mole) of 2-ethyl-2-(mesyloxyymethyl)-hexanal (1), 14.8 g (0.146 mole) of triethylamine, and 80 mL of 2-methoxyethyl ether was held at reflux for 24 h. The reaction mixture was poured into 3N HCl and extracted with 300 mL of methylene chloride. The methylene chloride layer was washed with 300 mL of 10% NaOH, dried over MgSO4 and concentrated in vacuo to remove 2-methoxyethyl ether. The residue was purified by HPLC (10% EtOAc-hexane) to give 20.5 g (58%) of 2 as an oil.
Example 1
3-Butyl-3-ethyl-5-phenyl-2,3-dihydrobenzothiepine (3), cis-3-Butyl-3-ethyl-5-phenyl-2,3-dihydrobenzothiepin-(5H)4-one (4a) and trans-3-Butyl-3-ethyl-5-phenyl-2,3-dihydro-benzothiepin-(5H)4-one (4b)





A mixture of 2.6 g (0.04 mole) of zinc dust, 7.2 g (0.047 mole) of TiCl3 and 80 mL of anhydrous ethylene glycol dinmethyl ether (DME) was held at reflux for 2 h. The reaction mixture was cooled to 5° C. To the reaction mixture was added drpowise a solution of 3.54 g (0.01 mole) of 2 in 30 mL of DME in 40 min. The reaction mixture was stirred at room temperature for 16 h and then was held at reflux for 2 h and cooled before being poured into brine. The organic was extract into methylene chloride. The methylene chloride extract was cried over MgSO4 and concentrated in vacuo. The residue was purified by HPLC (hexane) to give 1.7 g (43%) of 3 as an oil in the first fraction. The second fraction was discarded and the third fraction was further purifiedby by HPLC (hexane) to give 0.07 g (2%) of 4a in the earlier fraction and 0.1 g (3%) of 4b in the later fraction.
Example 2
cis-3-Butyl-3-ethyl-5-phenyl-2,3-dibydrobenothiepin-(5H)4-one-1,1-dioxide (5a) ad trans-3-Butyl-3-ethyl-5-phenyl-2,3-dihydro-benothiepin-(5H)4-one-1,1-dioxide (5b)





To a solution of 1.2 g (3.5 mmole) of 50-60% MCPBA in 20 mL of methylene chloride was added 0.59 g (1.75 mmole) of a mixture of 4a and 4b in 10 mL of methylene chloride. The reaction mixture was stirred for 20 h. An additional 1.2 g (1.75 mmole) of 50-60% MAPBA was added and the reaction mixture was stirred for an additional 3 h then was triturated with 50 mL of 10% NaOH. The insoluble solid was filtered. The methylene chloride layer of the filtrate was washed with brine, dried over MgSO4, and concentrated in vacuo. The residual syrup was purified by HPLC (5% EtOAc-hexane) to give 0.2 g (30%) of 5a as an oil in the first fraction and 0.17 g (26%) of 5b as an oil in the second fraction.
Example 3
(3a,4a,5b) 3-Butyl-3-ethyl-4-hydroxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1 1,1-dioxide (6a), (3a,4b,5a)− 3-Butyl-3-ethyl-4-hydroxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (6b), (3a,4a,5a) 3-Butyl-3-ethyl-4-hydroxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (6c), and
(3a,4b,5b) 3-Butyl-3-ethyl-4-hydroxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (6d)








A. Reduction of 5a and 5b with Sodium Borohydride

To a solution of 0.22 g (0.59 mmole) of 5b in 10 mL of ethanol was added 0.24 g (6.4 mmole) of sodium borohyride. The reaction mixture was stirred at room temperature for 18 h and concentrated in vacuo to remove ethanol. The residue was triturated with water and extracted with methylene chloride. The methylene chloride extract was dried over MgSO4 and concentrated in vacuo to give 0.2 g of syrup. In a separate experiment, 0.45 g of 5a was treated with 0.44 g of sodium borohydride in 10 mL of ethanol and was worked up as described above to give 0.5 g of syrup which was identical to the 0.2 g of syrup obtained above. These two materials were combined and purified by HPLC using 10% EtOAc-hexane as eluant. The first fraction was 0.18 g (27%) of 6a as a syrup. The second fraction was 0.2 g (30%) of 6b also as a syrup. The column was then elute with 20% EtOAc-hexane to give 0.077 g (11%) of 6c in the third fraction as a solid. Recrystallization from hexane gave a solid, mrp 179-181° C. Finally, the column was eluted with 30% EtOAc-hexane to give 0.08 g (12%) of 6d in the fourth fraction as a solid.
Recrystallization from hexane gave a solid, mp 160-161° C.
B. Conversion of 6a to 6c and 6d with NaOH and PTC
To a solution of 0.29 g (0.78 mmole) of 6a in 10 mL CH2Cl2, was added 9 g of 40% NaOH. The reaction mixture was stirred for 0.5 h at room temperature and was added one drop of Aliquat-336 (methyltricaprylylammonium chloride phase transer catalyst (PTC). The mixture was stirred for 0.5 h at room temperature before being treated with 25 mL of ice-crystals then was extracted with CH2Cl2 (3×10 ml), dried over MgSO4 anc concentrated in vacuo to recover 0.17 g of a colorless film. The components of this mixture were separated using an HPLC and eluted with EtOAc-hexane to give 12.8 mg (4%) of 2-(2-benzylphenylsulfonylmethyl)-2-ethylhexenal in the first fraction, 30.9 mg (11%) of 6c in the second fraction and 90.0 mg (31%) of 6d in the third fraction.
Oxidation of 6a to 5b
To a solution of 0.20 g (0.52 mmole) of 6a in 5 mL of CH2Cl2 was added 0.23 g (1.0 mmole) of pyridinium chlorochromate. The reaction mixture was stirred for 2 h then was treated with additional 0.23 g of pyridinium chlorochromate and stirred overnight. The dark reaction mixture was poured into a ceramic filterfrit containing silica gel and was eluted with CH2Cl2. The filtrate was concentrated in vacuo to recover 167 mg (87%) of 5b as a colorless oil.
Example 4
3-Butyl-3-ethyl-5-phenyl-2,3-dihydzobenzothiepine-1,1-dioxide (7)





To a solution of 5.13 g (15.9 mmole) of 3 in 50 mL of CH2Cl2 was added 10 g (31.9 mmole) of 50-60% MCPBA (m-chloroperoxybenzoic acid) portionwise causing a mild reflux and formation of a white solid. The reaction mixture was allowed to stir overnight under N2 and was triturated with 25 mL of water followed by 50 mL of 10% NaOH solution. The organic was extracted into CH2Cl2 (4×20 mL). The CH2Cl2 extract was dried over MgSO4 and evaporated to dryness to recover 4.9 g (87%) of an opalue viscous oil.
Example 5
(1aa,2b,8ba) 2-Butyl-2-ethyl-8b-phenyl-1a,2,3,8b-tetrahydro-benzothiepino[4,5-b]oxirene-4,4-dioxide (8a)
(1aa,2a,8ba) 2-Butyl-2-ethyl-8b-phenyl-1a,2,3,8b-tetrahydro-benzothiepino [4,5-b]oxirene-4,4-dioxide (8b)





To 1.3 g (4.03 mole) of 3 in 25 mL of CHCl3 was added portionwise 5 g (14.1 mmole) of 50-60% MCPBA causing a mild exotherm. The reaction mixture was stirred under N2 overnight and was then held at reflux for 3 h. The insoluble white slurry was filtered. The filtrate was extracted with 10% potassium carbonate (3×50 mL), once with brine, dried over MgSO4, and concentrated in vacuo to give 1.37 g of a light yellow oil. Purification by HPLC gave 0.65 g of crystalline product. This product is a mixture of two isomers. Trituration of this crystalline product in hexane recovered 141.7 mg (10%) of a white crystalline product. This isomer was chaacterized by NMR and mass spectra to be the (1aa,2b,8ba) isomer 8a. The hexane filtrate was concentrated in vacuo to give 206 mg of white film which is a mixture of 30% 8a and 70% 8b by 1H NMR.
Example 6
Cis-3-Butyl-3-ethyl-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (9a), trans-3-Butyl-3-ethyl-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (9b), and 3-Butyl-3-ethyl-4-hydroxy-5-cyclohexylidine-2,3,4,5-tetraydrobenzothiepine-1,1-dioxide (10)





A mixture of 0.15 g (0.4 mmole) of a 3:7 mixture of 8a and 8b was dissolved in 15 ml MeOH in a 3 oz. Fisher/Porter vessel, then was added 0.1 g of 10% Pd/c catalyst. This mixture was hydrogenated at 70 psi H2 for 5 h and filtered. The filtrate was evaporated to dryness in vacuo to recover 0.117 g of a colorless oil. This material was purified by HPLC eluting with EtOAc-hexane. The first fraction was 4.2 mg (3%) of 9b. The second fraction, 5.0 mg (4%), was a 50/50 mixtue of 9a and 9b. The third fraction was 8.8 mg (6%) of 6a. The fourth fraction was 25.5 mg (18%) of 6b. The fifth fraction was 9.6 mg (7%) of a mixture of 6b and a product believed to be 3-butyl-3-ethyl-4,5-dihydroxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide based on mass spectrum. The sixth fraction was 7.5 mg (5%) of a mixture of 6d and one of the isomers of 10, 10a.
Example 7
In another experiment, a product (3.7 g) from epoxidation of 3 with excess MCPBA in refluxing CHCl3 under air was hydrogenated int 100 mL of methanol using 1 g of 10% Pd/C catalyst and 70 psi hydrogen. The product was purified by HPLC to give 0.9 g (25%) of 9b, 0.45 g (13%) of 9a, 0.27 g (7%) of 6a, 0.51 g (14%) of 6b, 0.02 g (1%) of 6c, 0.06 g (2%) of one isomer of 10, 10a and 0.03 g (1%) of another isomer of 10, 10b.
Example 8
2-((2-Benzoylphenylthio)methyl)butyraldehyde (11)





To an ice bath cooled solution of 9.76 g (0.116 mole) of 2-ethylacrolein in 40 mL of dry THF was added 24.6 g (0.116 mole) of 2-mercaptobenzophenone in 40 mL of THF followed by 13 g (0.128 mole) of triethylanine. The reaction mixture was stirred at room temperature for 3 days, diluted with ether, and was washed successively with dilute HCl, brine, and 1 M potassium carbonate. The ether layer was dried over MgSO4 and concentrated in vacuo. The residue was purified by HPLC (10% EtOAc-hexane) to give 22 g (64%) of 11 in the second fraction. An attempt to further purifiy this material by kugelronr distillation at 0.5 torr (160-190° C.) gave a fraction (12.2 g) which contained starting material indicating a reversed reaction during distillation. This material was dissolved in ether (100 mL) and was washed with 50 mL of 1 M potassium carbonate three times to give 6.0 g of a syrup which was purified by HPLC (10% EtOAc-hexane) to give 5.6 g of pure 11.
Example 9
3-Ethyl-5-phenyl-2,3-dihydrobenzothiepine (12)





To a mixture of 2.61 g (0.04 mole) of zinc dust and 60 mL of DME was added 7.5 g (0.048 mole) of TiCl3. The reaction mixture was held at reflux for 2 h. A solutiom of 2.98 g (0.01 mole) of 11 was added dropwise in 1 h. The reaction mixture was held at reflux for 18 h, cooled and poured into water. The organic was extracted into ether. The ether layer was washed with brine and filtered through Celite. The filtrate was dried over MgSO4 and concentrated. The residual oil (2.5 g) was purified by HPLC to give 2.06 g (77%) of 12 as an oil in the second fraction.
Example 10
(1aa,2a,8ba) 2-Ethyl-8b-phenyl-1a,2,3,8b-tetrahydrobenzothiepino-[4,5-b]oxirene-4,4-dioxide (13)





To a solution of 1.5 g (5.64 mmole) of 12 in 25 ml of CHCl3 was added 6.8 g (19.4 mmole) of 50-60% MCPB portionwise causing an exothem and formation of a white solid. The mixture was stirred at room temperature overnight diluted with 100 ml methylene chloride and washed successively with 10% K2CO3 (4×50 ml), water (twice with 25 ml) and brine. The organic layer was then dried over MgSO4 and evaporated to dryness to recover 1.47 g of an off white solid. 1H NMR indicated that only one isomer is present. This solid was slurried in 200 ml of warm Et2O and filtered to give 0.82 g (46%) of 13 as a white solid, mp 185-186.5° C.
Example 11
(3a,4b,5a)-3-Ethyl-4-hydroxy-5-phenyl-2,3,4,5-tetrahydro-benzothiepine-1,1-dioxide (14a), (3a,4b,5b) 3-Ethyl-4-hydroxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (14b), and cis-3-Ethyl-5-phenyl-2,3,4,5-tetrahydro-bezothiepine-1,1-dioxide (15)





A mixture of 0.5 g (1.6 mole) of 13, 50 ml of acetic acid and 0.5 g of 10% Pd/C catalyst was hydrogenated with 70 psi hydrogen for 4 h. The crude reaction slurry was filtered and the filtrate was stirred with 150 ml of a saturated NaHCO3 solution followed by 89 g of NaHCO3 powder portionwise to neutralize the rest of acetic acid. The mixture was extracted with methylene chloride (4×25 ml), then the organic layer was dried over MgSO4 and concentrated in vacuo to give 0.44 g (87%) of a voluminous white solid which was purified by HPLC (EtOAc-Hexane) to give 26.8 mg (6%) of 15 in the first fraction, 272 mg (54%) of 14a as a solid, mp 142-143.5° C., in the second fraction, and 35 mg (7%) of impure 14b in the third fraction.
Example 12
2-Ethyl-2-((2-Hydroxymethylphenyl)thiomethyl)hexenal (16)





A mixture of 5.0 g (0.036 mole) of 2-mercaptobenzyl alcohol, 6.4 g (0.032 mole) of 1, 3.6 g (0.036 mole) of triethylamine and 25 mL of 2-methoxyethyl ether was held at reflux for 7 h. Additional 1.1 g of mercaptobenzyl alcohol and 0.72 g of triethylamine was added to the reaction mixture and the mixture was held at reflux for additional 16 h. The reaction mixture was cooled and poured into 6N HCl and extracted with methylene chloride. The methylene chloride extract was wasted twice with 10% NaOH, dried over MgSO4 and concentrated in vacto to give 9.6 g of residue. Purification by HPLC (20% EtOAc-hexane) gave 3.7 g (41%) of 16 as an oil.
Example 13
2-Ethyl-2-((2-formylphenyl)thiomethyl)hexenal (17)





A mixture of 3.7 g of 16, 5.6 g (0.026 mole) of pyridinium chlorochromate, 2 g of Celite and 30 mL of methylene chloride was stirred for 18 h and filtered through a bed of silica gel. The silica gel was eluted with methylene chloride. The combined methylene chloride eluant was purified by HPLC (20% ETOAc-hexane) to give 2.4 g (66%) of an oil.
Example 14
3-Butyl-3-ethyl-2,3-dihydrobenzothiepine (18)





A mixture of 2.6 g (0.04 mole) of zinc dust, 7.2 g (0.047 mole) of TiCl3, and 50 mL of DME was held at reflux for 2 h and cooled to room temperature. To this mixture was added 2.4 g (8.6 mmole) of 17 in 20 mL of DME in 10 min. The reaction mixture was stirred at room temperature for 2 h and held at reflux for 1 h then was let standing at room temperature over weekend. The reaction mixture was poured into dilute HCl and was stirred with methylene chloride. The methylene chloride-water mixture was filtered through Celite. The methylene chloride layer was washed with brine, dried over MgSO4, and concentrated in vacuo to give 3.0 g of residue. Purification by HPLC gave 0.41 g (20%) of 18 as an oil in the early fraction.
Example 15
(1aa,2a,8ba) 2-Butyl-2-ethyl-1a,2,3,8b-tetrahydro-benzothiepino[4,5-b]oxirene-4,4-dioxide (19a) and
(1aa,2b,8ba) 2-Butyl-2-ethyl-8b-phenyl-1a,2,3,8b-tetrahydro-benzothiepino[4,5-b]oxirene-4,4-dioxide (19b)





To a solution of 0.4 g of 0.4 g (1.6 mmole) of 18 in 30 mL of methylene chloride was added 2.2 g (3.2 mmole) of 50-60% MCPBA. The reaction mixture was stirred for 2 h and concentrated in vacuo. The residue was dissolved in 30 mL of CHCl3 and was held at reflux for 18 h under N2. The reaction mixture was stirred with 100 mL of 10% NaOH and 5 g of sodium sulfite. The methylene chloride layer was washed with brine, dried over MgSO4 and concentrated in vacuo. The residue was purified by HPLC (20% EtOAc-hexane) to give a third fraction which was further purified by HPLC (10% EtOSc-hexane) to give 0.12 g of syrup in the first fraction.
Recrystallization from hexane gave 0.08 g (17%) of 19a, mp 89.5-105.5° C. The mother liquor from the first fraction was combined with the second fraction and was further purified by HPLC to give additional 19a in the first fraction and 60 mg of 19b in the second fraction. Crystallization from hexane gave 56 mg of a white solid.
Example 16
3-Butyl-3-ethyl-4,5-dihydroxy-5-phenyl-2,3,4,5-tetrahydro-benzothiepine-1,1-dioxide (20)





This product was isolated along with 6b from hydrogenation of a mixture of 8a and 8b.
Example 17
3-Butyl-3-ethyl-4-hydroxy-5-phenylthio-2,3,4,5-tetrahydzo-benzothiepine-1,1-dioxide (21)





A mixture of 25 mg (0.085 mmole) of 19b, 0.27 g (2.7 mmole) of thiophenol, 0.37 g (2.7 mmole) of potassiium carbonate, and 4 mL of DMF was stirred at room temperature under N2 for 19 h. The reaction mixture was poured into water and extracted with methylene chloride. The methylene chloride layer was washed successively with 10% NaOH and brine, dried over NgSO4, and concentrated in vacuo to give 0.19 g of semisolid which contain substantial amounts of diphenyl disulfide. This material was purified by HPLC (5% EtOAc-hexane) to remove diphenyl disulfide in the first fraction. The column was then eluted with 20% EtOAc-hexane to give 17 mg of a first fraction, 4 mg of a second fraction and 11 mg of a third fraction which were three different isomers of 21, i.e. 21a, 21b, and 21c, respectively, by 1H NMR and mass spectra.
Example 18
Alternative Synthesis of 6c and 6d
A. Preparation from 2-((2-Benzoylphenylthio)methyl) -2-ethylhexanal (2)
Step 1. 2-((2-Benzoylphenylsulfonyl)methyl)-2-ethylhexanal (44)





To a solution of 9.0 g (0.025 mole) of compound 2 in 100 ml of methylene chloride was added 14.6 g (0.025 mol) of 50-60% MCPBA portionwise. The reaction mixture was stirred at room temperature for 64 h then was stirred with 200 ml of 1 M potassium carbonate and filtered through Celite. The methylene chloride layer was washed twice with 300 ml of 1 M potassium carbonate, once with 10% sodium hydroxide and once with brine. The insoluble solid formed during washing was removed by filtration through Celite. The methylene chloride solution was dried and concentrated in vacuo to give 9.2 g (95%) of semisolid. A portion (2.6 g) of this solid was purified by HPLC (10% ethyl acetate-hexane) to give 1.9 g of crystals, mp 135-136° C.
Step 2. 2-((2-Benzylphenylsulfozyl)methyl)-2-ethylhexanal (45)





A solution of 50 g (0.13 mole) of crude 44 in 250 ml of methylene chloride was divided in two portons and charged to two Fisher-Porter bottles. To each bottle was charged 125 ml of methanol and 5 g of 10% Pd/C. The bottles were pressurized with 70 psi of hydrogen and the reaction mixture was stirred at room temperature for 7 h before being charged with an additional 5 g of 10% Pd/C. The reaction mixture was again hydrogenated with 70 psi of hydrogen for 7 h. This procedure was repeated one more time but only 1 g of Pd/C was charged to the reaction mixture. The combined reaction mixture was filtered and concentrated in vacuo to give 46.8 g of 45 as brown oil.
Step 3. (3a,4a,5a) 3-Butyl-3-ethyl-4-hydroxy-5-phenyl-2,3,4,5-tetraydrobenzothiepine-1,1-dioxide (6c), and (3a,4b,5b) 3-Butyl-3-ethyl-4-hydroxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (6d)
To a solution of 27.3 g (73.4 mmole) of 45 in 300 ml of anhydrous THF cooled to 2° C. with an ice bath was added 9.7 g (73.4 mmole) of 95% potassium t-butoxide. The reaction mixture was stirred for 20 min, quenched with 300 ml of 10% HCl and extracted with methylene chloride. The methylene chloride layer was dried over magnesium sulfate and concentrated in vacuo to give 24.7 g of yellow oil. Purification by HPLC (ethyl acetate-hexane) yielded 9.4 g of recovered 45 in the first fraction, 5.5 g (20%) of 6c in the second fraction and 6.5 g (24%) of 6d in the third fraction.
B. Preparation from 2-hydroxydiphenylmethane
Step 1. 2-mercaptodiphenylmethane (46)





To a 500 ml flask was charged 16 g (0.33 mol) of 60% sodium hydride oil dispersion. The sodium hydride was washed twice with 50 ml of hexane. To the reaction flask was charged 100 ml of DMF. To this mixture was added a solution of 55.2 g (0.3 mol) of 2-hydroxydiphenylmethane in 200 ml of DMF in 1 h while temperature was maintained below 30° C. by an ice-water bath. After cormplete addition of the reagent, the mixture was stirred at room temperature for 30 min then cooled with an ice bath. To the reaction mixture was added 49.4 g (0.4 mole) of dimethyl thiocarboyl chloride at once. The ice bath was removed and the reaction mixture was stirred at room temperature for 18 h before being poured into 300 ml of water. The organic was extracted into 500 ml of toluene. The toluene layer was washed successively with 10% sodium hydroxide and brine and was concentrated in vacuo to give 78.6 g of a yellow oil which was 95% pure dimethyl O-2-benzylphenyl thiocarbamate. This oil was heated at 280-300° C. in a kugelrohhr pot under house vacuum for 30 min. The residue was kugelrohr distilled at 1 torr (180-280° C.) The distillate (56.3 g) was crystallized from methanol to give 37.3 g (46%) of the rearranged product dimethyl S-2-benzylphenyl thiocarbamate as a yellow solid. A mixture of 57 g (0.21 mole) of this yellow solid, 30 g of potassium hydroxide and 150 ml of methanol was stirred overnight then was concentrated in vacuo. The residue was diluted with 200 ml of water and extracted with ether. The aqueous layer was mace acidic with concentrate HCl, The oily suspension was extracted into ether. The ether extract was dried over magnesium sulfate and concentrated in vacuo. The residue was crystallized from hexane to give 37.1 g (88%) of 2-mercaptodiphenylmethane as a yellow solid.
Step 2. 2-((2-Benzylphenylthio)methyl)-2-ethylhexanal (47)





A mixture of 60 g (03 mole) of yellow solid from step 1, 70 g (0.3 mole) of compound 1 from preparation 1, 32.4 g (0.32 mole) of triethylaamine, 120 ml of 2-methoxyethyl ether was held at reflux for 6 hr and concentrated in vacuo. The residue was triturated with 500 ml of water and 30 ml of concentrate HCl. The organic was extracted into 400 ml of ether. The ethner layer was washed successively with brine, 10% sodium hydroxide and brine and was dried over magnesium sulfate and concentrated in vacuo. The residue (98.3 g) was purified by HPLC with 2-5% ethyl acetate-hexane as eluent to give 2-((2-benzylphenylthio)methyl)-2-ethylhexanal 47 as a yellow syrup.
Step 3. 2-((2-Benzylphenylsulfonyl)methyl)-2-ethylhexanal (45)





To a solution of 72.8 g (0.21 mole) of yellow syrup from step 2 in 1 liter of methylene chloride cooled to 10° C. was added 132 g of 50-60% MCPBA in 40 min. The reaction mixture was stirred for 2 h. An additional 13 g of 50-60% MCPBA was added to the reaction mixture. The reaction mixture was stirred for 2 h and filtered through Celite. The methylene chloride solution was washed twice with 1 liter of 1 M potassium carbonate then with 1 liter of brine. The methylene chloride layer was dried over magnesium sulfate and concentrated to 76 g of 2-((2-benzylphenylsulfonyl)methyl)-2-ethylhexanal 45 as a syrup.
Step 4. (3a,4a,5a) 3-Butyl-3-ethyl-4-hydroxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (6c), and
(3a,4b,5b) 3-Butyl-3-ethyl-4-hydroxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (6d)
Reaction of 45 with potassium t-butoxide according to the procedute in step 3 of procedure A gave pure 6c and 6d after HPLC.
Example 19
(3a,4b,5b) 3-Butyl-3-ethyl-4-hydroxy-8-methoxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (25) and (3a,4a,5a) 3-Butyl-3-ethyl-4-hydroxy-8-methoxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (26)
Step 1. Preparation of 2-((2-benzoyl-4-methoxy phenylthio)methyl)-2-ethylhexanal (22)





2-Hydroxy-4-methoxybenzophenone was converted to the dimethyl O-2-benzoyphenyl thiocarbamate by methods previously described in example 18. The product can be isolated by recrystallization from ethanol. Using this improved isolation procedure no chromatography was needed. The thermal rearrangement was performed by reacting the thiocarbaimate( 5 g) in diphenyl ether at 260° C. as previously described. The improved isolation procedure which avoided a chromatography step was described below.
The crude pyrolysis product was then heated at 65° C. in 100 ml of methanol and 100 ml of THF in the presence of 3.5 g of KOH for 4 h. After removing THF and methanol by rotary evaporation the solution was extracted with 5% NaOH and ether. The base layer was acidified and extracted with ether to obtain a 2.9 g of crude thiophenol product. The product was further puified by titrating the desired mercaptan into base with limited KOH. After acidification and extraction with ether pure 2-mercapto-4-methoxybenzophenone (2.3 g) was isolated.
2-mercapto-4-methoxybenzophenone can readily be converted to the 2-((2-benzoyl-4-methoxyphenylthio)methyl)-2-ethylhexanal (22) by reaction with 2-ethyl-2-(mesyloxymethyl)hexanal (1) as previously described.
Step 2. 2-((2-Benzoyl-5-methoxyphenylsulfonyl)methyl)-2-ethylhexanal (23)





Substrate 22 was readily oxidized to 2-((2-benzoyl-5-methoxyphenyl-sulfonyl)methyl)-2-ethylhexanal (23) as described in example 18.
Step 3. 2-((2-benzyl-5-methoxyphenylsulfonyl)methyl)-2-ethylhexanal (24)





Sulfone 23 was then reduced to 2-((2-benzyl-5-methoxyphenyl-sulfonyl)methyl)-2-ethylhexanal (24) as described in example 18.
Step 4. (3a,4b,5b) 3-Butyl-3-ethyl-4-hydroxy-8-methoxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (25) and (3a,4a,5a) 3-Butyl-3-ethyl-4-hydroxy-8-methoxy-5-phenyl-2,3,4,5-tetraLydrobenzothiepine-1,1-dioxide (26)








A 3-neck flask equipped with a powder addition funnel, thermocouple and nitrogen bubbler was charged with 19.8 g (0.05 mole) of sulfone 24 in 100 ml dry THF. The reaction was cooled to −1.6° C. internal temperature by means of ice/salt bath. Slowly add 5.61 g (0.05 mole) of potassium t-butoxide by means of the powder addition funnel. The resulting light yellow solution was maintained at −1.6° C. After 30 min reaction 400 ml of cold ether was added and this solution was extracted with cold 10% HCl. The acid layer was extracted with 300 ml of methylene chloride. The organic layers were combined and dried over magnesium sulfate and after filtration stripped to dryness to obtain 19.9 g of product. 1H NMR and glpc indicated a 96% conversion to a 50/50 mixture of 25 and 26. The only other observable compound was 4% starting sulfone 24.
The product was then dissolved in 250 ml of 90/10 hexane/ethyl acetate by warning to 50° C. The solution was allowed to cool to room temperature and in this way pure 26 can be isolated. The crystallization can be enhanced by addition of a seed crystal of 26. After 2 crystallizations the mother liquor which was now 85.4% 25 and has a dry weight of 8.7 g. This material was dissolved in 100 ml of 90/10 hexane/ethyl acetate and 10 ml of pure ethyl acetate at 40 C. Pure 25 can be isolated by seeding this solution with a seed crystal of 25 after storing it overnight at 0 C.
Example 20
(3a,4a,5a) 3-Butyl-3-ethyl-4,8-dihydroxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (27)





In a 25 ml round bottomed flask, 1 g of 26( 2.5 mmoles) and 10 ml methylene chloride were cooled to −78° C. with stirring. Next 0.7 ml of boron tribromide (7.5 mmole) was added via syringe. The reaction was allowed to slowly warm to room temperature and stirred for 6 h. The reaction was then diluted with 50 ml methylene chloride and washed with saturated NaCl and then water. The organic layer was dried over magnesium sulfate. The product (0.88 g) 27 was characterized by NMR and mass spectra.
Example 21
General Alkylation of phenol 27
A 25 ml flask was charged with 0.15 g of 27 (0.38 mmole), 5 ml anhydrous DMF, 54 mg of potassium carbonate (0.38 mmole) and 140 mg ethyl iodide (0.9 mmole). The reaction was stirred at room temperature overnight. The reaction was diluted with 50 ml ethyl ether and washed with water (25 ml) then 5% NaOH (20 ml) and then sat. NaCl. After stripping off the solvent the ethoxylated product 28 was obtained in high yield. The product was characterized by NMR and mass spectra. This same procedure was used to prepare products listed in table 1 from the corresponding iodides or bromides. For higher boiling alkyl iodides and bromides only one equivalent of the alkyl halide was used. 












TABLE 1





Compound No.
R







27
H


26
Me


28
Et


29
hexyl


30
Ac


31
(CH2)6-N-pthalimide









Example 22
(3a,4a,5a) 3-Butyl-3-ethyl-4-hydroxy-7-hydroxyamino-5-phenyl-2,3,4,5-tetraydrobenzothiepine-1,1-dioxide (37) and (3a,4b,5b) 3-Butyl-3-ethyl-4-hydroxy-7-hydroxyamino-5-phenyl-2,3,4,5-tetrahydobenzothiepine-1,1-dioxide (38)
Step 1. Preparation of 2-chloro-5-nitrodiphenylmethane (32)





Procedure Adapted from Reference:Synthesis-stuttgart 9 770-772 (1986) Olah G. Et al

Under nitrogen, a 3 neck flask was charged with 45 g (0.172 mole ) of 2-chloro-5-nitrobenzophenone in 345 ml methylene chloride and the solution was cooled to ice/water temperature. By means of an additional fur.nel, 150 g( 0.172 mole) of trifluoromethane sulfonic acid in 345 ml methylene chloride was added slowly. Next 30 g of triethylsilane (0.172 mole) in 345 ml methylene chloride was added dropwise to the chilled solution. Both addition steps (trifluoromethane sulfonic acid and triethylsilane) were repeated. After the additions were completed the reaction was allowed to slowly warm up to room temperature and stirred for 12 h under nitrogen. The reaction mixture was then poured into a chilled stirred solution of 1600 ml of saturated sodium bicarbonate. Gas evolution occurred. Poured into a 4 liter separatory funnel and separated layers. The methylene chloride layer was isolated and combined with two 500 ml methylene chloride extractions of the aqueous layer. The methylene chloride solution was dried over magnesium sulfate and concentrated in vacuo. The residue was recrystallized from hexane to give 39 g product. Structure 32 was confirmed by mass spectra and proton and carbon NMR.
Step 2. Preparation of 2-((2-benzyl-4-nitophenylthio)methyl)-2-ethylhexanal (33)





The 2-chloro-5-nitrodiphenylmethane product 32 (40 g, 0.156 mole) from above was placed in a 2 liter 2 neck flask with water condenser. Next 150 ml DMSO and 7.18 g (0.156 mole) of lithium sulfide was added and the solution was stirred at 75° C. for 12 h. The reaction was cooled to room temperature. and then 51.7 g of mesylate IV was added in 90 ml DMSO. The reaction mixture was heated to 80° C. under nitrogen. After 12 h monitored by TLC and added more mysylate if necessary. Continued the reaction until the reaction was completed. Next the reaction mixture was slowly poured into a 1900 ml of 5% acetic acueous solution with stirring, extracted with 4×700 ml of ether, and dried over MgSO4. After removal of ether, 82.7 g of product was isolated. The material can be further purified by silica gel chromatography using 95% hexane and 5% ethyl acetate. If pure mysylate was used in this step there was no need for further purificaion. The product 33 was characterized by mass spectra and NMR.
Step 3. Oxidation of the nitro product 33 to the sulfone 2-((2-benzyl-4-nitrophenylsulfonyl)methyl)-2-ethylhexanal (34)





The procedure used to oxidize the sulfide 33 to the sulfone 34 has been previously described.
Step 4. Reduction of 34 to 2-((2-benzyl-4-hydroxyaminophenylsulfonyl)methyl)-2-ethylhexanal (35)





A 15 g sample of 34 was dissolved in 230 ml of ethanol and placed in a 500 ml rb flask under nitrogen. Next 1.5 g of 10 wt. % Pd/C was added and hydrogen gas was bubbled through the solution at room temperature until the nitro substrate 34 was consumed. The reaction could be readily monitored by silica gel TLC using 80/20 hexane/EtOAc. Product 35 was isolated by filtering off the Pd/C and then stripping off the EtOH solvent. The product was characterized by NMR and mass spectra.
Step 5. Preparation of the 2-((2-benzyl-4-N,O-di-(t-butoxy-carbonyl)hydroxyaminophenylsulfonyl)methyl)-2-ethylhexanal (36)





A 13.35 g sample of 35 (0.0344 mole) in 40 ml of dry THF was stirred in a 250 ml round bottomed flask. Next added 7.52 g (0.0344 mole) of di-t-butyl dicarbonate in 7 ml THF. Heated at 60° C. overnight. Striped off THF and redissolved in methylene chloride. Extracted with 1% HCl; and then 5% sodium bicarbonate.
The product was further purified by coloun chromatography using 90/10 hexane/ethyl acetate and then 70/30 hexane/ethyl acetate. The product 36 was obtained (4.12 g) which appeared to be mainly the di-(t-butoxycarbonyl) derivatives by proton NMR.
Step 6. (3a,4a,5a) 3-Butyl-3-ethyl-4-hydroxy-7-hydroxyamino-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (37) and (3a,4b,5b) 3-Butyl-3-ethyl-4-hydroxy-7-hydroxyamino-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (38)








A 250 ml 3-neck round bottomed flask was charged with 4 g of 36 (6.8 mmoles), and 100 ml of anhydrous THF and cooled to −78° C. under a nitrogen atmosphere. Slowly add 2.29 g potassium tert-butoxide (20.4 mmoles) with stirring and maintaining a −78° C. reaction temperature. After 1 h at −78° C. the addition of base was completed and the temperature was brought to −10° C. by means of a ice/salt bath. After 3 h at −10° C., only trace 36 remained by TLC. Next add 35 ml of deionized water to the reaction mixture at −10° C. and stirred for 5 min. Striped off most of the THF and added to separatory funnel and extracted with ether until all of the organic was removed from the water phase. The combined ether phases were washed with saturated NaCl and then dried over sodium sulfate. The only products by TLC and NMR were the two BOC protected isomers of 37 and 38. The isomers were separated by silica gel chromatography using 85% hexane and 15% ethyl acetate; BOC-37 (0.71 g) and BOC-38 (0.78 g).
Next the BOC protecting group was removed by reacting 0.87 g of BOC-38 (1.78 mmoles) with 8.7 ml of 4 M HCl (34.8 mmoles) in dioxane for 30 min. Next added 4.74 g of sodium acetate (34.8 mmoles) to the reaction mixture and 16.5 ml ether and stirred until clear. After transferring to a separatory funnel extracted with ether and water and then dried the ether layer with sodium sulfate. After removing the ether, 0.665 g of 38 was isolated. Isomer 37 could be obtained in a similar procedure.
Example 23
(3a,4a,5a) 3-Butyl-3-ethyl-7-(n-hexylamino)-4-hydroxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (40) and (3a,4b,5b) 3-Butyl-3-ethyl-7-(n-hexylamino)-4-hydroxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (41)
Step 1. 2-((2-Benzyl-4-(n-hexylamino)phenylsulfonyl)methyl)-2-ethylhexanal (39)





In a Fischer porter bottle weighed out 0.5 g of 34 (1.2 mmoles) and dissolved in 3.8 ml of ethanol under nitrogen. Next added 0.1 g of Pd/C and 3.8 ml of hexanal. Seal and pressure to 50 psi of hydrogen gas. Stirred for 48 h. After filtering off the catalyst and removing the solvent by rotary evaporation 39 was isolated by column chromatography (0.16 g) using 90/10 hexane ethyl acetate and gradually increasing the mobile phase to 70/30 hexane/ethyl acetate. The product was characterized by NMR and mass spectra.
Step 2. (3a,4a,5a) 3-Butyl-3-ethyl-7-(n-hexylamino)-4-hydroxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (40) and (3a,4b,5b) 3-Butyl-3-ethyl-7-(n-hexylamino)-4-hydroxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide








A 2-neck, 25 ml round bottomed flask with stir bar was charged with 0.158 g 39 (0.335 mmole) and 5 ml anhydrous THF under nitrogen. Cool to −10° C. by means of a salt/water bath. Slowly add 0.113 g of potassium tert butoxide (0.335 mmole). After 15 min at −10° C. all of the starting material was consumed by TLC and only the two isomers 40 and 41 were observed. Next added 5 ml of chilled 10% HCl and stirred at −10° C. for 5 min. Transferred to a separatory funnel and extract with ether. Dried over sodium sulfate. Proton NMR of the dried product (0.143 g) indicated only the presence of the two isomers 40 and 41. The two isomers were separated by silica gel chromatography using 90/10 hexane ethyl acetate and gradually increasing the mobile phase to 70/30 hexane/ethyl acetate. 40 (53.2 mg); 41(58.9 mg).
Example 24
Quaternization of Amine Substrates 40 and 41
Amine products such as 40 and 41 can be readily alkylated to quaternary salts by reaction with alkyl halides. For example 40 in DMF with 5 equivalents of methyl iodide in the presence of 2,6 dimethyl lutidine produces the dimethylhexylamino quaternary salt.
Example 25
(3a,4b,5b) 3-Butyl-3-ethyl-4-hdroxy-5-(4-iodophenyl)-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (42)





In a 25 ml round bottomed flask 0.5 g (1.3 mmole) of 6d, 0.67 g of mercuric triflate were dissolved in 20 ml of dry methylene chloride with stirring. Next 0.34 g of Iodine was added and the solution was stirred at room temperature for 30 h. The reaction was then diluted with 50 ml methylene chloride and washed with 10 ml of 1 M sodium thiosulfate; 10 ml of saturated KI; and dried over sodium sulfate. See Tetrahedron, Vol. 50; No. 17, pp 5139-5146 (1994) Bachki, F. Et al.Mass spectrum indicated a mixture of 6d , mono iodide 42 and a diiodide adduct. The mixture was separated by column chromatography and 42 was characterized bt NMR and mass spectra.
Example 26
(3a,4b,5b) 3-Butyl-5-(4-carbomethoxyphenyl)-3-ethyl-4-hydroxy-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (43)





A 0.1 g sample of 42 ( 0.212 mmole), 2.5 ml dry methanol, 38 μl triethylamine (0.275 mmole), 0.3 ml toluene and 37 mg of palladium chloride (0.21 mmole) was charged to a glass lined mini reactor at 300 psi carbon monoxide. The reaction was heated at 100° C. overnight. The catalyst was filtered and a high yield of product was isolated.
The product was characterized by NMR and mass spectra.
Note the ester functionalized product 43 can be converted to the free acid by hydrolysis.
Example 27
(3a,4a,5a) 3-Butyl-3-ethyl-4-hydroxy-7-methoxy-5-phenyl-2,3,4,5-tetraydrobenzothiepine-1,1-dioxide (48), and (3a,4b,5b) 3-Butyl-3-ethyl-4-hydroxy-7-methoxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (49)
Step 1. 2-Mercapto-5-methoxybenzophenone (50)





Reaction of 66.2 g of 4-methoxythiophenol with 360 ml of 2.5 N n-butyllithium, 105 g of tetramethylethylenediamine and 66.7 g of benzonitrile in 600 ml cyclohexane according to the procedure in WO 93/16055 gave 73.2 g of brown oil which was kugelrohr distilled to remove 4-methoxythiophenlol and gave 43.86 g of crude 50 in the pot residue.
Step 2. 2-((2-Benzoyl-4-methoxyphenylthio)methyl)-2-ethylhexanal (51)





Reaction of 10 g (0.04 mole) of crude 50 with 4.8 g (0.02 mole)of mesylate 1 and 3.2 ml (0.23 mole) of triethylamine in 50 ml of diglyme according to the orocedure for the preparation of 2 gave 10.5 g of crude product which was purified by HPLC (5% ethyl acetate-hexane) to give 1.7 g (22%) of 51.
Step 3. 2-((2-Benzoyl-4-methoxyphenylsulfonyl)methyl)2-ethyl-hexanal (52)





A solution of 1.2 g (3.1 mmoles) of 51 in 25 ml of methylene chloride was reacted with 2.0 g (6.2 mmoles) of 50-60% MCPBA according to the procedure of step 2 of procedure A in example 18 gave 1.16 g (90%) of 52 as a yellow oil.
Step 4. 2-((2-Benzyl-4-methoxyphenylsulfonyl)methyl)-2-ethylhexanal (53)





Hydrogenation of 1.1 g of 52 according to the procedure of step 3 of procedure A of example 18 gave 53 as a yellow oil (1.1 g).
Step 5. (3a,4a,5a) 3-Butyl-3-ethyl-4-hydroxy-7-methoxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (48), and (3a,4b,5b) 3-Butyl-3-ethyl-4-hydroxy-7-methoxy-5-pbenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide





A solution of 1.1 g of 53, 0.36 g of potassium t-butoxide and 25 ml of anhydrous THF was held at reflux for 2 h and worked up as in step 4 of procedure A of example 18 to give 1.07 g of a crude product which was purified by HPLC to give 40 mg (4%) of 48 as crystals, mp 153-154° C. and 90 mg (8%) of 49 as solid, mp 136-140° C.
Example 28
5-Phenyl-2,3-dihydrospirobenzothiepine-3,1′-cyclohexane (57)





Step 1. 1-(Hydroxymethyl)-cyclohexanecarboxaldehyde (54)





To a cold (0° C. mixture of 100 g (0.891 mole) of cyclohexanecarboxaldehyde, 76.5 g of 37% of formaldehyde in 225 ml of mnethanol was added dropwise 90 ml of 1 N Sodium hydroxide in 1 h. The reaction mixture was stirred at room temperature over 48 then was evaporated to remove methanol. The reaction mixture was diluted with water and extracted with methylene chloride. The organic layer was washed with water, brine, and dried over sodium sulfate and concentrated under vacuum to give 75 g (59.7%) of thick oil. Proton NMR and mass spectra were consistent with the product.
Step 2. 1-(mesyloxymethyl)cyclohexanecarboxaldehyde (55)





To a cold (0° C. mixture of alcohol 54 (75 g, 0.54 mole) and 65.29 g (0.57 mole) of methanesulfonyl chloride in 80 ml of methylene chloride was added a solution of pyridine (47.96 g, 0.57 mole) in 40 ml of methylene chloride. The reaction mixture was stirred at room temperature for 18 h then quenched with water, acidified with conc. HCl and extracted with methylene chloride. The organic layer was washed with water, brine, and dried over sodium sulfate and concentrated under vacuum to give 91.63 g (77.8%) of thick oil. Proton NMR and mass spectra were consistent with the product.
Step 3. 1-((2-Benzoylphenylthio)methyl)cyclohexanecarboxaldehyde (56)





A mixture of 69 g (0.303 mole) of 2-mercaptobenzophenone, 82 g (0.303 mole) of mesylate 55, 32 g of triethyline, and 150 ml of diglyme was stirred and held at relux for 24 h. The mixture was cooled, poured into dil. HCl and extracted with methylene chloride. The organic layer was washed with 10% NaOH, water, brine, and dried over sodium sulfate and concentrated under vacuum to remove excess diglyme. This was purified by silica gel flush column (5% EtOAc-Hexane) and gave 18.6 g (75.9%) of yellow oil. Proton NMR and mass spectra were consistent with the product.
Step 4. 5-Phenyl-2,3-dihydrospirobenzothiepine-3,1′-cyclohexane (57)





To a mixture of 6.19 g of zinc dust and 100 ml of dry DME was added TiCl3 (16.8 g, 0.108 mole). The reaction mixture was heated to reflux for 2 h. A solution of compound 56 (8.3 g, 0.023 mole) in 50 ml of DME was added dropwise to the reaction mixture in 1 h and the mixture was held at reflux for 18 h. The mixture was cooled, poured into water and extracted with ether. The organic layer was washed with water, brine, and dried over sodium sulfate, filtered through celite and concentrated under vacuum. The residue was purified by HPLC (10% EtOAc:Hexane) to give 4.6 g (64%) of white solid, mp 90-91° C. Proton and carbon NMR and mass spectra were consistent with the product.
Example 29
8b-Phenyl-1a,2,3,8b-tetrahydrospiro(benzothiepino[4,5-b]oxirene-2,1′-cyclohexane)-4,4-dioxide (58)





To a solution of 57 (4.6 g, 15 mmole) in 50 ml chloroform under nitrogen was added 55% MCPBA (16.5 g, 52.6 mmole) portionwise with spatula. The reaction was held at reflux for 18 h and washed with 10% NaOH (3×), water, brine, and dried over sodium sulfate and concentrated under vacuum to give 5 g of crude prodct. This was recrystallized from Hexane/EtOAc to give 4.31 g (81%) of yellow solid, rp 154-155° C. Proton and carbon NMR and mass spectra were consistent with the product.
Example 30
trans-4-Hydroxy-5-phenyl-2,3,4,5-tetrahydo spiro(benzothiepine-3,1′-cyclohexane)-1,1-dioxide (59)





A mixture of 0.5 g (1.4 mmoles) of 58, 20 ml of ethanol,10 ml of methylene chloride and 0.4 g of 10% Pd/C catalyst was hydrogenated with 70 psi hydrogen for 3 h at room temperature. The crude reaction slurry was filtered through Celite and evaporated to dryness. The residue was purified by HPLC (10% EtOAc-Hexane, 25% EtOAc-Hexane). The first fraction was 300 mg (60%) as a white solid, mp99-100° C. Proton NMR showed this was a trans isomer. The second fraction gave 200 mg of solid which was impure cis isomer.
Example 31
cis-4-Hydroxy-5-phenyl-2,3,4,5-tetrahydro spiro(benzothiepine-3,1′-cyclohexane)-1,1-dioxide (60)





To a solution of 0.2 g (0.56 mmole) of 59 in 20 ml of CH2Cl2, was added 8 g of 50% NaOH and one drop of Aliquat-336 (methyltricaprylylammonium chloride) phase transfer catalyst. The reaction mixture was stirred for 10 h at room temperature. Twenty g of ice was added to the mixture and the mixture was extracted with CH2Cl2 (3×10 ml) washed with water, brine and dried over MgSO4 and concentrated in vacuo to recover 0.15 g of crude product. This was recrystallized from Hexane/EtOAc to give 125 mg of white crystal, mp 209-210° C. Proton and carbon NMR and mass spectra were consistent with the product.
Example 32
(3a,4a,5a) 3-Butyl-3-ethyl-4-hydroxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine (61), and (3a,4b,5b) 3-Butyl-3-ethyl-4-hydroxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine (62)





To a solution of 0.5 g (1.47 mmole) of compound 47 in 5 ml of anhydrous THF was added 0.17 g (1.47 mmole) of 95% potassium t-butoxide. The reaction mixture was stirred at room temperature for 18 h and quenched with 10 ml of 10% HCl. The organic was extracted into methylene chloride. The methylene chloride extract was dried over magnesium sulfate and concentrated in vacuo. The residue was purified by HPLC (2% EtOAc-hexane) to give 47 mg of 61 in the second fraction and 38 mg of 62 in the third fraction. Proton NMR and mass spectra were consistent with the assigned structures.
Exampole 33
(3a,4a,5a) 3-Butyl-3-ethyl-4-hydoxy-7-amino-5-phenyl-2,3,4,5-tetraydrobenzothiepine-1,1-dioxide (63) and (3a,4b,5b) 3-Butyl-3-ethyl-4-hydroxy-7-aino-5-phenyl-2,3,4,5-tetraydrobenzothiepine-1,1-dioxide (64)





An autoclave was charged with 200 mg of 37 in 40 cc ethanol and 0.02 g 10% Pd/C. After purging with nitrogen the clave was charged with 100 psi hydrogen and heated to 55 C. The reaction was monitored by TLC and mass spec and allowed to proceed until all of 37 was consumed. After the reaction was complete the catalvst was filtered and the solvent was removed in vacuo and the only observable product was amine 63. This same procedure was used to produce 64 from 38.
Example 34
(3a,4a,5a) 3-Butyl-3-ethyl-4-hydroxy-7-methoxy-5-(3′-methoxypenyl)-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxlde (65), and (3a,4b,5b) 3-Butyl-3-ethyl-4-hydroxy-7-methoxy-5-(3-methoxyphenyl)-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (66)





Alkylation of e-methoxyphenol with 3-methoxybenzyl chloride according to the procedure described in J. Chem. Soc, 2431 (1958) gave 4-methoxy-2-(3′-methoxybenzyl)phenol in 35% yield. This material was converted to compound 65, mp 138.5-141.5° C., and compound 66, mp 115.5-117.5° C., by the procedure similar to that in Example 18 method B.
Example 35
(3a,4a,5a) 3-Butyl-3-ethyl-4-hydroxy-7-methoxy-5-(3′-(trifluoromethyl)phenyl)-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (67), and (3a,4b,5b) 3-Butyl-3-ethyl-4-hydroxy-7-methoxy-5-(3′-(trifluoromethyl)phenyl)-2,3,4,5tetrahydrobenzothieoine-1,1-dioxide (68)





Alkylation of 4-methoxyphenol with 3-(trifluoromethyl)benzyl chloride according to the procedure described in J. Chem. Soc. 2431 (1958) gave 4-methoxy-2-(3′-(trifluoromethyl)benzyl)phenol. This material was converted to compound 67, mp 226.5-228° C., and compound 68, m?p 188-190° C., byu the procedure similar to that in Example 18 method B.
Example 36
(3a,4a,5a) 3-Butyl-3-ethyl-5-(4′-fluorophenyl)-4-hydroxy-7-methoxy-2,3,4,5-tetrahydroberzothiepine-1,1-dioxide (69), and (3a,4b,5b) 3-Butyl-3-ethyl-5-(4′-fluorophenyl)-4-hydroxy-7-methoxy-2,3,4,5-tetrahydtobenzothiepine-1,1-dioxide (70)





Alkylation of 4-methoxyphenol with 4-fluorobenzyl chloride according to the procedure described in J. Chem. Soc, 2431 (1958) gave 4-methoxy-2-(4′-fluorobenzyl)phenol. This material was converted to compound 69 and compound 70 by the procedure similar to that in Example 18 method B.
Example 37
(3a,4a,5a) 3-Butyl-3-ethyl-5-(3′-fluorophenyl)-4-hydroxy-7-methoxy-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (71), and (3a,4b,5b) 3-Butyl-3-ethyl-5-(3′-fluorophenyl)-4-hydroxy-7-methoxy-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (72)





Alkylation of 4-methoxyphenol with 3-fluorobenzyl chloride according to the procedure described in J. Chem. Soc, 2431 (1958) gave 4-methoxy-2-(3′-fluorobenzyl)phenol. This material was converted to compound 71 and compound 72 by the procedure similar to that in Example 18 method B.
Example 38
(3a,4a,1a) 3-Butyl-3-ethyl-5-(2′-fluoraphenyl)-4-hydroxy-7-methoxy-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (73), and (3a,4b,5b) 3-Butyl-3-ethyl-5-(2′-fluorolhenyl)-4-hydroxy-7-methoxy-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (74)





Alkylation of 4-methoxyphenol with 2-fluorobenzyl chloride according to the procedure described in J. Chem. Soc, 2431 (1958) gave 4-methoxy-2-(2′-fluorobenzyl)phenol. This material was converted to compound 73 and compound 74 by the procedure similar to that in Example 18 method B.
Example 39
(3a,4a,5a) 3-Butyl-7-bromo-3-ethyl-4-hydroxy-5-(3′-methoxyphenyl)-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (75), and (3a,4b,5b) 3-Butyl-7-bromo-3-ethyl-4-hydroxy-5-(3′-methoxyphenyl)-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (76)





Alkylation of 4-bromophenol with 3-methoxybenzyl chloride accorcing to the procedure described in J. Chenm. Soc, 2431 (1958) gave 4-bromo-2-(3′-methoxybenzyl)phenol. This material was converted to compound 75, mp 97-101.5° C., and compound 76, mp 102-106° C., by the procedure similar to that in Example 18 method B.
(3a,4a,5a) 3-Butyl-3-ethyl-7-fluoro-5-(4′-fluorophenyl)-4-hydroxy-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (77), and
(3a,4b,5b) 3-Butyl-3-ethyl-7-fluoro-5-(4′-fluorophenyl)-4-hydroxy-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (78)





Alkylation of 4-fluorophenol with 4-fluorobenzyl chloride according to the procedure described in J. Chem. Soc, 2431 (1958) gave 4-fluoro-2-(4′-fluorobenzyl)phenol. This material was converted to compound 77, mp 228-230° C., and compound 78, mp 134.5-139° C., by the procedure similar to that in Example 18 method B.
Example 41
(3a,4a,5a) 3-Butyl-3-ethyl-7-fluoro-4-hydroxy-5-(3′-methoxyphenyl)-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (79), and (3a,4b,5b) 3-Butyl-3-ethyl-7-fluoro-40hydroxy-5-(3′-methoxyhenyl)-2 1,1-dioxide (80)





Alkylation of 4-fluorophenol with 3-methoxybenzyl chloride according to the procedure described in J. Chem. Soc, 2431 (1958) gave 4-fluoro-2-(3′-methoxybenzyl)phenol. This material was converted to compound 79, as a solid and compound 80, mm 153-155° C., by the procedure similar to that in Example 18 method B.
Example 42
(3a,4b,5b) 3-Butyl-3-ethyl-5-(4′-fluorophenyl)-4-hydroxy-7-methylthio-2,3,4,5-tetrahydrobenzothieoine-1,1-dioxide (81)





A mixture of 0.68 (1.66 mmol) of compound 77, 0.2 g (5 mmol) of sodium methanethiolate and 15 ml of anhydrous DMF was stirred at room temperature for 16 days. The reaction mixture was dilute with ether and washed with water and brine and dried over MgSO4. The ether solution was concentrated in vacuo. The residue was purified by HPLC (20% ethyl acetate in hexanes). The first fraction was impure (3a,4a,5a) 3-butyl-3-ethyl-4-hydroxy-7-methylthio-5-(4′-fluorophenyl)-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide. The second fraction was compound 81, mp 185-186.5° C.
Example 43
(3a,4b,5b) 3-Butyl-3-ethyl-5-(4′-fluorophenyl)-4-hydroxy-7-(1-pyrrolidinyl)-2,3,4,5-tetrahydrobennzothiepine-1,1-dioxide (82)





A mixture of 0.53 g (1.30 mmol) of compound 78 and 5 ml of pyrrolidine was held at reflux for 1 h. The reaction mixture was diluted with ether and washed with water and brine and dried over MgSO4. The ether solution was concentrated in vacuo. The residue was crvstallized from ether-hexanes to give compound 82, mp 174.5-177° C.
Example 44
(3a,4b,5b) 3-Butyl-3-ethyl-5-(4′-flourophenyl)-4-hydroxy-7-(1-morpholinyl)-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (83)





A mixture of 0.4 g (0.98 mmol) of compound 78 and 5.0 g (56 mmol) of morpholine was held at reflux for 2 h and concentrated in vacuo. The residue was diluted with ether (30 ml) and washed with water and brine and dried over MgSO4. The ether solution was concentrated in vacuo. The residue was recrystallized from ether-hexanes to give compound 83, mp 176.5-187.5° C.
Example 45
(3a,4a,5a) 3-Butyl-3-ethyl-5-(4′-fluorophenyl)-4-hydroxy-7-methyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (84), and (3a,4b,5b) 3-Butyl-3-ethyl-5-(4′-fluorophenyl)-4-hydroxy-7-methyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (85)





Alkylation of 4-methylphenol with 4-fluorobenzyl chloride according to the procedure described in J. Chem. Soc, 2431 (1958) gave 4-methyl-2-(4′-fluorobenzyl)phenol). This material was converted to compound 84 and compound 85 by the procedure similar to that in Example 18 method B.
Example 46
(3a,4b,5b) 3-Butyl-3-ethyl-4-hydroxy-5-(4′-hydroxyphenyl)-7-methoxy-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (86), and
(3a,4b,5b) 3-Butyl-3-ethyl-4,7-dihydroxy-5-(4′-hydroxyohenyl)-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (87)





To a solution of 0.52 (1.2 mmol) of compound 66 in 20 ml of methylene chloride was added 1.7 g (6.78 mmol) of born tribromide. The reaction mixture was cooled to −78° C. and was stirred for 4 min. An additional 0.3 ml of boron tribromide was added to the reaction mixture and the reaction mixture was stirred at −78° C. for 1 h and quenced with 2 N HCl. The organic was extracted into ether. The ether layer was washed with brine, dried over MgSO4, and concentrated in vacuo. The residue (0.48 g) was purified by HPLC (30% ethyl acetate in hexanes). The first fraction was 0.11 g of compound 86 as a white solid, mp 171.5-173° C. The second fraction was crystallized from chloroform to give 0.04 g of compound 87 as a white solid, mp 264° C. (dec).
Example 47
(3a,4b,5b) 3-Butyl-3-ethyl-4,7-dihydroxy-5-(4′-fluorophenyl)-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (88)





Reaction of compound 70 with excess boron tribromide at room temperature and worked up as in Example 46 gave compound 88 after an HPLC purification.
Example 48
(3a,4b,5b) 3-Butyl-3-ethyl-5-(4′-fluorophenyl)-4-hydroxy-7-(1-azetidinyl)-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (89)





A mixture of 0.20 g (0.49 mmol) of compound 78, and 2.0 g (35 mmol) of aztidine was held at reflux for 3 h and concentrated in vacuo. The residue was diluted with ether (30 ml) and washed with water and brine and dried over MgSO4. The ether solution was concentrated on a steam bath. The separated crystals were filtered to give 0.136 g of 89 as prisms, mp 196.5-199.5° C.
Example 49
(3a,4a,5a) 3-Butyl-3-ethyl-5-(3′-methoxyphenyl)-4-hydroxy-7-methylthio-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (90). (3a,4b,5b) 3-Butyl-3-ethyl-5-(3′-methoxyphenyl)-4-hydroxy-7-methylthio-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (91)





A mixture of 0.4 g (0.95 mmol) or compound 79, 0.08 g (1.14 mmol) of sodium methanethiolate and 15 ml of anhydrous DMF was stirred at 60° C. for 2 h. An additional 1.4 mmol of sodium methanethiolate was added to the reaction mixture and the mixture was stirred at 60° C. for an additional 2 h. The reaction mixture was triturated with 100 ml of water and extracted methylene chloride. The methylene chloride water mixture was filtered through Celite and the methylene chloride layer was dried over MgSO4 and concentrated in vacuo. The first fraction (0.1 g) was compound 90, mp 117-121° C. The second fraction (0.16 g) was compound 91, mp 68-76° C.
Example 50
Preparation of Polyethyleneglycol Functionaled Benzothiepine A. 




A 50 ml rb flash under a nitrogen atmosphere was charged with 0.54 g of M-Tres-5000 (Polyethyleneglycol Tresylate [methoxy-PEG-Tres, MW 5000] purchased from Shearwater Polymers Inc., 2130 Memorial Parkway, SW, Huntsville, Ala. 35801), 0.055 g Compound No. 136, 0.326 C2CO3 and 2 cc anhydrous acetonitrile. The reaction was stirred at 30 C for 5 days and then the solution was filtered to remove salts. Next, the acetonitrile was removed under vacuum and the product was dissolved in THF and then precipitated by addition of hexane. The polymer precipitate was isolate by filtration from the solvent mixture (THF/hexane). This precipitation procedure was continued until no Compound No. 136 was detected in the precipitated product (by TLC SiO2). Next, the polymer precipitate was dissolved in water and filtered and the water soluble polymer was dialyzed for 48 hours through a cellulose dialysis tube (spectrum® 7, 45 mm×0.5 ft, cutoff 1,000 MW). The polymer solution was then removed from the dialysis tube and lycohilized until dried. The NMR was consistent with the desired product A and gel permeation chromatography indicated the presence of a 4500 MW polymer and also verified that no free Compound No. 136 was present. This material was active in the IBAT in vitro cell assay.
Example 51
Preparation of Compound 140





A 2-necked 50 ml round bottom Flask was charged with 0.42 g of Tres-3400 (Polyethyleneglycol Tresylate [Tres-PG-Tres, MW 3400] purchased from Shearwater Polymers Inc., 2130 Memorial Parkway, SW, Huntsville, Ala. 35801), 0.1 potassium carbonate, 0.100 g of Compound No. 111 and 5 ml anhydrous DMF. Stir for 6 days at 27° C. TLC indicated the disappearance of the starting Compound No. 111. The solution was transferred to a separatory funnel and diluted with 50 cc methylene chloride and then extracted with water. The organic layer was evaporated to dryness by means of a rotary evaporator. Dry wgt. 0.4875 g. Next, the polymer was dissolved in water and then dialyzed for 48 hours at 40° C. through a cellulose dialysis tube (spectrum® 7, 45 mm×0.5 ft, cutoff 1,000 MW). The polymer solution was then removed from the dialysis tube and lyophilized until dried 0.341 g). NMR was consistent with the desired product B.
Example 52





A 10 cc vial was charged with 0.21 g of Compound No. 136 (0.5 moles), 0.17 g (1.3 mmoles) potassium carbonate, 0.6 g (1.5 mmoles) of 1,2-bis-(2-iodoethoxy)-ethane and 10 cc DMF. The reaction was stirred for 4 days at room temperature and then worked up by washing with ether/water. The ether layer was stripped to dryness and the desired product Compound No. 134 was isolated on a silica gel column using 80/20 hexane ethyl acetate.
Example 53





Example 54





A two necked 25 ml round bottom Flask was charged when 0.5 g (1.24 mmoles) of 69462, 13 mls of anhydrous DMF, 0.055 g of 60% NaH dispersion and 0.230 g (0.62 mmoles) of 1,2-Bis [2-iodoethoxylethane] at 10° C. under nitogen. Next, the reaction was slowly heated to 40° C. After 14 hours all of the Compound No. 113 was consumed and the reaction was cooled to room temperature and extracted with ether/water. The ether layer was evaporated to dryness and then chromatographed on Silicage (80/20 ethyl acetate/hexane). Isolated Compound No. 112 (0.28 g) was characterized by NMR and mass spec.
Example 55





In a 50 ml round bottom Flask, add 0.7 g (1.8 mmoles) of Compound No. 136, 0.621 g of potassium carbonate, 6 ml DMF, and 0.33 g of 1,2-Bis [2-iodoethoxylethane]. Stir at 40° C. under nitrogen for 12 hours. The workup and isolation was the same procedure for Compound No. 112.
Examples 56 and 57
(Compound Nos. 131 and 137)
The compositions of these compounds are shown in Table 3.
The same procedure as for Example 55 except appropriate benzothiepine was used.
Example 58
(Compound No. 139)
The composition of this compound is shown in Table 3. Same procedure as for Example 55 with appropriate benzothiepine 1,6 diiodohexane was used instead of 1,2-Bis [2-iodoethoxylethane].
Example 59
(Compound No. 101) 




This compound is prepared by condensing the 7-NH2 benzothiepine with the 1,12-dodecane dicarboxylic acid or acid halide.
Example 60
(Compound No. 104) 




2-Chloro-4-nitrobenzophenone is reduced with triethylsilane and trifluoromethane sulfonic acid to 0.2-chloro-4-nitrodiphenylmethane 32. Reaction of 32 with lithium sulfide followed by reacting the resulting sulfide with mesylate IV gives sulfide-aldehyde XXIII. Oxidation of XXIII with 2 equivalents of MCPBA yields sulfone-aldehyde XXIV (see Scheme 5). Reduction of the sulfone-aldehyde XXV formaldehyde and 100 psi hydrogen and 55 C for 12 hours catalyzed by palladium on carbon in the same reaction vessel yields the substituted dimethylamine derivative XXVIII. Cyclization of XXVII with potassitn t-butoxide yields a mixture of substituted amino derivatives of this invention Compound No. 104. 




EXAMPLE 61





A 1 oz. Fisher-porter bottle was charged with 0.14 g (0.34 mmoles) of 70112, 0.97 gms (6.8 mmoles) of methyl iodide, and 7 ml of anhydrous acetonitrile. Heat to 50° C. for 4 days. The quat. Salt Compound No. 192 was isolated by concentrating to 1 cc acetonitrile and then precipitating with diethyl ether.
Example 62





A 0.1 g (0.159 mmoles) sample of Compound No. 134 was dissolved in 15 ml of anhydrous acetonitrile in a Fischer-porter bottle and then trimethylamine was bubbled through the solution for 5 minutes at 0° C. and then capped and warmed to room temperature. The reaction was stirred overnight and the desired product was isolated by removing solvent by rotary evaporation.
Example 63
(Compound No. 295) 




Sodium Hydride 60% (11 mg, 0.27 mmoles) in 1 cc of acetonitrile at 0° C. was reacted with 0.248 mmoles (0.10 g) of Compound No. 54 in 2.5 cc of acetonitrile at 0° C. Next, 0. (980 g 2.48 mmoles) of 1,2-Bis [2-iodoethoxylethane]. After warming to room temperature, stir for 14 hours. The product was isolated by column chromatography.
Example 64
(Compound No. 286) 




Following a procedure similar to the one described in Example 86, infra (see Compound No. 118), the title compound was prepared and purified as a colorless solid; mp 180-181° C.; 1H NMR (CHCl3) δ 0.85 (t, J=6 Hz, 3H—, 0.92 (t, J=6 Hz, 3H), 1.24-1.42 (m, 2H), 1.46-1.56 (m, 1H), 1.64-1.80 (m, 1H), 2.24-2.38 (m, 1H), 3.15 (AB, JAB=15 Hz, Δv=42 Hz, 2H), 4.20.(d, J=8 Hz, 1H), 5.13 (s, 2H), 5.53 (s, 1H), 6.46 (s, 1H), 6.68 (s, 1H), 7.29-7.51 (m, 10H), 7.74 (d, J=8 Hz, 1H), 8.06 (d, J=8 Hz, 1H). FABMS m/z 494 (M+H), HRMS calcd for (M+H) 494.2001, found 494.1993. Anal. Cald. for C28H31NOS5S: C, 68.13; H, 6.33; N, 2.84. Found: C, 68.19; H, 6.56; N, 2.74.
Example 65
(Compound No. 287) 




Following a procedure similar to the one described in Example 89, infra (see Compound No. 121), the title comnound was prepared and purified as a colorless solid: mp 245-246° C., 1H NMR (CDCl3) δ 0.84 (t, J=6 Hz, 3), 0.92 (t, J=6 Hz, 3H), 1.28, (d, J=8 Hz, 1H), 1.32-1.42 (m, 1H), 1.48-1.60 (m, 1H), 1.64-1.80 (m, 1H), 2.20-2.36 (m, 1H), 3.09 (AB, JAB=15 Hz, Δv=42 Hz, 2H), 3.97 (bs, 2H), 4.15 (d, J=8 Hz, 1H), 5.49 (s, 1H), 5.95 (s, 1H), 6.54 (d, J=7 Hz, 1H), 7.29-7.53 (m, 5H), 7.88 (d, J=8 Hz, 1H); ESMS 366 (M+Li). Anal. Calcd. for C20H25NO3S: C, 66.82; H, 7.01; N, 3.90. Found: C, 66.54; H, 7.20; N, 3.69.
Example 66
(Compound No, 288) 




Following a procedure similar to the one described in Example 89, infra (see Compound No. 121), the title compound was prepared and purified by silica gel chromatography to give the desired product as a colorless solid: mp 185-186° C.; 1H NMR (CDCl3) δ1.12 (s, 3H), 1.49 (s, 3H), 3.00 (d, J=15 Hz, 1H), 3.28 (d, J=15 Hz, 1H), 4.00 (s, 1H), 5.30 (s, 1H), 5.51 (s, 1H), 5.97 (s, 1H), 6.56 (dd, J=2.1, 8.4 Hz, 1H), 7.31-7.52 (m, 5H), 7.89 (d, J=8.4 Hz, 1H). MS (FAB+) (M+H) m/z 332.
Example 67
(Compound No. 289) 




Following a procedure similar to the one described in Example 89 (see Compound No. 121), the title compound was prepared and purified by silica gel chromatography to give the desired product as a white solid: mp 205-206° C.; 1H NMR (CDCl3) δ 0.80-0.95 (m, 6H), 1.10-1.70 (m, 7H), 2.15 (m, 1H), 3.02 (d, J=15.3 Hz, 2H), 3.15 (d, J=15.1 Hz, 2H), 3.96 (s, br, 2H), 4.14 (d, J=7.8 Hz, 1H), 5.51 (s, 1H), 5.94 (d, J=2.2, 1H), 6.54 (dd, J=8.5, 2.2 Hz, 1H), 7.28-7.50 (m, 6H), 7.87 (d, J=8.5 Hz, 1H). MS (FAB): m/z 388 (M+H).
Example 68
(Compound No. 290) 




Following a procedure similar to the one described in Example 89, infra (see Compound No. 121), the title compound was prepared and purified as a colorless solid: mp=96-98° C., 1H NMR (CDCl3) δ 0.92 (t, J=7 Hz, 6H), 1.03-1.70 (m, 11H), 2.21 (t, J=8 Hz, 1H), 3.09 (AB, JAB=18 Hz, Δv=38 Hz, 2H). 3.96 (bs, 2H), 4.14 (d, J=7 Hz, 1H), 5.51 (s, 1H), 5.94 (s, 1H), 6.56 (d, J=9 Hz, 1H), 7.41-7.53 (m, 6H:), 7.87 (d, J=8 Hz, 1H); FABMS m/z 416 (M+H).
Example 69





Following a procedure similar to the one described in Example 86, infra (see Compound No. 118), the title compound was prepared and purified as a colorless solid: 1H NMR (CDCl3) δ 0.91 (t, J=7 Hz, 6H), 1.02-1.52 (m, 11H), 1.60-1.70 (m, 1H), 2.23 (t, J=8 Hz, 1H), 3.12 (AB, JAB=18 Hz, Δv=36 Hz, 2H), 4.18 (d, J=7 Hz, 1H), 5.13 (s, 2H), 5.53 (s, 1H), 6.43 (s, 1H), 6.65 (s, 1H), 7.29-7.52 (m, 10H), 7.74 (d, J=9 Hz, 1H), 8.03 (d, J=8 Hz, 1H); ESMS m/z 556 (M+Li).
Example 70
(Compound No. 292) 




Following a procedure similar to the one described in Example 89, infra (see Compound No. 121), the title compound was prepared and purified as a colorless solid: mp=111-112.5° C., 1H NMR (CDCl3) δ 0.90 (t, J=8 Hz, 6H), 1.03-1.50 (m, 10H), 1.55-1.70 (m, 2H), 2.18 (t, J=12 Hz, 2H), 3.07 (AB, JAB=15 Hz, Δv=45 Hz, 2H), 4.09 (bs, 2H), 5.49 (s, 1H), 5.91 (s, 1H), 6.55 (d, J=9 Hz, 1H), 7.10 (t, J=7 Hz, 2H), 7.46 (t, J=6 Hz, 2H), 7.87 (d, J=9 Hz, 1H).
Example 71
(Compound No. 293) 




During the preparation of Compound No. 290 from Compound No. 291 using BBr3, the title compound was isolated: 1H NMR (CDCl3) δ 0.85 (t, J=6 Hz, 6H), 0.98-1.60 (m, 10H), 1.50-1.66 (m, 2H), 2.16 (t, J=8 Hz, 1H), 3.04 (AB, JAB=15 Hz, Δv=41 Hz, 2H), 4.08 (s, 1H), 4.12 (s, 1H), 5.44 (s, 1H), 5.84 (s, 1H), 6.42 (d, J=9 Hz, 1H), 7.12 (d, J=8 Hz, 2H), 7.16-7.26 (m, 10H), 7.83 (d, J=8 Hz, 1H); ESMS m/z 512 (M+Li).
Example 72
(Compound No. 294)
Following a procedure similar to the one described in Example 60 (Compound No. 104), the title commound was prepared and purified as a colorless solid: 1H NMR (CDCl3) δ 0.90 (t, J=6 Hz, 6H), 1.05-1.54 (m, 9H), 1.60-1.70 (m, 1H), 2.24 (t, J=8 Hz, 1H), 2.80 (s, 6H), 3.05 (AB, JAB=15 Hz, Δv=42 Hz, 2H), 4.05-4.18 (m, 2H), 5.53 (s, 1H), 5.93 (s, 1H), 6.94 (d, J=9 Hz, 1H), 7.27-7.42 (m, 4H), 7.45 (d, J=8 Hz, 2H), 7.87 (d, J=9 Hz, 1H); ESMS m/z 444 (M+H).
Structures of the compounds of Examples 33 to 72 are shown in Tables 3 and 3A.
Examples 73-79, 87, 88 and 91-102
Using in each instance a method generally described in those of Examples 1 to 72 appropriate to the substituents to be introduced, compounds were prepared having the structures set forth in Table 3. The starting materials illustrated in the reaction schemes shown above were varied in accordance with principles of organic synthesis well known to the art to introduce the indicated substituents in the 4- and 5-positions (R3, R4, R5, R6) and in the indicated position on the benzo ring (Rx).
Structures of the the compounds produced in Examples 73-102 are set forth in Tables 3 and 3A.
Examples 80-84
Preparation of 115, 116, 111, 113
Preparation of 4-chloro-3-[4-methoxyphenylmethyl]-nitrobenzene.
In a 500 ml 2-necked rb flask weigh out 68.3 gms phosphorus pentachloride (0.328 mole 1.1 eq). Add 50 mls chlorobenzene. Slowly add 60 gms 2-chloro-5-nitrobenzoic acid (0.298 mole). Stir at room temp overnight under N2 then heat 1 hr at 50C.
Remove chlorobenzene by high vacuum. Wash residue with hexane. Dry wt=55.5 gms.
In the same rb flask, dissolve acid chloride (55.5 g 0.25 mole) from above with 100 mls anisole (about 3.4 eq). Chill solution with ice bath while purging with N2. Slowly add 40.3 g aluminum chloride (1.2 eq 0.3 mole). Stir under N2 for 24 hrs.
After 24 hrs, the solution was poured into 300 mls 1N HCl soln. (cold). Stir this for 15 min. Extract several times with diethyl ether. Extract organic layer once with 2% aqueous NaOH then twice with water. Dry organic layer with MgSO4, dry on vac line. Solid is washed well with ether and then ethanol before drying. Wt=34.57 g (mixture of meta, ortho and para).












Elemental
theory
found

















C
57.65
57.45


H
3.46
5.51


N
4.8
4.8


Cl
12.15
12.16









With the next step of the reduction of the ketone with trifluoromethane sulfonic aid and triethyl silane, crystallization with ethyl acetate/hexane affords pure 4-chloro-3-[4-methoxy-phenylmethyl]-nitrobenzene.
4-Chloro-3-[4-methoxy-phenylmethyl]-nitrobenzene was then reacted as specified in the synthesis of 117 and 118 from 2-chloro-4-nitrophenylmethane. From these procedures 115 and 116 can be synthesized. Compounds 111 and 113 can be synthesized from the procedure used to prepare compound 121.
Compound 114 can be prepared by reaction of 116 with ethyl mercaptan and aluminum trichloride.
Examples 85 and 86
Preparation of 117 and 118
2-Chloro-4-nitrobenzophenone is reduced with triethylsilane and trifluoromethane sulfonic acid to 2-chloro-4-nitrodiphenylmethane 32. Reaction of 32 with lithium sulfide followed by reacting the resulting sulfide with mesylate IV gives sulfide-aldehyde XXIII. Oxidation of XXIII with 2 equivalents of MCPBA yields sulfone-aldehyde XXIII. Oxidation of XXIII with 2 equivalents of MCPBA yields sulfone-aldehyde XXIV (see Scheme 5):
The sulfone-aldehyde (31.8 g) was dissolved in ethanol/toluene and placed in a parr reactor with 100 ml toluene and 100 ml of ethanol and 3.2 g of 10% Pd/C and heated to 55 C and 100 psi of hydrogen gas for 14 hours. The reaction was then filtered to remove the catalyst. The amine product (0.076 moles, 29.5 g) from this reaction was then reacted with benzyl chloroformate (27.4 g) in toluene in the presence of 35 g of potassium carbonate and stirred at room temperature overnight. After work up by extraction with water, the CBZ protected amine product was furthe purified by precipitation from toluene/hexane.
The CBZ protected amine product was then reacted with 3 equivalents of potassium t-butoxide in THF at O C to yield compounds 117 and 118 which were separated by silica gel column chromatography.
Examples 89 and 90
Preparation of 121 or 122
Compound 118 (0.013 moles, 6.79 g) is dissolved in 135 ml of dry chloroform and cooled to −78 C, next 1.85 ml of boron tribromide (4.9 g) was added and the reaction is allowed to warm to room temperature. Reaction is complete after 1.5 hours. The reaction is cuenched by addition of 10% potassium carbonate at 0 C and extract with ether. Removal of ether yields compound 121. A similar procedure can be used to produce 122 from 117.
Examples 93-96
Compounds 126, 127, 128 and 129 as set forth in Table 3 were prepared substantially in the manner described above for compounds 115, 116, 111 and 113, respectively, except that fluorobenzene was used as a starting material in place of anisole.







TABLE 3







Specific comp  unds (#102-111, 113-130, 132-


134, 136, 138, 142-144, 262-296)






















Ex.
Cp#
R1
R2
R3
R4
R5
R6
(Rx)q


















61
102
Et-
n-Bu-
HO—
H—
Ph-
H—
I−, 7-










(CH3)3N+—


73
103
n-Bu-
Et-
HO—
H—
Ph-
H—
I−, 7-










(CH3)3N+—


60
104
Et-
n-Bu-
HO—
H—
Ph-
H—
7-(CH3)2N—


74
105
Et-
-n-Bu-
HO—
H—
Ph-
H—
7-










CH3SO2NH—


75
106
Et-
-n-Bu-
HO—
H—
Ph-
H—
7-Br—CH2—










CONH—


76
107
n-Bu-
Et-
HO—
H—
-p-n-C10H21—
H—
7-NH2—








—O-Ph-



77
108
Et-
n-Bu-
HO—
H—
Ph-
H—
7-










C5H11CONH—


78
109
Et-
n-Bu-
HO—
H—
-p-n-C10H21—
H—
7-NH2—








—O-Ph-



79
110
Et-
n-Bu-
HO—
H—
Ph-
H—
7-CH3CONH—


80
111
n-Bu-
Et-
HO—
H—
p-EO-Ph-
H—
7-NH2—


81
113
Et-
n-Bu-
HO—
H—
p-EO-Ph-
H—
7-NH2—


82
114
Et-
n-Bu-
HO—
H—
p-CH3O-Ph-
H—
7-NH2—


83
115
n-Bu-
Et-
HO—
H—
p-CH3O-Ph-
H—
7-NH-CBZ


84
116
Et-
n-Bu-
HO—
H—
p-CH3O-Ph-
H—
7-NH-CBZ


85
117
n-Bu-
Et-
HO—
H—
Ph-
H—
7-NH-CBZ


86
118
Et-
n-Bu-
HO—
H—
Ph-
H—
7-NH-CBZ


87
119
Et-
n-Bu-
HO—
H—
Ph-
H—
7-NHCO2-t-










Bu


88
120
n-Bu-
Et-
HO—
H—
Ph-
H—
7-NHCO2-t-










Bu


89
121
Et-
n-Bu-
HO—
H—
Ph-

7-NH2—


90
122
n-Bu-
Et-
HO—
H—
Ph
H—
7-NH2—


91
123
Et-
n-Bu-
HO—
H—
Ph-
H—
7-n-C6H13—










NH—


92
124
n-Bu-
Et-
HO—
H—
Ph-
H—
7-n-C6H13—










NH—


62
125
Et-
n-Bu-
HO—
H—
Ph-
H—
I−, 8-










(CH3)3N+(CH2CH2O)3—


93
126
n-Bu-
Et-
HO—
H—
p-F-Ph-
H—
7-NH-CBZ


94
127
n-Bu-
Et-
HO—
H—
p-F-Ph-
H—
7-NH2—


95
128
Et-
n-Bu-
HO—
H—
p-F-Ph-
H—
7-NH-CBZ


96
129
Et-
n-Bu-
HO—
H—
p-F-Ph-
H—
7-NH2—


97
130
Et-
n-Eu-
HO—
H—
Ph-
H—
I−, 8-










(CH3)3N+










C6H12O—


98
132
Et-
n-Bu-
HO—
H—
Ph-
H—
8-phthal-










imidyl-










C6H12O—


99
133
Et-
n-Bu-
HO—
H—
Ph-
H—
8-n-C10H21—


52
134
Et-
n-bu-
HO—
H—
Ph-
H—
8-I-










(C2H4O)3—


100
136
Et-
n-Bu-
HO—
H—
Ph-
H—
8-HO—


101
138
n-Bu-
Et-
HO—
H—
Ph
H—
8-CH3CO2—


49
90
Et-
n-Bu-
H—
HO—
H—
m-CH3O-Ph-
7-CH3S—


49
91
Et-
n-Bu-
HO—
H—
m-CH3O-Ph-
H—
7-CH3S—


48
89
Et-
n-Bu-
HO—
H—
p-F-Ph-
H—
7-(N)-










azetidine


34
66
Et-
n-Bu-
HO—
H—
m-CH3O-Ph-
H—
7-CH3O—


34
65
Et-
n-Bu-
H—
HO—
H—
m-CH3O-Ph-
7-CH3O—


35
68
Et-
n-Bu-
HO—
H—
m-CF3-Ph-
H—
7-CH3O—


35
67
Et-
n-Bu-
H—
HO—
H—
m-CF3-Ph-
7-CH3O—


46
87
Et-
n-Bu-
HO—
H—
m-HO-Ph-
H—
7-HO—


46
86
Et-
n-Bu-
HO—
H—
m-HO-Ph-
H—
7-CH3O—


36
70
Et-
n-Bu-
HO—
H—
p-F-Ph-
H—
7-CH3O—


36
69
Et-
n-Bu-
H—
HO—
H—
p-F-Ph-
7-CH3O—


47
88
Et-
n-Bu-
HO—
H—
p-F-Ph-
H—
7-HO—


39
76
Et-
n-Bu-
HO—
H—
m-CH3O-Ph-
H—
7-Br—


39
75
Et-
n-Bu-
H—
HO—
H—
m-CH3O-Ph-
7-Br—


40
77
Et-
n-Bu-
H—
HO—
H—
p-F-Ph-
7-F—


40
78
Et-
n-Bu-
HO—
H—
p-F-Ph-
H—
7-F—


41
79
Et-
n-Bu-
H—
HO—
H—
m-CH3O-Ph-
7-F—


41
80
Et-
n-Bu-
HO—
H—
m-CH3O-Ph-
H—
7-F—


37
72
Et-
n-Bu-
HO—
H—
m-F-Ph-
H—
7-CH3O—


38
73
Et-
n-Bu-
H—
HO—
H—
o-F-Ph-
7-CH3O—


37
71
Et-
n-Bu-
H—
HO—
H—
m-F-Ph-
7-CH3O—


38
74
Et-
n-Bu-
HO—
H—
o-F-Ph-
H—
7-CH3O—


42
81
Et-
n-Bu-
HO—
H—
p-F-Ph-
H—
7-CH3S—


45
85
Et-
n-Bu-
HO—
H—
p-F-Ph-
H—
7-CH3—


45
84
Et-
n-Bu-
H—
HO—
H—
p-F-Ph-
7-CH3—


44
83
Et-
n-Bu-
HO—
H—
n-F-Ph-
H—
7-(N)-










morpholine


43
82
Et-
n-Bu-
HO—
H—
p-F-Ph-
H—
7-(N)-










pyrrolidine


64
286
Et-
Et-
HO—
H—
Ph-
H—
7-NH-CBZ


65
287
Et-
Et-
HO—
H—
Ph-
H—
7-NH2—


66
288
CH3—
CH3—
HO—
H—
Ph-
H—
7-NH2


67
289
n-
n-
HO—
H—
Ph-
H—
7-NH2—




C3H7—
C3H7—



68
290
n-Bu-
n-Bu-
HO—
H—
Ph-
H—
7-NH2—


69
291
n-Bu-
n-Bu-
HO—
H—
Ph-
H—
7-NH-CBZ


70
292
n-Bu-
n-Bu-
HO—
H—
p-F-Ph-
H—
7-NH2—


71
293
n-Bu-
n-Bu-
HO—
H—
Ph-
H—
7-PhCH2N—


72
294
n-Bu-
n-Bu-
HO—
H—
Ph-
H—
7-(CH3)2N—


63
295
Et-
n-Bu-
HO—
H—
p-I—
H—
7-NH2—








(C2H4O)3—









Ph-



102
296
Et-
n-Bu-
HO—
H—
I−, p-
H—
7-NH2—








(CH3)3N+









(C2H4O)3-Ph-
















TABLE 3A





Bridged Benzothiephenes (#101, 112, 131, 135, 137, 139-141)






















CPD #101
(Ex. 59)







CPD #112
(Ex. 53)







CPD #131
(Ex. 56)







CPD #135
(Ex. 55)







CPD #137
(Ex. 57)







CPD #139
(Ex. 58)







CPD #140
(Ex. 51)


3400 MW polyethyleneglycol bridge







CPD #141
(Ex. 50)









Examples 104-231
Using in each instance a method generally described in those of Examples 1 to 72 appropriate to the substituents to be introduced, including where necessary other common synthesis expedients well known to the art, compounds are prepared having the structures set forth in Table 4. The starting materials illustrated in the reaction schemes shown above are varied in accordance with principles of organic synthesis well knownn to the art in order to introduce the indicated substituents in the 4- and 5-positions (R3, R4, R5, R6) and in the indicated position on the benzo ring (Rx).







TABLE 4







Alternative compound #1 (#302-312, 314-430)
















Cpd #
R5
(Rx)q












302
p-F-Ph-
7-(1-aziridine)


303
p-F-Ph-
7-EtS—


304
p-F-Ph
7-CH3S(O)—


305
p-F-Ph-
7-CH3S(O)2—


306
p-F-Ph-
7-PhS—


307
p-F-Ph-
7-CH3S(O)2—




9-CH3S—


308
p-F-Ph-
7-CH3O—




9-CH3O—


309
p-F-Ph-
7-Et-


310
p-F-Ph-
7-iPr-


311
p-F-Ph-
7-t-Bu-


312
p-F-Ph-
7-(1-pyrazole)-


314
m-CH3O-Ph
7-(1-azetidine)


315
m-CH3O-Ph
7-(1-aziridine)


316
m-CH3O-Ph
7-EtS—


317
m-CH3O-Ph
7-CH3S(O)—


318
m-CH3O-Ph
7-CH3S(O)2—


319
m-CH3O-Ph-
7-PhS—


320
m-CH3O-Ph
7-CH3S—




9-CH3S—


321
m-CH3O-Ph
7-CH3O—




9-CH3O—


322
m-CH3O-Ph
7-Et-


323
m-CH3O-Ph
7-iPr-


324
m-CH3O-Ph
7-t-Bu-


325
p-F-Ph-
6-CH3O—




7-CH3O—




8-CH3O—


326
p-F-Ph-
7-(1-azetidine)




9-CH3—


327
p-F-Ph-
7-EtS—




9-CH3—


328
p-F-Ph-
7-CH3S(O)—




9-CH3—


329
p-F-Ph-
7-CH3S(O)2—




9-CH3—


330
p-F-Ph-
7-PhS—




9-CH3—


331
p-F-Ph-
7-CH3S—




9-CH3—


332
p-F-Ph-
7-CH3O—




9-CH3—


333
p-F-Ph-
7-CH3—




9-CH3—


334
p-F-Ph-
7-CH3O—




9-CH3O—


335
p-F-Ph-
7-(1-pyrrole)


336
p-F-Ph-
7-(N)-N′-methylpiperazine


337
p-F-Ph-
Ph-


338
p-F-Ph-
7-CH3C(═CH2)—


339
n-F-Ph-
7-cyclpropyl


340
p-F-Ph-
7-(CH3)2NH—


341
p-F-Ph-
7-(N)-azetidine




9-CH3S—


342
p-F-Ph-
7-(N-pyrrolidine)




9-CH3S—


343
p-F-Ph-
7-(CH3)2N—




9-CH3S—


344
m-CH3O-Ph-
7-(1-pyrazole)


345
m-CH3O-Ph-
7-(N)-N′-methylpiperazine


346
m-CH3O-Ph-
Ph-


347
m-CH3O-Ph-
7-CH3C(═CH2)—


348
m-CH3O-Ph-
7-cyclopropyl


349
m-CH3O-Ph-
7-(CH3,)2NH—


350
m-CH3O-Ph-
7-(N)-azetidine




9-CH3S—


351
m-CH3O-Ph-
7-(N-pyrrolidine)-




9-CH3S—


352
m-CH3O-Ph-
7-(CH3)2N—




9-CH3S—


353
m-CH3O-Ph-
6-CH3O—




7-CH3O—




8-CH3O—


354
m-CH3O-Ph-
7-(1-azetidine)




9-CH3—


355
m-CH3O-Ph-
7-EtS—




9-CH3—


356
m-CH3O-Ph-
7-CH3S(O)—




9-CH3—


357
m-CH3O-Ph-
7-CH3S(O)2—




9-CH3—


358
m-CH3O-Ph-
7-PhS—




9-CH3—


359
m-CH3O-Ph-
7-CH3S—




9-CH3—


360
m-CH3O-Ph-
7-CH3O—




9-CH3—


361
m-CH3O-Ph-
7-CH3—




9-CH3—


362
m-CH3O-Ph-
7-CH3O—




9-CH3O—


363
thien-2-yl
7-(1-aziridine)


364
thien-2-yl
7-EtS—


365
thien-2-yl
7-CH3S(O)—


366
thien-2-yl
7-CH3S(O)2—


367
thien-2-yl
7-PhS—


368
thien-2-yl
7-CH3S—




9-CH3S—


369
thien-2-yl
7-CH3O—




9-CH3O—


370
thien-2-yl
7-Et-


371
thien-2-yl
7-iPr


372
thien-2-yl
7-t-Bu-


373
thien-2-yl
7-(1-pyrrole)-


374
thien-2-yl
7-CH3O—


375
thien-2-yl
7-CH3S—


376
thien-2-yl
7-(1-azetidine)


377
thien-2-yl
7-Me-


378
5-Cl-thien-2-yl
7-(1-azetidine)


379
5-Cl-thien-2-yl
7-(1-aziridine)


380
5-Cl-thien-2-yl
7-EtS—


381
5-Cl-thien-2-yl
7-CH3S(O)—


382
5-Cl-thien-2-yl
7-CH3S)O2—


383
5-Cl-thien-2-yl
7-PhS—


384
5-Cl-thien-2-yl
7-CH3S—




9-CH3S—


385
5-Cl-thien-2-yl
7-CH3O—




9-CH3O—


386
5-Cl-thien-2-yl
7-Et-


387
5-Cl-thien-2-yl
7-iPr


388
5-Cl-thien-2-yl
7-t-Bu-


389
5-Cl-thien-2-yl
7-CH3O—


390
5-Cl-thien-2-yl
7-CH3S—


391
5-Cl-thien-2-yl
7-Me


392
thien-2-yl
7-(1-azetidine)




9-CH3—


393
thien-2-yl
7-EtS—




9-CH3—


394
thien-2-yl
7-CH3S(O)—




9-CH3—


395
thien-2-yl
7-CH3S(O)2—




9-CH3—


396
thien-2-yl
7-PhS—




9-CH3—


397
thien-2-yl
7-CH3S—




9-CH3—


398
thien-2-yl
7-CH3O—




9-CH3—


399
thien-2-yl
7-CH3—




9-CH3—


400
thien-2-yl
7-CH3O—




9-CH3O—


401
thien-2-yl
7-(1-pyrazrole)


402
thien-2-yl
7-(N)-N′-methylpiperazine


403
thien-2-yl
Ph-


404
thien-2-yl
7-CH3C(═CH2)—


405
thien-2-yl
7-cyclopropyl


406
thien-2-yl
7-(CH3)2NH—


407
thien-2-yl
7-(N)-azetidine




9-CH3S—


408
thien-2-yl
7-(N-pyrrolidine)




9-CH3S—


409
thien-2-yl
7-(CH3)2N—




9-CH3S—


411
5-Cl-thien-2-yl
7-(1-pyrazrole)


412
5-Cl-thien-2-yl
7-(N)-N′-methylpiperazine


413
5-Cl-thien-2-yl
Ph-


414
5-Cl-thien-2-yl
7-CH3C(═CH2)—


415
5-Cl-thien-2-yl
7-cyclopropyl


416
5-Cl-thien-2-yl
7-(CH3)2N—


417
5-Cl-thien-2-yl
7-(N)-azetidine




9-CHeS—


418
5-Cl-thien-2-yl
7-(N-pyrrolidine)-




9-CH3S—


419
5-Cl-thien-2-yl
7-(CH3)2N—




9-CH3S—


420
5-Cl-thien-2-yl
7-(1-azetidine)




9-CH3—


421
5-Cl-thien-2-yl
7-EtS—




9-CH3—


422
5-Cl-thien-2-yl
7-CH3S(O)—




9-CH3—


423
5-Cl-thien-2-yl
7-CH3S(O)2—




9-CH3—


424
5-Cl-thien-2-yl
7-PhS—




9-CH3—


425
5-Cl-thien-2-yl
7-CH3S—




9-CH3—


426
5-Cl-thien-2-yl
7-CH3O—




9-CH3—


427
5-Cl-thien-2-yl
7-CH3—




9-CH3—


428
5-Cl-thien-2-yl
7-CH3O—




9-CH3O—


429
thien-2-yl
6-CH3O—




7-CH3O—




8-CH3O—


430
5-Cl-thien-2-yl
6-CH3O—




7-CH3O—




8-CH3O—









Examples 232-1394
Using in each instance a method generally described in those of Examples 1 to 72 appropriate to the substituents to be introduced, including where necessary other common synthesis expedients well known to the art, compounds are prepared having the structures set forth in Table 1. The starting materials illustrated in the reaction schemes shown above are varied in accordance with principles of organic synthesis well known to the art in order to introduce the indicated substituents in the 4- and 5-positions (R3, R4, R5, R6) and in the indicated position on the benzo ring (Rx).
Example 1395
Dibutyl 4-fluorobenzene Dialdehyde 




Step 1: Preparation of Dibutyl 4-fluoro Benzene Dialdehyde
To a stirred solution of 17.5 g (123 mmol) of 2,5-difluorobenzaldehyde (Aldrich) in 615 mL of DMSO at ambient temperature was added 6.2 g (135 mmol) of lithium sulfide (Aldrich). The dark red solution was stirred at 75 C for 1.5 hours, or until the starting material was completely consumed, and then 34 g (135 mmol) of dibutyl mesylate aldehyde was added at about 50 C. The reaction mixture was stirred at 75 C for three hours or until the reaction was completed. The cooled solution was poured into water and extracted with ethyl acetate. The combined extracts were washed with water several times, dried (MgSO4) and concentrated in vacuo. Silica gel chromatographic purification of the crude product gave 23.6 g (59%) of fluorobenzene dialdehyde as a yellow oil: 1H NMR (CDCl3) d 0.87 (t, J=7.05 Hz, 6H), 1.0-1.4 (m, 8H), 1.5-1.78 (m, 4H), 3.09 (s, 2H), 7.2-7.35 (m, 1H), 7.5-7.6 (m, 2H), 9.43 (s, 1H) 10.50 (d, J=2.62 Hz, 1H)
Step 2. Preparation of dibutyl 4-fluorobenzyl alcohol
To a solution of 22.6 g (69.8 mmol) of the dialdehyde obtained from Step 1 in 650 mL of THF at −60 C was added 69.8 mL (69.8 mmol) of DIBAL (1M in THF) via a syringe. The reaction mixture was stirred at −40 C for 20 hours. To the cooled solution at −40 C was added sufficient amount of ethyl acetae to quench the excess of DIBAL, followed by 3 N HCl. The mixture was extracted with ethyl acetate, washed with water, dried (MgSO4), and concentrated in vacuo. Silica gel chromatographic purification of the crude product gave 13.5 g (58%) of recovered starting material, and 8.1 g (36%) of the desired fluorobenzyl alcohol as a colorless oil: 1H NMR (CDCl3) d 0.88 (t, J=7.05 Hz, 6H), 1.0-1.4 (m, 8H), 1.5-1.72 (m, 4H), 1.94 (br s, 1H), 3.03 (s, 2H), 4.79 (s, 2H), 6.96 (dt, J=8.46, 3.02 Hz, 1H), 7.20 (dd, J=9.47, 2.82 Hz, 1H), 7.42 (dd, J=8.67, 5.64, 1H), 9.40 (s, 1H).
Step 3: Preparation of dibutyl 4-fluoroberzyl bromide
To a solution of 8.1 g (25 mmol) of benzyl alcohol obtained from Step 2 in 100 mL of DMF at −40 C was added 47 g (50 mmol) of bromotriphenyhosphonium bromide (Aldrich). The resulting solution was stirred cold for 30 min, then was allowed to warm to 0 C. To the mixture was added 10% solution of sodium sulfite and ethyl acetate. The extract was washed a few times with water, dried (MgSO4), and concentrated in vacuo. The mixture was stirred in small amount of ethyl acetate/hexane mixture (1:4 ratio) and filtered through a pad of silica gel, eluting with same solvent mixture.
The combined filtrate was concentrated in vacuo to give 9.5 g (98%) of the desired product as a colorless oil: 1H NMR (CDCl3) d 0.88 (t, J=7.05 Hz, 6H), 1.0-1.4 (m, 8H), 1.55-1.78 (m, 4H), 3.11 (s, 2H), 4.67 (s, 2H), 7.02 (dt, J=8.46, 3.02 Hz, 1H) , 7.15 (dd, J=9. 47, 2.82 Hz, 1H), 7.46 (dd, J=8.67, 5.64, 1H), 9.45 (s, 1H).
Step 4: Preparation of Sulfonyl 4-fluorobenzyl Bromide
To a solution of 8.5 g (25 mmol) of sulfide obtained from Step 3 in 200 mL of CH2Cl2 at 0° C. was added 15.9 g (60 mmol) of mCPBA (64% peracid). The resulting solution was stirred cold for 10 min, then was allowed to stirred ambient temperature for 5 hours. To the mixture was added 10% solution of sodium sulfite and ethyl acetate. The extract was washed several times with saturated Na2CO3, dried (MgSO4), and concentrated in vacuo to give 10.2 g (98%) of the desired product as a colorless oil: 1H NMR (CDCl3) d 0.91 (t, J=7.05 Hz, 6H), 1.03-1.4 (m, 8H), 1.65-1.82 (m, 2H) , 1.90-2.05 (m, 2H), 3.54 (s, 2H), 5.01 (s, 2H), 7.04-7.23 (m, 1H), 7.30 (dd, J=8.87, 2.42 Hz, 1H), 8.03 (dd, J=8.86, 5.64, 1H), 9.49 (s, 1H).
Example 1396








    
    
        Generic Scheme X: The nucleophilic substitution of an appropriately substituted 2-fluorobenzaldehyde with lithium sulfide or other nucleophilic sulfide anion in polar solvent (such as DMF, DMA, DMSO, etc), followed by the addition of dialkyl mesylate aldehyde (X), provided a dialkyl benzene dialdehyde Y. DIBAL reduction of the dialdehyde at low temperature yielded benzyl alcohol motoaldehyde Z. Conversion of benzyl alcohol to benzyl bromide, followed by oxidation of sulfide to sulfone yielded the key intermediate W.
    
    


Preparation of N-propylsulfonic Acid
To a solution of 51 mg (111 μm) Compound X in ethanol (400 μl) was added 1,3 propane sultone (19.5 μl, 222 μm). The reaction was stirred in a sealed vial at 55° C. for 25 hr. Sample was concentrated under a nitrogen stream and purified by reversed phase chromatography using acetonitrile/wate as eluent (30-45%) and afforded the desired material as an off-white solid (28.4 mg, 44%): 1H NMR (CDCl3) d 0.82-0.96 (m, 6H), 1.11-1.52 (m of m, 10H), 1.58-1.72 (m, 1H), 2.08-2.21 (m, 1H), 2.36-2.50 (m, 2H), 2.93 (s, 6H), 3.02-3.22 (m of m, 5H), 3.58-3.76 (m, 2H), 4.15 (s, 1H), 5.51 (s, 1H), 6.45-6.58 (m, 1H), 6.92-7.02 (m, 1H), 7.35-7.41 (m, 1H), 7.41-7.51 (m, 2H), 8.08 (d, J=8.1 Hz, 1H), 8.12-8.25 (m, 1H); MS ES- M−H m/z 579.
Example 1397
The 7-fluoro, 9-fluoro and 7,9-difluoro analogs of benzothiepine compounds of this invention can be reacted with sulfur and nitrogen nucleophiles to give the corresponding sulfur and nitrogen substituted analogs. The following example demonstrates the synthesis of these analogs.
3,3-Dibutyl-5a-(4′-fluorophenyl)-4a-hydroxy-7-methylthio-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide. 




A mixture of 0.4 g Of 3,3-dibutyl-7-fluoro-5a-(4′-fluorophenyl)-4a-hydroxy-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide, prepared by previously described method, 0.12 g of sodium methanethiolate and 20 ml of DM was stirred at 50 C for 3 days. An additional 0.1 g of sodium methanethiolate was added to the reaction mixture and the mixture was stirred for additional 20 h at 50 C then was concentrated in vacuo. The residue was triturated with water and extracte with ether. The ether extract was dried over MgSO4 and concentrated in vacuo to 0.44 g of an oil. Purification by HPLC (10% EtOAc in hexane) gave 0.26 g of needles, mp 164-165.5% C.
3,3-Dibutyl-9-dimethylaino-7-fluoro-5a-(4′-fluorophenyl)-4a-hydroxy-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide and 7,9-Bis(dimethylamino)-3,3-dibutyl-5a-(4′-fluorophenyl)-4a-hydroxy-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide. 




A solution of 0.105 g of 3,3-dibutyl-7,9-difluoro-5a-(4′-fluorophenyl)-4a-hydroxy-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide, prepared by the method described previously, in 20 ml of 2 N dimethylamine in THF was heated at 160 C in a sealed Parr reactor overnight. The reaction mixture was cooled and concentrated in vacuo. The residue was triturated with 25 ml of water and extracted with ether. The ether extract was dried over MgSO4 and concentrated in vacuo. The resdue was purified by HPLC (10% EtOAc in hexane) to give 35 mg of an earlier fraction which was identified as 3,3-dibutyl-9-dimethylemiino-7-fluoro-5a-(4′-fluorophenyl)-4a-hydroxy-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide, MS (CI) m/e 480−(M++1), and 29 mg of a later fraction which was identified as 7,9-bis(dimethylanino)-3,3-dibutyl-5a-(4′-fluorophenyl)-4a-hydroxy-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide, MS (CI) m/e 505 (M+ +1).
The compounds of this invention can also be synthesized using cyclic sulfate (A, below) as the reagent as shout in the following scheme. The following example describes a procedure for using the cyclic sulfate as the reagent. 




Dibutyl cyclic sulfite: 




A solution of 2,2-dibutyl-1,3-propandiol (103 g, 0.548 mol) and triethylamin (221 g, 2.19 mol) in anhydrous methylene chloride (500 ml) and was stirred at 0 degrees C. under nitrogen. To the mixture, thionyl chloride (97.8 g, 0.82 mol) was added dropwise and within 5 min the solution turned yellow and then turned black when the addition was completed within half an hour. The reaction mixture was stirred for 3 hrs. GC showed that there was no starting material left. The mixture was washed with ice water twice then with brine twice. The organic phase was dried over magnesium sulfate and concentrated under vacuum to give the cyclic sulfite 128 g (100%) as a black oil. Mass spectrum (MS) was consistent with the product.
To a solution of the above compound (127.5 g, 0.54 mol) in 600 ml acetonitrile and 500 ml of water cooled in an ice bath under nitrogen was added ruthenium (III) chloride (1 g) and sodium periodate (233 g, 1.08 mol). The reaction was stirred overnight and the color of the solution turned black. GC showed that there was no starting material left. The mixture was extracted with 300 ml of ether and the ether extract was washed three times with brine. The organic phase was dried over magnesium sulfate and passed through celite. The filtrate was concentrated under vacuum and gave the cyclic sulfate 133 g (97.8%) as an oil. Proton, carbon NMR and MS were consistent with the product.
2-[(2-(4′-Fluorobenzyl)-4-methylphenylthio)methyl]-2-butylhexanol: 




Sodium hydride (60% oil dispersion), 0.27 g (6.68 mmole), was washed with hexane and the hexane wash was decanted. To the washed sodium, hydride was added 20 ml of 2-methoxyethyl ether (diglyme) and the mixture was cooled in an ice bath. A solution of 1.55 g (6.68 mmole) of 2-(4′-fluorobenzyl)-4-methylbenzenethiol in 10 ml of 2-methoxyethyl ether was added dronwise to the reaction mixture in 15 min. A mixture of 2.17 g (8.68 mmole) of the dibutyl cyclic sulfate in 10 ml of 2-methoxyethyl ether was added once and stirred for 30 min at 0 C then at room temperature for 1 hr under nitrogen. GC showed that there was no thiol left. The solvent was evaporated and triturated wth water then was extracted with ether twice. The water layer was separated, treated with 20 ml of 10% NaOH then was boiled for 30 min and cooled, acidified with 6N HCl and boiled for 10 min. The reaction mixture was cooled and extracted with ether. The organic layer was washed successively with water and brine, dried over magnesium sulfate and concentrated under vacuum to give 2.47 g (92.5%) of an oil. Proton NMR, 13C NMR and MS were consistent with the product.
2-[(2-(4′-Fluorobenzyl)-4-methylphenylthio)methyl]-2-butylhexanal: 




To a solution of the above product (2 g, 4.9 mmol) in 40 ml methylene chloride cooled in an ice bath under nitrogen was added pyridinium chlorochromate (2.18 g, 9.9 mmol) at once. The reaction was stirred with 3 hrs and filtered through a bed of silica gel. The filtrate was concentrated under vacuum to give 1.39 g (70%) of an oil. Proton, carbon NMR and MS were consistent with the product.
2-[(2-(4′-Fluorobenzyl)-4-methylphenylsulfonyl)methyl]-2-butylhexanal 




To a solution of the above product (0.44 g, 1.1 mmole) in 20 ml methylene chloride solution cooled in an ice bath under nitrogen was added 70% m-chloroperbenzoic acid (0.54 g, 2.2 mmol) at once. The reaction mixture was stirred for 18 hrs and filtered. The filtrate was washed successively with 10% NaOH (3×), water and brine, dried over magnesium sulfate and concentrated under vacum to give 0.42 g (90%) of an oil. Proton, carbon NMR and MS were consistent with the product.
3,3-Dibutyl-7-methyl-5a-(4′-fluorophenyl)-4a-hydroxy-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide: 




A mixture of 0.37 g (0.85 mmol) of the above product in 30 ml of anhydrous THF was stirred at 0% C. Then potassium t-butoxide (102 mg, 0.85 mmol) was added. After 3 hrs, TLC showed that there was a product and some starting material left. The crude reaction mixture was acidified with 10% HCl and extracted with ether. The ether extract was washed successively with water and brine, dried with MgSO4 and concentrated under vacuum. The residue was purified by HPLC (10% EtOAc-Hexane). The first fraction was 0.1 g of starting material as an oil and the second fraction was a white solid, 0.27 g (75%). Proton NMR and carbon N were consistent with the desired product. Mass spectrum (CI) also confirmed the product, m/e 433 (M+ 1).
Example 1398
Step 1 




In an inert atmosphere, weigh out 68.3 gms phosphorus pentachloride (0.328 mole Aldrich 15,777-5) into a 2-necked 500 ml round bottom flask. Fit flask with a N2 inlet adapter and suba seal. Remove from inert atmosphere and begin N2 purge. Add 50 mls anhydrous chlorobenzene (Aldrich 28,451-3) to the PCl5 via syringe and begin stirring with magnetic stir bar.
Weigh out 60 gas 2-chloro-5-nitrobenzoic acid (0.298 mole Aldrich 12,511-3). Slowly add to the chlorobenzene solution while under N2 purge. Stir at room temperature overnight. After stirring at room temperature for −20 hrs, place in oil bath and heat at 50C for 1 hr. Remove chlorobenzene by high vacuum. Wash residue with anhydrous hexane. Dry acid chloride wt=61.95 gms. Store in inert and dry atmosphere.
In inert atmosphere, dissolve acid chloride with 105 mls anhydrous anisole (0.97 mole Aldrich 29,629-5). Place solution in a 2-necked 500 ml round bottom flask.
Weigh out 45.1 gms aluminum chloride (0.34 moles Aldrich 29, 471-3) and place in a solid addition funnel. Fit reaction flask with addition funnel and a N2 inlet adapter. Remove from inert atmosphere. Chill reaction solution with ice bath and begin N2 purge. Slowly add AlCl3 to chilled solution. After addition is complete, allow to warm to room temperature. Stir overnight
Quench reaction by pouring into a solution of 300 mls 1N HCl and ice. Stir 15 min. Extract twice with ether. Combine organic layers and extract twice with 2% NaOH, then twice with deionized H2O. Dry with MgSO4, filter and rotovap to dryness. Remove anisole by high vacuum. Crystalize product from 90% ethanol 10% ethyl acetate. Dry on vacuum line. Wt=35.2 gms. Yield 41%. Obtain NMR and mass spec (m/z=292).

Step 2 




Dissolve 38.10 gms (0.131 moles) of the benzophenone from step 1 in 250 mls anhydrous methylene chloride. Place in a 3 liter flask fitted with N2 inlet, addition funnel and stopper. Stir with magnetic stir bar. Chill solution with ice bath.
Prepare a solution of 39.32 gms trifluoro methene sulfonic acid (0.262 mole Aldrich 15, 853-4) and 170 mls anhydrous methylene chloride. Place in addition funnel and add dropwise to chilled solution under N2. Stir 5 minutes after addition is complete.
Prepare a solution of 22.85 gms triethyl silane (0.197 mole Aldrich 23, 019-7) and 170 mls anhydrous methylene chloride. Place in addition funnel and add dropwise to chilled solution under N2. Stir 5 minutes after addition is complete.
Prepare a second solution of 39.32 gms trifluoromethane sulfonic acid and 170 mls anhydrous methylene chloride. Place in addition funnel and add dropwise to chilled solution under N2. Stir 5 minutes after addition is complete.
Prepare a second solution of 22.85 gms triethyl silane and 170 mls anhydrous methylene chloride. Place in addition funnel and add dropwise to chilled solution under N2. After all additions are made allow to slowly warm to room temperature overnight. Stir under N2 overnight.
Prepare 1300 mls saturated NaHCO3 in a 4 liter beaker. Chill with ice bath. While stirring vigorously, slowly add reaction mixture. Stir at chilled temperature for 30 min. Pour into a separatory funnel and allow separation. Remove organic layer and extract aqueous layer 2 times with methylene chloride. Dry organic layers with MgSO4. Crystallize from ethanol. Dry on vacuum line. Dry wt=28.8 gms. Confirm by NMR and mass spec (m/z=278).

Step 3 




Dissolve 10.12 gms (0.036 moles) of product 2 with 200 mls anhydrous DMSO. Place in a 500 ml round bottom flask with magnetic stir bar. Fit flask with water condenser, N2 inlet, and stopper. Add 1.84 gms Li2S (0.040 moles Aldrich 21, 324-1). Place flask in oil bath and heat at 75° C. under N2 overnight then cool to room temperature.
Weigh out 10.59 gms dibutyl mesylate (0.040 moles). Dissolve with anhydrous DMSO and add to reaction solution. Purge well with N2, heat overnight at 80° C.
Cool to room temperature. Prepare 500 mls of 5% acetic acid in a 2 liter beaker. While stirring, slowly add reaction mixture. Stir 30 min. Extract with ether 3 times. Combine organic layers and extract with water and sat'd NaCl. Dry organic layer with MgSO4, filter and rotovap to dryness. Dry oil on vacuum line. Obtain pure product by column chromatography using 95% hexane and 5% ethyl acetate as the mobile phase. Dry wt=7.8 gms. Obtain NMR and mass spec (m/z=444).

Step 4 




Dissolve 9.33 gms (0.021 moles) of product 3 with 120 mls anhydrous methylene chloride. Place in a 250 ml round bottom flask with magnetic stir bar. Fit flask with N2 inlet and stopper. Chill solution with ice bath under N2 purge. Slowly add 11.54 gms 3-chloroperbenzoic acid (0.0435 moles, Fluka 25800, −65%). After addition is complete warm to room temperature and monitor reaction by TLC. Reaction goes quickly to the sulphoxide intermediate but takes 8 hrs to convert to the sulphone. Chill solution over night in freezer. Filter solid from reaction, extract filtrate with 10% K2CO3. Extract aqueous layer twice with methylene choride. Combine organic layers and dry with MgSO4. Filter and rotovap to dryness. Obtain pure product by crystallizing from ethanol or isolating by column chromatography. Obtain NMR and mass spec (m/z=476).

Step 5 




Reaction is done in a 300 ml stainless steel Parr stirred mini reactor. Place 9.68 gms (0.0204 moles) of product 4 in reactor base. Add 160 mls ethanol. For safety reasons next two compounds are added in a N2 atmosphere glove bag. In glove bag, add 15.3 mls formaldehyde (0.204 moles, Aldrich 25,254-9, about 37 wt % in water) and 1.45 gms 10% Pd/Carbon (Aldrich 20, 569-9). Seal reactor before removing from glove bag. Purge reactor three times with H2. Heat to 55° C. under H2. Run reaction at 200 psig H2, 55° C., and a stir rate of 250 rpm. Run overnight under these conditions.
Cool reactor and vent H2. Purge with N2. Check progress of run by TLC. Reaction is a mixture of desired product and intermediate. Filter reaction mixture over a bed of celite washing well with ether. Rotovap and redissolve with ether. Extract with water. Dry organic layer with MgSO4, filter and rotovap to dryness. Dry on vacuum line.
Charge reactor again with same amounts, seal reactor and run overnight under same conditions. After second run all of the material has been converted to the desired product. Cool and vent H2 pressure. Purge with N2. Filter over a bed of celite, washing well with ether. Rotovap to dryness. Dissolve with ether and extract with water. Dry organic layer with MgSO4, filter and rotovap to dryness. Dry on vacuum line. Obtain NR and mass spec (m/z=474).

Step 6 




Dissolve 8.97 gms (0.0189 mole) of product 5 with 135 mls anhydrous THF. Place in a 250 ml round bottom flask with magnetic stir bar. Fit flask with N2 inlet and stopper. Chill solution with ice/salt bath under N2 purge. Slowly add 2.55 gms potassium t-butoxide (0.227 mole Aldrich 15,667-1). After addition is complete, continue to stir at −10° C. monitoring by TLC. Once reaction is complete, quench by adding 135 mls 10% HCl stirring 10 min. Extract three times with ether. Dry organic layer with MgSO4, filter and rotovap to dryness. Crystallize from ether. Obtain NMR and mass spec (m/z=474).

Step 7 




Dissolve 4.67 gms (0.01 moles) of product 6 with 100 mls anhydrous chloroform. Place in a 250 ml round bottom flask with magnetic stir bar. Fit flask with N2 inlet adapter and suba seal. Chill solution with dry ice/acetone bath under a N2 purge. Slowly add, via syringe, 2.84 mls boron tribromide (0.03 moles Aldrich 20,220-7). Stir at cold temperature for 15 min after addition then allow to warm to room temperature. Monitor reaction progress by TLC. Reaction is usually complete in 3 hrs.
Chill solution with ice bath. Quench with 100 mls 10% K2CO3 while stirring rapidly. Stir 10 min. then transfer to sep funnel and allow separation. Remove aqueous layer. Extract organic layer once with 10% HCl, once H2O, and once with saturated NaCl solution. Dry organic layer with MgSO4, filter and rotovap to dryness. Crystallize product from ether. Obtain NMR and mass spec (m/z=460).

Step 8 




Weigh 0.38 gms NaH (9.57 mmoles Aldrich 19,923-0 60% disp. in mineral oil) in a 250 ml round bottom flask with magnetic stir bar. Fit flask with N2 inlet and stopper. Chill NaH with ice bath and begin N2 purge.
Dissolve 4.0 gms (8.7 mmoles) of product 7 with 60 mls anhydrous DMF. Add to the cold NaH. Stir at cold temperature for 30 min. Add 1.33 gas K2CO3 (9.57 mmoles Fisher P-208).
Dissolve 16.1 gms 1,2-bis-(2-iodoethoxy)ethane (43.5 mmoles Aldrich 33,343-3) with 60 mls anhydrous DMF. Add to cold reaction mixture. Warm to room temperature then heat to 40° C. overnight under N2.
Cleanup by diluting with ether and extracting sequentially with 5% NaOH, H2O, and saturated NaCl. Dry organic layer with MgSO4, filter and dry. Obtain pure product by column chromatography using 75% hexane 25% ethyl acetate as the mobile phase. Obtain NMR and mass spec (m/z=702).

Step 9 




Dissolve 1.0 gms (1.43 mmoles) of product 8 with 10 mls anhydrous acetonitrile. Place in a 3 ounce Fischer-Porter pressure reaction vessel with magnetic stir bar. Add 2.9 gms triethyl aine (28.6 mmoles Aldrich 23,962-3) dissolved in 10 mls anhydrous acetonitrile. Purge well with N2 then close system. Heat at 45° C. Monitor reaction by TLC. Reaction is usually complete in 48 hrs.
Perform cleanup by removing acetonitrile under vacuum. Redissolve with anhydrous chloroform and precipitate quaternary ammonium salt with ether. Repeat several times. Dry to obtain crystalline product. Obtain NMR and mass spec (m/z=675).
Example 1399
Step 1. Preparation of 1 




To a solution of 144 g of KOH (2560 mmol) in 1.1 L of DMSO was added 120 g of 2-bromobenzyl alcohol (641 mmol) slowly via addition funnel. Then was added 182 g of methyliodide (80 mL, 1282 mmol) via addition funnel. Stirred at ambient temperature for fifteen minutes. Poured reaction contents into 1.0 L of water and extracted three times with ethyl acetate. The organic layer was dried over MgSO4 and concentrated in vacuo. Purified by silica-gel chromatography through a 200 mL plug using hexanes (100%) as elutant yielded 103.2 g (80%) of 1 as a clear colorless liquid. 1H NMR (CDCl3) d 3.39 (s, 3H), 4.42 (s, 2H), 7.18-7.27 (m, 2H), 7.12 (d, J=7.45, 1H), 7.50 (s, 1H).

Step 2. Preparation of 2 




To a cooled (−78° C.) solution of 95 g (472 mmol) or 1 in 1.5 L THF was added 240 mL of 2.5 M n-butyl lithium (576 mmol). The mixture was stirred for one hour, and then to it was added 180 g of zinc iodide (566 mmol) dissolved in 500 ml THF. The mixture was stirred thirty minutes, allowed to warm to 5 C, cooled to −10° C. and to it was added 6 g of Pd(Ph3)4 (5.2 mmol) and 125 g 2,5-difluorobenzoyl chloride (708 mmol). The mixture was stirred at ambient temperature for 18 hoursand then cooled to 10° C., quenched with water, partitioned between ethyl acetate and water, and washed organic layer with 1N HCL and with 1N NaOH. The organic layer was dried over MgSO4 and concentrated in vacuo. Purification by silica gel chromatography (Waters Prep-500) using 5% ethyl acetate/hexanes as elutant gave 53.6 g (43%) of 2 as an orange oil. 1H NMR (CDCl3) d 3.40 (s, 3H), 4.51 (s, 2H), 7.12-7.26 (m, 3H), 7.47 (t, J=7.50, 1H), 7.57 (d, J=7.45, 1H), 7.73 (d, J=7.45, 1H) , 7.80 (s, 1H).

Step 3. Preparation of 3 




A solution of 53 g (202.3 mmol) of 2 and 11.2 g Li2S (242.8 mmol) in 250 mL DMF was heated to 100° C. for 18 hours. The reaction was cooled (0° C.) and 60.7 g of X (the cyclic sulfate compound of example 1397) (242.8 mmol) in 50 mL DMF was added. Stirred at ambient temperature for 18 hours then condensed in vacuo. Added 1 L water to organic residue and extracted twice with diethyl ether. Aqueous layer acidified (pH 1) and refluxed 2 days. Cooled to ambient temperature and extracted with methylene chloride, dried organic layer over MgSO4 and condensed in vacuo. Purification by silica gel chromatography (Waters Prep-500) using 10% ethyl acetate/hexanes as elutant gave 42.9 g (48%) of 3 as a yellow oil. 1H NMR (CDCl3) d 0.86 (t, J=7.25 Hz, 6H), 1.10-1.26 (m, 12H), 2.83 (s, 2H), 3.32 (s, 2H), 3.40 (s, 3H), 4.48 (s, 3H), 7.02 (dd, J=8.26 Hz and 2.82 Hz, 1H), 7.16 (dt, J=8.19 Hz and 2.82 Hz, 1H), 7.45 (t, J=7.65 Hz, 1H), 7.56-7.61 (m, 2H), 7.69 (d, J=7.85 Hz, 1H), 7.74 (s, 1H),

Step 4. Preparation of 4 




To a cooled (−40° C.) solution of 42.9 g (96.2 mmol) of 3 in 200 mL of methylene chloride was added 21.6 g trifluoromethane sulfonic acid (12.8 mL, 144 mmol) followed by the addition of 22.4 g triethyl silane (30.7 mL, 192.4 mmol). Stirred at −20° C. for two hours, quenched with water and warmed to ambient temperature.
Partitioned between methylene chloride and water, dried the organic layer over MgSO4 and condensed in vacuo. Purification by silica gel chromatography (Waters Prep-500) using 10% ethyl acetate/hexanes as elutant gave 24.2 g (60%) of 4 as a oil. 1H NMR (CDCl3) d 0.89 (t, J=7.05 Hz, 6H), 1.17-1.40 (m, 12H), 1.46 (t, J=5.84 Hz, 1H), 2.81 (s, 2H), 3.38 (s, 3H), 3.43 (d, J=5.23 Hz, 2H), 4.16 (s, 2H), 4.42 (s, 2H), 6.80 (d, J=9.67 Hz, 1H), 6.90 (t, J=8.46 Hz, 1H), 7.09 (d, J=7.45 Hz, 1H), 7.15-7.21 (m, 2H), 7.25-7.32 (m, 2H), 7.42 (m, 1H).

Step 5. Preparation of 5 




To a cooled (15-18° C.) solution of 24.2 g (55.8 mmol) of 4 in 100 mL DMSO was added 31.2 g sulfur trioxide pyridine complex (195 mmol). Stirred at ambient temperature for thirty minutes. Poured into cold water and extracted three times with ethyl acetate. Washed organics with 5% HCl (300 mL) and then with brine (300 mL), dired organics over MgSO4 and condensed in vacuo to give 23.1 g (96%) of 5 as a light brown oil. 1H NMR (CDCl3) d 0.87 (t, J=7.05 Hz, 6H), 1.01-1.32 (m, 8H), 1.53-1.65 (m, 4H), 2.98 (s, 2H). 3.38 (s, 3H), 4.15 (s, 2H), 4.43 (s, 2H), 6.81 (dd, J=9.66 Hz and 2.82 Hz, 1H), 6.91 (t, J=8.62 Hz, 1H), 7.07 (d, J=7.46 Hz, 1H), 7.14 (s, 1H), 7.19 (d, J=7.65 Hz, 1H), 7.26-7.32 (m, 1H), 7.42 (dd, J=8.66 Hz and 5.64 Hz, 1H), 9.40 (s, 1H).

Step 6. Preparation of 6 




To a cooled (0° C.) solution of 23.1 g (53.6 mmol) of a 5 in 200 mL methylene chloride was added 28.6 g meta cholorperoxy-benzoic acid (112.6 mmol). Stirred at ambient temperature for 24 hours. Quenched with 100 mL 10% Na2SO3, partitioned between water and methylene chloride. Dried organic layer over MgSO4 and condensed in vacuo to give 24.5 g (98%) of 6 as a light yellow oil. 1H NMR (CDCl3) d 0.86-1.29 (m, 14H), 1.58-1.63 (m, 2H), 1.82-1.91 (m, 2H), 3.13 (s, 2H), 3.39 (s, 3H), 4.44 (s, 2H), 4.50 (s, 2H), 6.93 (d, J=9.07 Hz, 1H), 7.10-7.33 (m, 5H), 8.05 (s, 1H), 9.38 (s, 1H).

Step 7. Preparartion of 7 




To a solution of 24.5 g (52.9 mmol) of 6 in 20 mL of THF contained in a stainless steel reaction vessel was added 100 mL of a 2.0 M solution of dimethyl amine and 20 mL of neat dimethyl amine. The vessel was sealed and heated to 110° C. for 16 hours. The reaction vessel was cooled to ambient temperatue and the contents concentrated in vacuo. purification by silica gel chromatography (Waters Prep-500) using 15% ethyl acetate/hexanes gave 21.8 g (84%) of 7 as a clear colorless oil. 1H NMR (CDCl3) d 0.85 (t, J=7.25 Hz, 6H), 0.93-1.29 (m, 8H), 1.49-1.59 (m, 2H), 1.70-1.80 (m, 2H), 2.98 (s, 8H) , 3.37 (s, 3H) , 4.41 (s, 2H), 4.44 (s, 2H), 6.42 (s, 1H), 6.58 (dd, J=9.0 Hz and 2.61 Hz, 1H), 7.13 (d, J=7.45 Hz, 1H), 7.21 (s, 1H), 7.28 (t, J=7.85 Hz, 1H), 7.82 (d, J=9.06 Hz, 1H), 9.36 (s, 1H).

Step 8. Preparation of 8 




A solution of 21.8 g (44.8 mmol) of 7 in 600 mL of THF was cooled to 0° C. 58.2 mL of a 1 M solution of potassium t-butoxide was added slowly, maintaining the temperature at <5° C. Stirred for 30 minutes, then quenched with 50 mL of saturated almmonium chloride. The organic layer was partitioned between ethyl acetate and water, dried over MgSO4 and concentrated in vacuo. Purification by recrystalization from −10% ethyl acetate/hexanes gave 15.1 g of 8 as a white solid. The mother liquor was purified by silica gel chromatography (Waters Prep-500) using 30% ethyl acetate/hexanes as the elutant to give 3.0 g of 8 as a white solid. MS (FABLi+) m/e 494.6. HRMS (EI+) calculated for M+H 487.2756. Found 487.2746.

Step 9. Preparation of 9 




A solution of 2.0 g (4.1 mmol) of 8 in 20 mL of methylene chloride was cooled to −60° C. 4.1 mL of a 1M solution of boron tribromide was added. Stirred at ambient temperature for thirty minutes. Cooled reaction to −10° C. and quenched with 50 mL of water. The organic layer was partitioned between methylene chloride and water, dried over MgSO4 and concentrated. in vacuo. Purification by recrystalization from 50% ethyl acetate/methylene chloride gave 1.95 g (89%) of 9 as a white solid. MS (FABH+) m/e 537. HAMS (FAB) calculated for M 536.1834. Found 536.1822.

Step 10. Preparation of 10 




A solution of 1.09 g (2.0 mmol) of 9 and 4.9 g (62 mmol) of pyridine in 30 mL of acetonitrile was stirred at ambient temperature for 18 hours. The reaction was concentrated in vacuo. Purification by recrystallization from methanol/diethyl ether gave 1.19 g (96%) of 10 as an off white solid. MS (FAB*) m/e 535.5.
Example 1398
Step 1. Preparation of 2 




To a solution of 6.0 g of dibutyl 4-fluorobenzene dialdehyde of cxample 1395 (14.3 mmol) in 72 mL of toluene and 54 mL of ethanol was added 4.7 g 3-nitrobenzeneboronic acid (28.6 mmol), 0.8 g of tetrakis (triphenylphosphine) palladium (0) (0.7 mmol) and 45 mL of a 2 M solution of sodium carbonate in water. This heterogeneous mixture was refluxed for three hours, then cooled to amibient temperature and partitioned between ethyl acetate and water. The organic layer was dried over MgSO4 and concentrated in vacuo. Purification by silica gel chromatography (Waters Prep-2000) using ethyl acetate/hexanes (25/75) gave 4.8 g (73%) of the title compound as a yellow solid. 1H NMR (CDCl3) d 0.88 (t, J=7.45 Hz, 6H), 0.99-1.38 (m, 8H), 1.62-1.75 (m, 2H), 1.85-2.00 (m, 2H), 3.20 (s, 2H), 4.59.(s, 2H), 6.93 (dd, J=10.5 and 2.4 Hz, 1H), 7.15 (dt, J=8.4 and 2.85 Hz, 1H), 7.46-7.59 (m, 2H), 8.05-8.16 (m, 3H), 9.40 (s, 1H).

Step 3. Preparation of 3 




A solution of 4.8 g (10.4 mmol) of 2 in 500 mL THF was cooled to 0° C. in an ice bath. 20 mL of a 1 M solution of potassium t-butoxide was added slowly, maintaining the temperature at <5° C. Stirring was continued for 30 minutes, then the reaction was quenched with 100 mm of saturated ammonium chloride. The mixture was partitioned between ethyl acetate and water; the organic layer was washed with brine, then dried (MgSO4) and concentrated in vacuo. Purification by silica gel chromatography through a 100 ml plug using CH2Cl2 as eluent yielded 4.3 g (90%) of 3 as a pale yellow foam. 1H NMR (CDCl3) d 0.93 (t, J=7.25 Hz, 6H), 1.00-1.55 (m, 8H), 1.59-1.74 (m, 3H), 2.15-2.95 (m, 1H), 3.16 (qAB, JAB=15.0 Hz, ΔV=33.2 Hz, 2H), 4.17 (d, J=6.0 Hz, 1H), 5.67 (s, 1H), 6.34 (dd, J=9.6 and 3.0 Hz, 1H), 7.08 (dt, J=8.5 and 2.9 Hz, 1H), 7.64 (t, J=8.1 Hz, 1H), 7 81 (d, J=8.7 Hz, 1H), 8.13 (dd, J=9.9 and 3.6 Hz, 1H), 8.23-8.30 (m, 1H), 8.44 (s, 1H). MS(FABH+) m/e (relative intensity) 464.5 (100), 446.6 (65). HRMS calculated for M+H 464.1907. Found 464.1905.

Step 4. Preparation of 4 




To a cooled (0° C.) solution of 4.3 g (9.3 mmol) of 3 in 30 ml THF contained in a stainless steel reaction vessel was added 8.2 g dimethyl amine (182 mmol). The vessel was sealed and heated to 110° C. for 16 hours. The reaction vessel was cooled to ambient temperature and the contents concentrated in vacuo. Puification by silica gel chromatography (Waters Prep-2000) using an ethyl acetate/hexanes gradient (10-40% ethyl acetate) gave 4.0 g (88%) of 4 as a yellow solid. NMR (CDCl3) d 0.80-0.95 (m, 6H), 0.96-1.53 (m, 8H), 1.60-1.69 (m, 3H), 2.11-2.28 (m, 1H), 2.79 (s, 6H), 3.09 (qAB, JAB=15.0 Hz, DV=45.6 Hz, 2H), 4.90 (d, J=9.0 Hz, 1H), 5.65 (s, 1H), 5.75 (d, J=2.1 Hz, 1H), 6.52 (dd, J=9.6 and 2.7 Hz, 1H), 7.59 (t, J=8.4 Hz, 1H), 7.85 (d, J=7.80 Hz, 1H), 7.89 (d, J=9.0 Hz, 1H) , 8.20 (dd, J=8.4 and 1.2 Hz, 1H), 8.43 (s, 1H). MS(FABH+) m/e (relative intensity) 489.6 (100), 471.5 (25). HRMS calculated for M+H 489.2423. Found 489.2456.

Step 5. Preparation of 5 




To a suspension of 1.0 g (2.1 mmol) of 4 in 100 ml ethanol in a stainless steel Parr reactor was added 1 g 10% palladium on carbon. The reaction vessel was sealed, purged twice with H2, then charged with H2 (1.0 psi) and heated to 45° C. for six hours. The reaction vessel was cooled to ambient temperature and the contents filtered to remove the catalyst. The filtrate was concentrated in vacuo to give 0.9 g (96%) of 5. 1H NMR (CDCl3) d 0.80-0.98 (m, 6. H), 1.00-1.52 (m, 10H), 1.52-1.69 (m, 1H), 2.15-2.29 (m, 1H), 2.83 (s, 6H), 3.07 (qAB, JAB=15.1 Hz, DV=44.2 Hz, 2H), 3.70 (s, 2H), 4.14 (s, 1H), 5.43 (s, 1H), 6.09 (d, J=2.4 Hz, 1H), 6.52 (dd, J=12.2 and 2.6 Hz, 1H), 6.65 (dd, J=7.8 and 1.8 Hz, 1H), 6.83 (s, 1H), 6.93 (d, J=7.50 Hz, 1H), 7.19 (t, J=7.6 Hz, 1H), 7.89 (d, J=8.9 Hz, 1H). MS(FABH+) m/e (relative intensity) 459.7 (100). HRMS calculated for M+H 459.2681. Found 459.2670.
Step 6. Preparation of 6
To a solution of 914 mg (2.0 mmol) of 5 in 50 ml THF was added 800 mg (4.0 mmol) 5-bromovaleroyl chlorice. Next was added 4 g (39.6 mmol) TEA. The reaction was stirred 10 minutes, then partitioned between ethyl acetate and brine. The organic layer was dried (MgSO4) and concentrated in vacuo. Purification by silica gel chromatography through a 70 ml MPLC column using a gradient of ethyl acetate (20-50%) in hexane as eluent yielded 0.9 g (73%) of 6 as a pale yellow oil. 1H NMR (CDCl3) d 0.84-0.95 (m, 6H), 1.02-1.53 (m, 10H), 1.53-1.68 (m, 1H), 1.80-2.00 (m, 4H), 2.12-2.26 (m, 4H), 2.38 (t, J=6.9 Hz, 2H), 2.80 (s, 6H), 3.07 )qAB, JAB=15.6 Hz, DV=40.4 Hz, 2H), 3.43 (t, J=6.9 Hz, 2H), 4.10 (s, 1H), S.51 (s, 1H), 5.95 (d, J=2.4 Hz, 1H), 6.51 (dd, J=9.3 and 2.7 Hz, 1H), 7.28 (s, 1H), 7.32-7.41 (m, 2h), 7.78 (d, J=8.1 Hz, 1H), 7.90 (d, J=9.0 Hz, 1H).

Step 7. Preparation of 7 




To a solution of 0.9 g (1.45 mmol) of 6 in 25 ml acetonitrile add 18 g (178 mmol) TEA. Heat at 55° C. for 16 hours. The reaction mixture was cooled to ambient temperature and concentrated in vacuo. Purification by reverse-phase silica gel chromatography (Waters Delta Prep 3000) using an acetonitrile/water gradient containing 0.05% TFA (20-65% acetonitrile) gave 0.8 g (73%) of 7 as a white foam. 1H NMR (CDCl3) d 0.80-0.96 (m, 6H), 0.99-1.54 (m, 19H), 1.59-1.84 (m, 3H), 2.09-2.24 (m, 1H), 2.45-2.58 (m, 2H), 2.81 (s, 6H) 3 .09 (qAB, JAB=15.6 Hz, DV=18.5 Hz, 2H), 3.13-3.31 (m, 8H), 4.16 (s, 1H), 5.44 (s, 1H), 6.08 (d, J=1.8 Hz, 1H), 6.57 (dd, J=9.3 and 2.7 Hz, 1H), 7.24 (t, J=7.5 Hz, 1H), 7.34 (t, J=8.4 Hz, 1H), 7.56 (d, J=8.4 Hz, 1H), 7.74 (s, 1H), 7.88 (d, J=9.0 Hz, 1H), 9.22 (s, 1H). HRMS calcd 642.4304; observed 642.4343.
Example 1400
Step 1 




A 12-liter, 4-neck round-bottom flask was equipped with reflux codenser, N2 gas adaptor, mechanical stirrer, and an addition funnel. The system was purged with N2.
A slurry of sodium hydride (126.0 g/4.988 mol) in toluene (2.5 L) was added, and the mixture was cooled to 6° C. A solution of 4-fluorophenol (560.5 g/5.000 mol) in toluene (2.5 L) was added via addition funnel over a period of 2.5 h. The reaction mixture was heated to reflux (100 C) for 1 h. A solution of 3-methoxybenzyl chloride (783.0 g/5.000 mol) in toluene (750 mL) was added via addition funnel while maintaining reflux. After 15 h. refluxing, the mixture was cooled to room temperature and poured into H2O (2.5 L). After 20 min. stirring, the layers were separated, and the organic layer was extracted with a solution of potassium hydroxide (720 g) in MeOH (2.5 L). The MeOH layer was added to 20% aqueous potassium hydroxide, and the mixture was stirred for 30 min. The mixture was then washed 5 times with toluene. The toluene washes were extracted with 20% aq. KOH. All 20% aq. KOH solutions were combined and acidified with concentrated HCl. The acidic solution was extracted three times with ethyl ether, dried (MgSO4), filtered and concentrated in vacuo. The crude product was purified by Kugelrohr distillation to give a clear, colorless oil (449.0 g/39% yield). b.p.: 120-130 C/50 mtorrHg. 1H NMR and MS [(M+H)+=233] confirmed desired structure.

Step 2 




A 12-liter, 3-neck round-bottom flask was fitted with mechanical stirrer and N2 gas adaptor. The system was purged with N2. 4-Fluoro-2-(3-methoxybenzyl)-phenol (455.5 g/1.961 mol) and dimethylformamide were added. The solution was cooled to 6 C, and sodium hydride (55.5 g/2.197 mol) was added slowly. After warming to room temperature, dimethylthiocarbamoyl chloride (242.4 g/1.961 mol) was added. After 15 h, the reaction mixture was poured into H2O (4.0 L), and extracted two times with ethyl ether. The combined organic layers were washed with H2O and saturated aqueous NaCl, dried (MgSO4), filtered, and concentrated in vacuo to give the product (605.3 g, 97% yield). 1H NMR and MS [(M+H)+=320] confirm desired structure.

Step 3 




A 12-liter, round-bottom flask was eqipped with N2 gas adaptor, mechanical stirrer, and reflux condenser. The system was purged with N2. 4-Fluoro-2-(3methoxybenzyl)-phenyldimethylthiocarbamate (605.3 g/1.895 mol) and phenyl ether (2.0 kg) were added, and the solution was heated to reflux for 2 h. The mixture was stirred for 64 h. at room temparature and then heated to reflux for 2 h. After cooling to room temperature, MeOH (2.0 L) and THF (2.0 L) were added, and the solution was stirred for 15 h. Potassium hydroxide (425.9 g/7.590 mol) was added, and the mixture was heated to reflux for 4 h. After cooling to room temparature, the mixture was concentrated by rotavap, dissolved in ethyl ether (1.0 L), and extracted with H2O. The aqueous extracts were combined, acidified with concentrated HCl, and extracted with ethyl ether The ether extracts were dried (MgSO4), filtered, and concentrated in vacuo to give an amber oil (463.0 g, 98% yield). 1H NMR confirmed desired structure.

Step 4 




A 5-liter, 3-neck, round-bottom flask was equipped with N2 gas adaptor and mechanical stirrer. The system was purged with N2. 4-Fluoro-2-(3-methoxybenzyl)-thiophenol (100.0 g/403.2 mmol) and 2-methoxyethyl ether (1.0 L) were added and the solution was cooled to 0 C. Sodium hydride (9.68 g/383.2 mmol) was added slowly, and the mixture was allowed to warm to room temperature, 2,2-Dibutylpropylene sulfate (110.89 g/443.6 mmol) was added, and the mixture was stirred for 64 h. The reaction mixture was concentrated by rotavap and dissolved in H2O. The aqueous solution was washed with ethyl ether, and concentrated H2SO4 was added. The aoueous solution was heated to reflux for 30 min, cooled to room temperature, and extracted with ethyl ether. The ether solution was dried (MgSO4), filtered, and conc'd in vacuo to give an amber oil (143.94 g/85% yield). 1H NMR and MS [(M+H)+=419] confirm the desired structure.

Step 5 




A 2-liter, 4-neck, round-bottom flask was equipped with N2 gas adaptor, and mechanical stirrer. The system was purged with N2. The corresponding alcohol (143.94 g/343.8 mmol) and CH2Cl2 (1.0 L) were added and cooled to 0 C. Pyridinium chlorochromate (140.53 g/651.6 mmol) was added. After 6 h., CH2Cl2 was added. After 20 min, the mixture was filtered through silica gel, washing with CH2Cl2. The filtrate was concentrated in vacuo to give a dark yellow-red oil (110.6 g, 77% yield). 1H NMR and MS [(M+H)+=417] confirm the desired structure.

Step 6 




A 2-liter, 4-neck, round-bottom flask was equipped with N2 gas adaptor and mechanical stirrer. The system was purged with N2. The corresponding sulfide (110.6 g/265.5 mmol) and CH2Cl2 (1.0 L) were added. The solution was cooled to 0 C, and 3-chloroperbenzoic acid (158.21 g/531.7 mmol) was added portionwise. After 30 mm, the reaction mixture was allowed to warm to room teemperature After 3.5 h, the reaction mixture was cooled to 0 C and filtered through a fine fritted funnel. The filtrate was washed with 10% aqueous K2CO3. An emulsion formed which was extracted with ethyl ether. The organic layers were combined, dried (MgSO4), filtered, and concentrated in vacuo to give the product (93.2 g, 78% yield). 1H NMR confirmed the desired structure.

Step 7 




A 2-liter, 4-neck, round-bottom flask was equipped with N2 gas adaptor, mechanical stirrer, and a powder addition funnel. The system was purged with N2. Tine corresponding aldehyde (93.2 g/208 mmol) and THF (1.0 L) were added, and the mixture was cooled to 0 C. Potassium tert-butoxide (23.35 g/208.1 mmol) was added via addition funnel. After 1 h, 10% aq/HCl (1.0 L) was added. After 1 h, the mixture was extracted three times with ethyl ether, dried (MgSO4), filtered, and concentrated in vacuo. The crude product was purified by recryst. from 80/20 hexane/ethyl acetate to give a white solid (32.18 g). The mother liquor was concentrated in vacuo and recrystelized from 95/5 toluene/ethyl acetate to give a white solid (33.60 g/combined yield: 71%). 1H NMR confirmed the desired product.

Step 8 




A Fisher porter bottle was fitted with N2 line and magnetic stirrer. The system was purged with N2. The corresponding fluoro-compound (28.1 g/62.6 mmol) was added, and the vessel was sealed and cooled to −78 C. Dimethylamine (17.1 g/379 mmol) was condensed via a CO2/acetone bath and added to the reaction vessel. The mixture was allowed to warm to room temperature and was heated to 60 C. After 20 h, the reaction mixture was allowed to cool and was dissolved in ethyl ether. The ether solution was washed with H2O, saturated aqueous NaCl, dried (MgSO4), filtered, and concentrated in vacuo to give a white solid (28.5 g/96% yield). 1H NMR confirmed the desired structure.

Step 9 




A 250-mL, 3-neck, round-bottom flask was equipped with N2 gas adaptor and magnetic stirrer. The system was purged with N2. The corresponding methoxy-compound (6.62 g/14.0 mmol) and CHCl3 (150 mL) were added. The reaction mixture was cooled to −78 C, and boron tribromide (10.50 g/41.9 mmol) was added. The mixture was allowed to warm to room temperature After 4 h, the reaction mixture was cooled to 0 C and was quenched with 10% K2CO3 (100 mL). After 10 min, the layers were separated, and the aqueous layer was extracted two times with ethyl ether. The CHCl3 and ether extracts were combined, washed with saturated aqueous NaCl, dried (MgSO4), filtered, and concentrated in vacuo to give the product (6.27 g/98% yield). 1H NMR confirmed the desired structure.

Step 10 




In a 250 ml single neck round bottom Flask with stir bar place 2-diethylamineoethyl chloride hydochloride (fw 172.10 g/mole) Aldrich D8, 720-1 (2.4 mmol,4.12 g), 34 ml dry ether and 34 ml of 1N KOH(aqueous). Stir 15 minutes and then separate by ether extraction and dry over anhydrous potassium carbonate.
In a separate 2-necked 250 ml round bottom flask with stir bar add sodium hydride (60% dispersion in mineral oil, 100 mg, 2.6 mmol) and 34 ml of DMF. Cool to ice temperature. Next add phenol product(previous step) 1.1 g (2.4 mmilomoles in 5 ml DMF and the ether solution prepared above. Heat to 40C for 3 days. The product which contained no starting material by TLC was diluted with ether and extracted with 1 portion of 5% NaOH, followed by water and then brine. The ether layer was dried over magnesium sulfate and isolated by removing ether by rotary evaporation (1.3 gms). The product may be further purified by chromatography (SiO2 99% ethyl acetate/1% NH4OH at 5 ml/min.). Isolated yield: 0.78 g (mass spec, and H1 NMR)

Step 11 




The product from step 10 (0.57 gms, 1.02 millimole 5w 558.83 g/mole) and 1.6 gms iodoethane (10.02 mmol) was placed in 5 ml acetonitrile in a fischer-porter bottle and heated to 45 C for 3 days. The solution was evaporated to dryness and redissolved in 5 mls of chloroform. Next ether was added to the chloroform solution and the resulting mixture was chilled. The desired product is isolated as a precipitate 0.7272 gms. Mass spec M−I=587.9, H NMR).
Example 1401
Step 1 




A 12-liter, 4-neck round-bottom flask was equipped with reflux condenser, N2 gas adaptor, mechanical stirrer, and an addition funnel the system was purged with N2. A slurry of sodium hydride (126.0 g/4.988 mol) in toluene (2.5 L) was added, and the mixture was cooled to 6 C. A solution of 4-fluorophenol (560.5 g/5.000 mol) in toluene (2.5 L) was added via addition funnel over a period of 2.5 h. The reaction mixture was heated to reflux (100 C) for 1 h. A solution of 3-methoxybenzyl chloride (783.0 g/5.000 mol) in toluene (750 mL) was added via addition funnel while maintaining reflux. After 15 h. refluxing, the mixture was cooled to room temperature and poured into H2O (2.5 L). After 20 min. stirring, the layers were separated, and the organic layer was extracted with a solution of potassium hydroxide (720 g) in MeoH (2.5 L). The MeOH layer was added to 20% aqueous potassium hydroxide, and the mixture was stirred for 30 min. The mixture was then washed 5 times with toluene. The toluene washes were extracted with 20% aq. KOH. All 20% aqueous KOH solutions were combined and acidified with concentrated HCl. The acidic solution was extracted three times with ethyl ether, dried over MgSO4, filtered and concentrated in vacuo. The crude product was purified by Kugelrohr distillation to give a clear, colorless oil (449.0 g/39% yield). b.p.: 120-130 C/50 mtorrHg. 1H NMR and MS [(M+H)+=233] confirmed desired structure.

Step 2 




A 12-liter, 3-neck round-bottom flask was fitted with mechanical stirrer and N2 gas adaptor. The system was purged with N2. 4-Fluoro-2-(3-methoxybenzyl)-phenol (455.5 g/1.961 mol) and dimethylformamide were added. The solution was cooled to 6 C, and sodium hydride (55.5 g/2.197 mol) was added slowly. After warming to room temperature, dimethylthiocarbamoyl chloride (242.4 g/1.961 mol) was added. After 15 h, the reaction mixture was poured into H2O (4.0 L), and extracted two times with ethyl ether. The combined organic layers were washed with H2O and saturated aqueous NaCl, dried over MgSO4, filtered, and concentrated in vacuo to give the product (605.3 g, 97% yield). 1H NMR and MS [M+H]+=320] confirm desired structure.

Step 3 




A 12-liter, round-bottom flask was equipped with N2 gas adaptor, mechanical stirrer, and reflux condenser. The system was purged with N2. 4-Fluoro-2-(3-methoxybenzyl) phenyldimethylthiocarbamate (605.3 g/1.895 mol) and phenyl ether (2.0 kg) were added, and the solution was heated to reflux for 2 h. The mixture was stirred for 64 h. at room temperature and then heated to reflux for 2 h. After cooling to room temperature, MeOH (2.0 L) and THF (2.0 L) were added, and the solution was stirred for 15 h. Potassium hydroxide (425.9 g/7.590 mol) was added, and the mixture was heated to reflux for 4 h. After cooling to room temperature, the mixture was concentrated by rotavap, dissolved in ethyl ether (1.0 L), and extracted with H2O. The aqueous extracts were combined, acidified with conc. HCl, and extracted with ethyl ether. The ether extracts were dried (MgSO4), filtered, and concentrated in vacuo to give an amber oil (463.0 g, 98% yield). 1H NMR confirmed desired structure.

Step 4 




A 5-liter, 3-neck, round-bottom flask was equipped with N2 gas adaptor and mechanical stirrer. The system was purged with N2. 4-Fluoro-2-(3-methoxybenzyl)-thiophenol (100.1 g/403.2 mmol) and 2-methoxyethyl ether (1.0 L) were added and the solution was cooled to 0 C. Sodium hydride (9.68 g/383.2 mmol) was added slowly, and the mixture was allowed to warm to room temperature 2,2-Dibutylpropylene sulfate (110.89 g/443.6 mmol) was added, and the mixture was stirred for 64 h. The reaction mixture was concentrated by rotavap and dissolved in H2O. The aqueous solution was washed with ethyl ether, and conc. H2SO4 was added. The aqueous solution was heated to reflux for 30 min, cooled to room temperature, and extracted with ethyl ether. The ether solution was dried (MgSO4), filtered, and concentrated in vacuo to give an amber oil (143.94 g/85% yield). 1H NMR and MS [(M+H)+=419] confirm the desired structure.

Step 5 




A 2-liter, 4-neck, round-bottom flask was equipped with N2 gas adaptor, and mechanical stirrer. The system was purged with N2. The corresponding alcohol (143.94 g/343.8 mmol) and CH2Cl2 (1.0 L) were added and cooled to 0 C. Pyridinium chlorochromate (140.53 g/651.6 mmol) was added. After 6 h., CH2Cl2 was added. After 20 min, the mixture was filtered through silica gel, washing with CH2Cl2. The filtrate was concentrated in vacuo to give a dark yellow-red oil (110.6 g, 77% yield). 1H NMR and MS [(M+H)+=417] confirm the desired structure.

Step 6 




A 2-liter, 4-neck, round-bottom flask was equipped with N2 gas adaptor and mechanical stirrer. The system was purged with N2. The corresponding sulfide (110.6 g/265.5 mmol) and CH2Cl2 (1.0 L) were added. The solution was cooled to 0 C, and 3-chloroperbenzoic acid (158.21 g/531.7 mmol) was added portionwise. After 30 min. the reaction mixture was allowed to warm to room temperature After 3.5 h, the reaction mixture was cooled to 0 C and filtered through a fine fritted funnel. The filtrate was washed with 10% aqueous K2CO3. An emulsion formed which was extracted with ethyl ether. The organic layers were combined, dried (MgSO4), filtered, and concentrated in vacuo to give the product (93.2 g, 78% yield). 1H NMR confirmed the desired structure.

Step 7 




A 2-liter, 4-neck, round-bottom, flask was equipped with N2 gas adaptor, mechanical stirrer, and a powder addition funnel. The system was purged with N2. The corresponding aldehyde (93.2 g/208 mmol) and THF (1.0 L) were added, and the mixture was cooled to 0 C. Potassium tert-butoxide (23.35 g/208.1 mmol) was added via addition funnel. After 1h, 10% aq/HCl (1.0 L) was added. After 1 h, the mixture was extracted three times with ethyl ether, dried (MgSO4), filtered, and concentrated in vacuc. The crude product was purified by recrystallized from 80/20 hexane/ethyl acetate to give a white solid (32.18 g). The mother liquor was concentrated in vacuo and recrystallized from 95/5 toluene/ethyl acetate to give a white solid (33.60 g, combined yield: 71%). 1H NMR confirmed the desired product.

Step 8 




A Fisher porter bottle was fitted with N2 line and magnetic stirrer. The system was purged with N2. The corresponding fluoro-compound (28.1 g/62.6 mmol) was added, and the vessel was sealed and cooled to −78 C. Dimethylamine (17.1 g/379 mmol) was condensed via a CO2/acetone bath and added to the reaction vessel. The mixture was allowed to warm to room temperature and was heated to 60 C. After 20 h, the reaction mixture was allowed to cool and was dissolved in ethyl ether. The ether solution was washed with H2O, saturated aqueous NaCl, dried over MgSO4, filtered, and concentrated in vacuo to give a white solid (28.5 g/96% yield). 1H NMR confirmed the desired structure.

Step 9 




A 250-mL, 3-neck, round-bottom flask was equipped with N2 gas adaptor and magnetic stirrer. The system was purged with N2. The corresponding methoxy-compound (6.62 g/14.0 mmol) and CHCl3 (150 mL) were added. The reaction mixture was cooled to −78 C, and boron tribromide (10.50 g/41.9 mmol) was added. The mixture was allowed to warm to room temperature After 4 h, the reaction mixture was cooled to 0 C and was quenched with 10% K2CO3 (100 mL). After 10 min, the layers were separated, and the aqueous layer was extracted two times with ethyl ether. The CHCl3 and ether extracts were combined, washed with saturated aqueous NaCl, dried over MgSO4, filtered, and concentrated in vacuo to give the product (6.27 g/98% yield). 1H NMR confirmed the desired structure.

Step 10 




In a 250 ml single neck round bottom flask with stir bar place 2-diethylamineoethyl chloride hydochloride (fw 172.10 g/mole) Aldrich D8, 720-1 (2.4 millimoles, 4.12 g), 34 ml dry ether and 34 ml of 1N KOH (acueous). Stir 15 minutes and then separate by ether extraction and dry over anhydrous potassium carbonate.
In a separate 2-necked 250 ml round bottom flask with stir bar add sodium hydride (60% dispersion in mineral oil, 100 mg, (2.6 mmol) and 34 ml of DMF. Cool to ice temperature. Next add phenol product (previous step) 1.1 g (2.4 mmol in 5 ml DMF and the ether solution prepared above. Heat to 40C for 3 days. The product which contained no starting material by TLC was diluted with ether and extracted with 1 portion of 5% NaOH, followed by water and then brine. The ether layer was dried over Magnesium sulfate and isolated by removing ether by rotary evaporation (1.3 gms). The product may be further purified by chromatography (silica 99% ethyl acetate/1% NH40H at 5 ml/min.). Isolated yield: 0.78 g (mass spec, and H1 NMR)

Step 11 




The product from step 10 (0.57 gms, 1.02 millimole fw 558.83 g/mole) and iodoethane (1.6 gms (10.02 mmol) was place in 5 ml acetonitrile in a Fischer-Porter bottle and heated to 45 C for 3 days. The solution was evaporated to dryness and redissolved in 5 mls of chloroform. Next ether was added to the chloroform solution and the resulting mixture was chilled. The desired product is isolated as a precipitate 0.7272 gms. Mass spec M−I=587.9, 1H NMR).
Biological Assays
The utility of the compounds of the present invention is shown by the following assays. These assays are performed in vitro and in animal models essentially using a procedure recognized to show the utility of the present invention.
In Vitro Assay of Compounds That Inhibit IBAT-Mediated Uptake of [14C]-Taurocholate (TC) in H14 Cells
Baby hamster kidney cells (BHK) transfected with the cDNA of human IBAT (H14 cells) are seeded at 60,000 cells/well in 96 well Top-Count tissue culture plates for assays run within in 24 hours of seeding, 30,000 cells/well for assays run within 48 hours, and 10,000 cells/well for assays run within 72 hours.
On the day of assay, the cell monolayer is gently washed once with 100 ml assay buffer (Dulbecco's Modified Eaglets medium with 4.5 g/L glucose+0.2% (w/v) fatty acid free bovine serum albumin- (FAF)BSA). To each well 50 ml of a two-fold concentrate of test compound in assay buffer is added along with 50 ml of 6 mM [14C]-taurocholate in assay buffer (final concentration of 3 mm [14C]-taurocholate). The cell culture plates are incubated 2 hours at 37° C. prior to gently washing each well twice with 100 ml 4° C. Dulbecco's phosphate-buffered saline (PBS) containing 0.2% (w/v) (FAF)BSA. The wells are then gently washed once with 100 ml 4° C. PBS without (FAF)BSA. To each 200 ml of liquid scintillation counting fluid is added, the plates are heat sealed and shaken for 30 minutes at room temperature prior to measuring the amount of radioactivity in each well on a Packard Top-Count instrument.
In Vitro Assay of Compounds That Inhibit Uptake of [14C]-Alanine
The alanine uptake assay is performed in an identical fashion to the taurocholate assay, with the exception that labeled alanine is substituted for the labeled taurocholate.
In Vivo Assay of Compounds That Inhibit Rat Ileal Uptake of [14C]-Taurocholate into Bile
(See “Metabolism of 3a,7b-dihydroxy-7a-methyl-5b-cholanoic acid and 3a,7b-dihydroxy-7a-methyl-5b-cholanoic acid in hamsters” in Biochimica et Biophysica Acta 833 (1985) 196-202 by Une et al.)
Male wistar rats (200-300 g) are anesthetized with inactin @100 mg/kg. Bile ducts are cannulated with a 10′′ length of PE10 tubing. The small intestine is exposed and laid out on a gauze pad. A canulae (1⁄8′′ luer lock, tapered female adapter) is inserted at 12 cm from the junction of the small intestine and the cecum.
A slit is cut at 4 cm from this same junction (utilizing a 8 cm length of ileum). 20 ml of warm Dulbecco's phosphate buffered saline, pH 6.5 (PBS) is used to flush out the intestine segment. The distal opening is cannulated with a 20 cm length of silicone tubing (0.02′′ I.D.×0.037′′ O.D.). The proximal cannulae is hooked up to a peristaltic pump and the intestine is washed for 20 min with warm PBS at 0.25 ml/min. Temperature of the gut segment is monitored continuously. At the start of the experiment, 2.0 ml of control sample ([14C]-taurocholate @ 0.05 mi/ml with 5 mM cold taurocholate) is loaded into the gut segment with a 3 ml syringe and bile sample collection is begun. Control sample is infused at a rate of 0.25 ml/min for 21 min. Bile samples fractions are collected every 3 minute for the first 27 minutes of the procedure. After the 21 min of sample infusion, the ileal loop is washed out with 20 ml of warm PBS (using a 30 ml syringe), and then the loop is washed out for 21 min with warm PBS at 0.25 ml/min. A second perfusion is initiated as described above but this with test compound being administered as well (21 min administration followed by 21 min of wash out) and bile sampled every 3 min for the first 27 min. If necessary, a third perfusion is performed as above that typically contains the control sample.
Measurement of Hepatic Cholesterol Concentration (HEPATIC CHOL)
Liver tissue was weighed and homogenized in chloroform:methanol (2:1). After homogenization and centrifugation the supernatant was separated and dried under nitrogen. The residue was dissolved in isopropanol and the cholesterol content was measured enzymatically, using a combination of cholesterol oxidase and peroxidase, as described by Allain, C. A., et al. (1974) Clin. Chen. 20, 470.
Measurement of Hepatic HMG CoA-reductase Activity (HMG COA)
Hepatic microsomes were prepared by homogenizing liver samples in a phosphate/sucrose buffer, followed by centrifugal separation. The final pelleted material was resuspended in buffer and an aliquot was assayed for HMG CoA reductase activity by incubating for 60 minutes at 37° C. in the presence of 14 C-HMG-CoA (Dupont-NEN). The reaction was stopped by adding 6N HCl followed by centrifugation. An aliquot of the supernatant was separated, by thin-layer chromatography, and the spot corresponding to the enzyme product was scraped off the plate, extracted and radioactivity was determined by scintillation counting. (Reference: Akerlund, J. and Bjorkhem, I. (1990) J. Lipid Res. 31, 2159).
Determination of Serum Cholesterol (SER.CHOL, HDL-CHOL, TGI and VLDL+LDL)
Total serum cholesterol (SER.CHOL) was measured enzymatically using a commercial kit from Wako Fine Chemicals (Richmond, Va.); Cholesterol C11, Catalog No. 276-64909. HDL cholesterol (HDL-CHOL) was assayed using this same kit after precipitation of VLDL and LDL with Sigma Chemical Co. HDL Cholesterol reagent, Catalog No. 352-3 (dextran sulfate method). Total serum triglycerides (blanked) (TGI) were assayed enzymatically with Sigma Chemical Co. GPO-Trinder, Catalog No. 337-B. VLDL and LDL (VLDL+LDL) cholesterol concentrations were calculated as the difference between total and HDL cholesterol.
Measurement of Hepatic Cholesterol 7-a-Hydroxylase Activity (7a-OHase)
Hepatic microsomes were prepared by homogenizing liver samples in a phosphate/sucrose buffer, followed by centrifugal separation. The final pelleted material was resuspended in buffer and an aliquot was assayed or cholesterol 7-a-hydroxylase activity by incubating for 5 minutes at 37° C. in the presence of NADPH. Following extraction into petroleum ether, the organic solvent was evaporated and the residue was dissolved in acetonitrile/methanol. The enzymatic product was separated by injecting an aliquot of the extract onto a C18 reversed phase HPLC column and quantitating the eluted material using UV detection at 240 nm. (Reference: Horton, J. D., et al. (1994) J. Clin. Invest. 93, 2084).
Measurement of Fecal Bile Acid Concentration (FBA)
Total fecal output from individually housed hamsters was collected for 24 or 48 hours, dried under a stream of nitrogen, pulverized and weighed. Approximately 0.1 gram was weighed out and extracted into an organic solvent (butanol/water). Following separation and drying, the residue was dissolved in methanol and the amount of bile acid present was measured enzymatically using the 3a-hydroxysteroid steroid dehydrogenase reaction with bile acids to reduce NAD. (Reference: Mashige, F., et al. (1981) Clin. Chem. 27, 1352).
[3H]taurocholate Uptake in Rabbit Brush Border Membrane Vesicles (BBMV)
Rabbit Ileal brush border membranes were prepared from frozen ileal mucosa by the calcium precipitation method describe by Malathi et al. (Reference: (1979) Biochinmica Biophysica Acca, 554, 259). The method for measuring taurocholate was essentially as described by Kramer e. al. (Reference: (1992) Biochimica Biophysica Acta, 1111, 93) except the assay volume was 200 μl instead of 100 μl. Briefly, at room temperature a 190 μl solution containing 2 μM [3H]-taurocholate(0.75 μCi), 20 mM tris, 100 mM NaCl, 100 mm mannitol pH 7.4 was incubated for 5 sec with 10 μl of brush border membrane vesicles (60-120 μg protein). The incubation was initiated by the addition of the BBMV while vortexing and the reaction was stopped by the addition of 5 ml of ice cold buffer (20 mM Hepes-tris, 150 mM KCl) followed immediately by filtration through a nylon filter (0.2 μm pore) and an additional 5 ml wash with stop buffer.
Acyl-COA; Cholesterol Acyl Transferase (ACAT)
Hamster liver and rat intestinal microsomes were prepared from tissue as described previously (Reference: (1980) J. Biol. Chem. 255, 9098) and used as a source of ACAT enzyme. The assay consisted of a 2.0 ml incubation containing 24 μM Oleoyl-CoA (0.05 μCi) in a 50 mM sodium phosphate, 2 mM DTT ph 7.4 buffer containing 0.25% BSA and 200 μg of microsomal protein. The assay was initiated by the addition of oleoyl-CoA. The reaction went for 5 min at 37° C. and was terminated by the addition of 8.0 ml of chloroform/methanol (2:1). To the extraction was added 125 μg of cholesterol oleate in chloroform methanol to act as a carrier and the organic and aqueous phases of the extraction were separated by centrifugation after thorough vortexing. The chloroform phase was taken to dryness and then spotted on a silica gel 60 TLC plate and developed in hexane/ethyl ether (9:1). The amount of cholesterol ester formed was determined by measuring the amount of radioactivity incorporated into the cholesterol oleate spot on the TLC plate with a Packard instaimager.
Data from each of the noted compounds in the assays described above is as set forth in TABLES 5, 6, 7, and 8 as follows:











TABLE 5







In vitro %






Inhibition
% Inhibition




of TC
of Alanine
% of Control


COM-
IC50
Uptake @
Uptake @
Transport of TC in


POUND
uM*
100 uM #
100 uM #
Rat Ileum @ 0.1 mM #



















Benzothiaze
2

 0
45.4 +/− 0.7


pine =


12

25


 3

0


 4a

3


 5a

34


 5b
40

 0
72.9 ± 5.4 @ 0.5 mM


 4b

9


18

6


14b

18


14a

13


13

23


15
60


19a

0


19b

15


 8a

41


Mixture of

69


8a and 8b


Mixture of
6


9a and 9b


 6a
5


 6b

85


 9a
5

 0% @ 25
53.7 +/− 3.9





mM


Mixture of
13


6a and 20


Mixture of
0.8

14% @ 25


6d and 10a


mM


21a

37


21c

52


21b

45


 6c
2

 58.5
68.8 +/− 5.7 at 0.4






mM


 6d
0.6

 77.7
16.1 +/− 1.1 @ 0.5






mM 30.2 +/− 0.9 @






0.15 mM


17

10


 7
50

 49.3


10a
7

 77.6
62.4 =/− 2.5 @ 0.2






mM


10b
15

68.6


25
0.1

 4% @ 10
26.0 +/− 3.3





mM


26
2

31% @ 25
87.9 +/− 1.5





mM


27
5

 7% @ 20





mM


28
8

31% @ 20





mM


29

88 @ 50




mM


30

96 @ 50




mM


31

41 @ 50




mM


37
3

 0% @ 5





mM


38
0.3

11% @ 5
20.6 +/− 5.7





mM


40

49 @ 50




mM


41
2

 0% @ 20





mM


42
1.5


43
1.5

16% @ 25





mM


48
2

22% @ 20





mM


49
0.15

21% @ 200
21.2 +/− 2.7





mM


57

51 @ 50




mM


58

20 @ 50




mM


59
70


60
9

 59


61
30

175


62
10


63

90 @ 6




mM


64

100 @ 6 




mM





*In vitro Taurocholate Cell Uptake 


# Unless otherwise noted 


= Comparative Example is Example No. 1 in WO 93/16055. 


















TABLE 6 






TC-uptake
TC-uptake






(H14
Ileal
TC-uptake
ACAT
ACAT



cells)
Loop
(BBMV)
(liver)
intestine


Compound
IC(50)
EC(50)
IC(50)
IC(50)
IC(50)







COMP.
  1 mM
74 mM
  3 mM
20 mM
20 mM


EXAMPLE


6d
0.6 mM
31 mM
1.5 mM
25 mM
20 mM


*38 
0.3 mM
12 mM
  2 mM
15 mM
N.D.


49
0.1 mM
12 mM
N.D.
 6 mM
N.D.


25
0.1 mM
20 mM
0.8 mM
 8 mM
 8 mM





Comparative Example No. 1 in WO 93/16055 













TABLE 7







EFFICACY OF COMPOUND NO. 25


IN CHOLESTEROL-FED HAMSTERS












4% CHOLES-
0.2%


PARAMETER
CONTROL
TYRAMINE
CPD. NO. 25











WEIGHT (G)
(mean ± SEM. *p < 0.05, A-Student's t,



B-Dunnett's)










day 1
117 (2)
114 (6)
117 (5)


day 14
127 (3)
127 (3)
132 (4)


LIVER WEIGHT (G)
5.4 (0.3)
4.9 (0.4)
5.8 (0.2)


SER.CHOL (mg %)
143 (7)
119 (4)
126 (2)




*A, B
*A, B


HDL-CHOL (mg %)
89 (4)
76 (3) *A, B
76 (1) *A, B


VLDL + LDL
54 (7)
42 (3)*A
50 (3)


TGI (mg %)
203 (32)
190 (15)
175 (11)


HEPATIC 
2.5 (0.3)
1.9 (0.1) *A, B
1.9 (0.1)


CHOL (mg/g)


*A, B


HMG COA
15.8 (7.6)
448.8 (21.6)
312.9 (37.5)


(pm/mg/min.)

*A, B
*A, B


7a-OHase
235.3 (25.1)
357.2 (28.3)
291.0 (6.0) *A


(pm/mg/min.)

*A, B


24 HR. FECAL
2.3 (0.1)
2.7 (0.1) *A, B
2.4 (0.04)


Wt (G)


FBA
6.2 (0.8)
12.3 (1.5)
11.9 (0.5)


(mM/24 H/100 g)

*A, B
*A, B
















TABLE 8







EFFICACY OF COMPOUND NO. 25


IN RAT ALZET MINIPUMP MODEL













20 MPL/DAY



PARAMETER
CONTROL
CPD. NO. 25














WEIGHT (G)
(mean ± SEM, *p < 0.05, A-Student's t,




B-Dunnett's)











day 1
307 (4)
307 (3)



day 8
330 (4)
310 (4) *A, B



LIVER WEIGHT (G)
15.5 (0.6)
14.6 (0.4)



SER.CHOL (mg %)
85 (3)
84 (3)



HEPATIC CHOL (mg/g)
21 (0.03)
2.0 (0.03)



HMG COA pm/mg/min
75.1 (6.4)
318.0 (40.7) *A, B



7a-OHase (pm/mg/min)
281.9 (13.9)
535.2 (35.7) *A, B



24 HR. FECAL WT (G)
5.8 (0.1)
5.7 (0.4)



FBA (mM/24 H/100 g)
17.9 (0.9)
39.1 (4.5) *A, B










Additional taurocholate uptake tests were conducted in the following compounds listed in Table 9.







TABLE 9







Biological Assay Data for Some Compounds


of the Present Invention












Human TC
Alanine Uptake



Compound
IC50
Percent Inhibition



Number
(μM)
@ μM















101

  0 @ 1.0



102
0.083



103

  13 @ 0.25



104
0.0056



105
0.6



106
0.8



107

14.0 @ 0.063



108
0.3



109

 2.0 @ 0.063



110
0.09



111
2.5



112
3.0



113
0.1



114
0.19



115
8.0



116
0.3



117

12.0@ 0.625



118
0.4



119
1.3



120

34.0 @ 5.0



121
0.068



122
1.07



123
1.67



124

14.0 @ 6.25



125
18.0



126

  18 @ 1.25



127
0.55



128
0.7



129
0.035



131
1.28



132

 5.4 @ 0.063



133
16.0



134
0.3



135
22.0



136
0.09



137
2.4



138
3.0



139
>25.0



142
0.5



143
0.03



144
0.053



262
0.07



263
0.7



264
0.2



265
2.0



266
0.5



267
0.073



268
0.029



269
0.08



270
0.12



271
0.07



272
0.7



273
1.9



274
0.18



275

 5.0 @ 0.25



276
0.23



277
0.04



278
3.0



279
0.4



280
0.18



281
0.019



282
0.021



283
0.35



284
0.08



286
19.0



287
4.0



288

10.0 @ 6.25



289
0.23



290
0.054



291
0.6



292
0.046



293
1.9



294
0.013



295
1.3



296
1.6



1005
0.0004



1006
0.001



1007
0.001



1008
0.001



1009
0.001



1010
0.001



1011
0.001



1012
0.0015



1013
0.002



1014
0.002



1015
0.002



1016
0.002



1017
0.002



1018
0.002



1019
0.002



1020
0.002



1021
0.002



1022
0.002



1023
0.002



1024
0.002



1025
0.002



1026
0.002



1027
0.002



1028
0.002



1029
0.002



1030
0.002



1031
0.002



1032
0.002



1033
0.002



1034
0.002



1035
0.002



1036
0.002



1037
0.0022



1038
0.0025



1039
0.0026



1040
0.003



1041
0.003



1042
0.003



1043
0.003



1044
0.003



1045
0.003



1046
0.003



1047
0.003



1048
0.003



1049
0.003



1050
0.003



1051
0.003



1052
0.003



1053
0.003



1054
0.003



1055
0.003



1056
0.003



1057
0.003



1058
0.003



1059
0.003



1060
0.0036



1061
0.004



1062
0.004



1063
0.004



1064
0.004



1065
0.004



1066
0.004



1067
0.004



1068
0.004



1069
0.004



1070
0.004



1071
0.004



1072
0.004



1073
0.004



1074
0.004



1075
0.0043



1076
0.0045



1077
0.0045



1078
0.0045



1079
0.005



1080
0.005



1081
0.005



1082
0.005



1083
0.005



1084
0.005



1085
0.005



1086
0.005



1087
0.005



1088
0.0055



1089
0.0057



1090
0.006



1091
0.006



1092
0.006



1093
0.006



1094
0.006



1095
0.006



1096
0.006



1097
0.006



1098
0.006



1099
0.0063



1100
0.0068



1101
0.007



1102
0.007



1103
0.007



1104
0.007



1105
0.007



1106
0.0073



1107
0.0075



1108
0.0075



1109
0.008



1110
0.008



1111
0.008



1112
0.008



1113
0.009



1114
0.009



1115
0.0098



1116
0.0093



1117
0.01



1118
0.01



1119
0.01



1120
0.01



1121
0.01



1122
0.011



1123
0.011



1124
0.011



1125
0.012



1126
0.013



1127
0.013



1128
0.017



1129
0.018



1130
0.018



1131
0.02



1132
0.02



1133
0.02



1134
0.02



1135
0.021



1136
0.021



1137
0.021



1138
0.022



1139
0.022



1140
0.023



1141
0.023



1142
0.024



1143
0.027



1144
0.028



1145
0.029



1146
0.029



1147
0.029



1148
0.03



1149
0.03



1150
0.03



1151
0.031



1152
0.036



1153
0.037



1154
0.037



1155
0.039



1156
0.039



1157
0.04



1158
0.06



1159
0.06



1160
0.062



1161
0.063



1162
0.063



1163
0.09



1164
0.093



1165
0.11



1166
0.11



1167
0.12



1168
0.12



1169
0.12



1170
0.13



1171
0.14



1172
0.14



1173
0.15



1174
0.15



1175
0.17



1176
0.18



1177
0.18



1178
0.19



1179
0.19



1180
0.2



1181
0.22



1182
0.25



1183
0.28



1184
0.28



1185
0.28



1186
0.3



1187
0.32



1188
0.35



1189
0.35



1190
0.55



1191
0.65



1192
1.0



1193
1.0



1194
1.6



1195
1.7



1196
2.0



1197
2.2



1198
2.5



1199
4.0



1200
6.1



1201
8.3



1202
40.0



1203

  0 @ 0.063



1204
0.05



1205
0.034



1206
0.035



1207
0.068



1208
0.042



1209

  0 @ 0.063



1210
0.14



1211
0.28



1212
0.39



1213
1.7



1214
0.75



1215
0.19



1216
0.39



1217
0.32



1218
0.19



1219
0.34



1220
0.2



1221
0.041



1222
0.065



1223
0.28



1224
0.33



1225
0.12



1226
0.046



1227
0.25



1228
0.038



1229
0.049



1230
0.062



1231
0.075



1232
1.2



1233
0.15



1234
0.067



1235
0.045



1236
0.05



1237
0.07



1238
0.8



1239
0.035



1240
0.016



1241
0.047



1242
0.029



1243
0.63



1244
0.062



1245
0.32



1246
0.018



1247
0.017



1248
0.33



1249
10.2



1250
0.013



1251
0.62



1252
29.



1253
0.3



1254
0.85



1255
0.69



1256
0.011



1257
0.1



1258
0.12



1259
16.5



1260
0.012



1261
0.019



1262
0.03



1263
0.079



1264
0.21



1265
0.24



1266
0.2



1267
0.29



1268
0.035



1269
0.024



1270
0.024



1271
0.011



1272
0.047



1273
0.029



1274
0.028



1275
0.024



1276
0.029



1277
0.018



1278
0.017



1279
0.028



1280
0.76



1281
0.055



1282
0.17



1283
0.17



1284
0.011



1285
0.027



1286
0.068



1287
0.071



1288
0.013



1289
0.026



1290
0.017



1291
0.013



1292
0.025



1293
0.019



1294
0.011



1295
0.014



1296
0.063



1297
0.029



1298
0.018



1299
0.012



1300
1.0



1301
0.15



1302
1.4



1303
0.26



1304
0.25



1305
0.25



1306
1.2



1307
3.1



1308
0.04



1309
0.24



1310
1.16



1311
3.27



1312
5.0



1313
6.1



1314
0.26



1315
1.67



1316
3.9



1317
21.0



1319

11.0 @ 0.25



1321

11.1 @ 5.0



1322

 3.0 @ 0.0063



1323

 4.0 @ 0.0063



1324

43.0 @ 0.0008



1325

 1.0 @ 0.0063



1326

36.0 @ 0.0008



1327

 3.0 @ 0.0063



1328

68.0 @ 0.0063



1329

 2.0 @ 0.0063



1330

 9.0 @ 0.0063



1331

57.0 @ 0.0008



1332

43.0 @ 0.0008



1333

  0 @ 0.0063



1334

50.0 @ 0.0008



1335

38.0 @ 0.0008



1336

45.0 @ 0.0008



1337

  0 @ 0.0063



1338

 1.0 @ 0.25



1339

  0 @ 0.063



1340

 9.0 @ 0.063



1341

 1.0 @ 0.063



1342

 1.0 @ 0.063



1345

13.0 @ 0.25



1347
0.0036



1351
0.44



1352
0.10



1353
0.0015



1354
0.006



1355
0.0015



1356
0.22



1357
0.023



1358
0.008



1359
0.014



1360
0.003



1361
0.004



1362
0.019



1363
0.008



1364
0.006



1365
0.008



1366
0.015



1367
0.002



1368
0.005



1369
0.005



1370
0.002



1371
0.004



1372
0.004



1373
0.008



1374
0.007



1375
0.002



1449
0.052



1450
0.039



1451
0.014










The examples herein can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.
Novel compositions of the invention are illustrated in attached Exhibits A and B.
The invention being thus described, it is apparent that the same can be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the present invention, and all such modifications and equivalents as would be obvious to one skilled in the art are intended to be included within the scope of the following claims.







TABLE C2







Alternative compounds #2 (Families F101-F123)

















Family Cpd#
R1 = R2
R5
(Rx)q





F101
CHOSEN FROM
Ph-
CHOSEN FROM



TABLE D *

TABLE D


F102
CHOSEN FROM
p-F-Ph-
CHOSEN FROM



TABLE D

TABLE D


F103
CHOSEN FROM
m-F-Ph-
CHOSEN FROM



TABLE D

TABLE D


F104
CHOSEN FROM
p-CH3O-Ph-
CHOSEN FROM



TABLE D

TABLE D


F105
CHOSEN FROM
m-CH3O-Ph-
CHOSEN FROM



TABLE D

TABLE D


F106
CHOSEN FROM
p-(CH3)2N-Ph-
CHOSEN FROM



TABLE D

TABLE D


F107
CHOSEN FROM
m-(CH3)2N-Ph
CHOSEN FROM



TABLE D

TABLE D


F108
CHOSEN FROM
I−, p-(CH3)3—N+-Ph-
CHOSEN FROM



TABLE D

TABLE D


F109
CHOSEN FROM
I−, m-(CH3)3—N+-Ph-
CHOSEN FROM



TABLE D

TABLE D


F110
CHOSEN FROM
I−, p-(CH3)3—N+-CH2CH2-
CHOSEN FROM



TABLE D
(OCH2CH2)2—O-Ph-
TABLE D


F111
CHOSEN FROM
I−, m-(CH3)3—N+—CH2CH2—
CHOSEN FROM



TABLE D
(OCH2CH2)2—O-Ph-
TABLE D


F112
CHOSEN FROM
I−, p-(N,N-
CHOSEN FROM



TABLE D
dimethylpiperazine)-(N′)-
TABLE D




CH2—(OCH2CH2)2—O-Ph-



F113
CHOSEN FROM
I−, m-(N,N-
CHOSEN FROM



TABLE D
dimethylpiperazine)-(N′)-
TABLE D




CH2—(OCH2CH2)2—O-Ph-



F114
CHOSEN FROM
m-F-Ph-
CHOSEN FROM



TABLE D
p-CH3O—
TABLE D


F115
CHOSEN FROM
3,4,dioxy-methylene-Ph-
CHOSEN FROM



TABLE D

TABLE D


F116
CHOSEN FROM
m-F-Ph-
CHOSEN FROM



TABLE D
p-F-Ph-
TABLE D


F117
CHOSEN FROM
m-CH3O—
CHOSEN FROM



TABLE D
p-F-Ph-
TABLE D


F118
CHOSEN FROM
4-pyridine
CHOSEN FROM



TABLE D

TABLE D


F119
CHOSEN FROM
N-methyl-4-pyridinium
CHOSEN FROM



TABLE D

TABLE D


F120
CHOSEN FROM
3-pyridine
CHOSEN FROM



TABLE D

TABLE D


F121
CHOSEN FROM
N-methyl-3-pyridinium
CHOSEN FROM



TABLE D

TABLE D


F122
CHOSEN FROM
2-pyridine
CHOSEN FROM



TABLE D

TABLE D


F123
CHOSEN FROM
p-CH3O2C-Ph-
CHOSEN FROM



TABLE D

TABLE D





Similar families can be generated where R1 <> R2, such as R1 Et and R2 = n-Bu, but (Rx)q is chosen from table C1.

## Claims

1. A pharmaceutical composition comprising:
a first amount of an ileal bile acid transport (IBAT) inhibitor of formula (I), a second amount of an HMG Co-A reductase inhibitor, and a pharmaceutically acceptable carrier, 
wherein said formula (I) is represented by: 




wherein: 
q is an integer from 1 to 4; 
n is an integer from 0 to 2; 
R1 and R2 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, haloalkyl, alkylaryl, arylalkyl, alkoxy, alkoxyalkyl, dialkylamino, alkylthio, (polyalkyl)aryl, and cycloalkyl, 
wherein alkyl, alkenyl, alkynyl, haloalkyl, alkylaryl, arylalkyl, alkoxy, alkoxyalkyl, dialkylamino, alkylthio, (polyalkyl)aryl, and cycloalkyl optionally are substituted with one or more substituents selected from the group consisting of OR9, NR9R10, N−R9R10RWA−, SR9, S+R9R10A−, P+R9R10R11A−, S(O)R9, SO2R9, SO3R9, CO2R9, CN, halogen, oxo, and CONR9R10, 
wherein alkyl, alkenyl, alkynyl, alkylaryl, alkoxy, alkoxyalkyl, (polyalkyl)aryl, and cycloalkyl optionally have one or more carbons replaced by O, NR9, N+R9R10A−, S, SO, SO2, S+R9A−, P+R9R10A−, or phenylene, 
wherein R9, R10, and RW are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, acyl, heterocycle, heteroaryl, ammoniumalkyl, arylalkyl, and alkylammoniumalkyl; or 
R1 and R2 taken together with the carbon to which they are attached form C3-C10 cycloalkylidene; 
R3 and R4 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, acyloxy, aryl, heterocycle, heteroaryl, OR9, NR9R10, SR9, S(O)R9, SO2R9, and SO3R9, wherein R9 and R10 are as defined above; or 
R3 and R4 together form ═O, ═NOR11, ═S, ═NNR11R12, ═NR9, or CR11R12, wherein R11 and R12 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, arylalkyl, alkenylalkyl, alkynylalkyl, heterocycle, heteroaryl, carboxyalkyl, carboalkoxyalkyl, cycloalkyl, cyanoalkyl, OR9, NR9R10, SR9, S(O)R9, SO2R9, SO3R9, CO2R9, CN, halogen, oxo, and CONR9R10, wherein R9 and R10 are as defined above, provided that both R3 and R4 cannot be OH, NH2, or SH, or 
R11 and R12 together with the nitrogen or carbon atom to which they are attached form a cyclic ring; 
R5 and R6 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, beterocycle, heteroaryl, quatemary heterocycle, quarternary heteroaryl, SR9, S(O)R9, SO2R9, and SO3R9, 
wherein alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycle, heteroaryl, quaternary heterocycle, and quaternary heteroaryl can be substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, polyalkyl, poiyether, aryl, haloalkyl, cycloalkyl, heterocycle, heteroaryl, arylalkyl, quaternary heterocycle, quaternary heteroaryl, halogen, oxo, OR13, NR13R14, SR3, S(O)R13, SO2R13, SO3R13, NR13OR14, NR13NR14R15, NO2, CO2R13, CN, OM, SO2OM, SO2NR13R14, C(O)NR13R14, C(O)OM, COR13, P(O)R13R14, P+R13R14R15A−, P(OR13)OR14, S+R13R14A−, and N+R9R10R11A−, 

wherein: 
A− is a pharmaceutically acceptable anion and M is a pharmaceutically acceptable cation, said alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle, and heteroaryl can be further substituted with one or more substituents selected from the group consisting of OR7, NR7R8, SR7, S(O)R7, SO2R7, SO3R7, CO2R7, CN, oxo, CONR7R8, N+R7R8RA−, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycle, heteroaryl, arylalkyl, quaternary heterocycle, quatemary heteroaryl, P(O)R7R8, P+R7R89A−, and P(O)(OR7)OR8 and 
wherein said alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle, and hetercaryl, can optionally have one or more carbons replaced by O, NR7, N+R7R8A−, S, SO, SO2, S+R7A−, PR7, P(O)R7, P+R7R8A, or phenylene, and R13, R14, and R15 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, polvalkyl, aryl, arylalkyl, cycloalkyl, heterocycle, heteroaryl, quatemary heterocycle, quatemary heteroaryl, and quaternary heteroarylalkyl, 
wherein alkyl, alkenyl, alkynyl, arylalkyl, heterocycle, heteroaryl, and polyalkyl optionally have one or more carbons replaced by O, NR9, N+R9R10A−, S, SO, SO2, S+R9A−, PR9, P+R9R10A−, P(O)R9, phenylene, carbohydrate, amino acid, peptide, or polypeptide, and 
R13, R14, and R15 are optionally substituted with one or more groups selected from the group consisting of sulfoalkyl, heterocycle, heteroaryl, quatemary heterocycle, quaternary heteroaryl, OR9, NR9R10, N+R9R11R12A−, SR9, S(O)R9, SO2R9, SO3R9, oxo, CO2R9, CN, halogen, CONR9R10, SO2OM, SO2NR9R10, PO(OR16)OR17, P+R9R10R11A−, S+R9R10A−, and C(O)OM, 
wherein R16 and R17 are independently selected from the substituents constituting R9 and M; or 
R14 and R15, together with the nitrogen atom to which they are attached, form a cyclic ring; 
R7 and R8 are independently selected from the group consisting of hydrogen and alkyl; and 
one or more Rx are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, polyalkyl, acyloxy, aryl, arylalkyl, halogen, haloalkyl, cycloalkyl, heterocycle, heteroaryl, polyether, quaternary heterocycle, quatemary heteroaryl, OR13, NR13R14, SR13, S(O)R13, S(Q)2R13, SO3R13, S+R13R14A−, NR13OR14, NR13NR14R15, NO2, CO2R13, CN, OM, SO2OM, SO2NR13R14, NR14C(O)R13, C(O)NR13R14, NR14C(O)R13, C(O)OM, COR13, OR18, S(O)nNR18, NR13R18, NR18OR14, N+R9R11R12A−, P+R9R11R12A−, amino acid, peptide, polypeptide, and carbohydrate, 
wherein alkyl, alkenyl, alkynyl, cycloalkyl, aryl, polyalkyl, heterocycle, heteroaryl, acyloxy, arylalkyl, haloalkyl, polyether, quaternary heterocycle, and quaternary heteroaryl can be further substituted with OR9, NR9R10, n+R9R11R12A−, SR9, S(O)R9, SO2R9, SO3R9, oxo, CO2R9, CN, halogen, CONR9R10, SO2OM, SO2NR9R10, PO(OR16)OR17, P+R9R11R12A−, S+R9R10A−, or C(O)M, and 
wherein R18 is selected from the group consisting of acyl, arylalkoxycarbonyl, arylalkyl, beterocycle, heteroaryl, alkyl, quaternary heterocycle, and quatemary heteroaryl, wherein acyl, arylalkoxycarbonyl, arylalkyl, heterocycle, heteroaryl, alkyl, quaternary heterocycle, and quaternary heteroaryl optionally are substituted with one or more substituents selected from the group consisting of OR9, NR9R10, N+R9R11R12A−, SR9, S(O)R9, SO2R9, SO3R9, oxo, CO2R9, CN, halogen, CONR9R10, SO3R9, SO2OM, SO2NR9R10, PO(OR16)C)R17, and C(O)OM, 
wherein in Rx, one or more carbons are optionally replaced by O, NR13, N+R13R14A−, S, SO, SO2, S+R13A−, PR13, P(O)R13, P+R13R14A−, phenylene, amino acid, peptide, polypeptide, carbohydrate, polyether, or polyalkyl, 
wherein in said polyalkyl, phenylene, amino acid, peptide, polypeptide, and carbohydrate, one or more carbons are optionally replaced by O, NR9, N+R9R10A−, S, SO, SO2, S+R9A−, PR9, P+R9R10A−, or P(O)R9; 
wherein quaternary heterocycle and quatemary heteroaryl are optionally substituted with one or more groups selected from the group consisting of alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle, heteroaryl, arylalkyl, halogen, oxo, OR13, NR13R14, SR13, S(O)R13, SO2R13, SO3R13, NR13OR14, NR13NR14R15, NO2, CO2R13, CN, OM, SO2OM, SO2NR13R14, C(O)NR13R14, C(O)OM, COR13, P(O)R13R14, P+R13R14R15A−, P(OR13)OR14, S+R13R14A−, and N+R9R11R12A−, 
provided that both R5 and R6 cannot be hydrogen, OH, or SH, and R5 is OH, R1, R2, R3, R4, R7, and R8 cannot all be hydrogen; 
provided that when R5 or R6 is phenyl, only one of R1 or R2 is H; 
provided that when q1 and Rx is styryl anilido or anilinocarbonyl, only one of R5 or R6 is alkyl; or 

a pharmaceutically acceptable salt, solvate, or prodrug thereof, 
wherein said first amount is provided in a dosage range from about 0,3 mg/kg bodyweight/day to about 100 mg/kg bodyweight/day and 
wherein said first and second amounts of said inhibitors together comprise an anti-hyperlipidemic condition effective amount.

2. The pharmaceutical composition of claim 1 wherein said dosage range is from about 1 mg/kg bodyweight/day to about 50 mg/kg bodyweight/day.

3. The pharmaceutical composition of claim 2 wherein said dosage range is from about 3 mg/kg bodyweight/day to about 10 mg/kg bodyweightlday.

4. The pharmaceutical composition of claim 1 wherein said dosage range is subdivided into from about 2 to about 6 subdoses/day.

5. The pharmaceutical composition of claim 1 wherein said HMG Co-A reductase inhibitor is selected from the group consisting of pitavastatin, rosuvastatin, mevastatin, and cenvastatin.

6. The pharmaceutical composition of claim 1, wherein R5 and R6 are independently selected from the group consisting of H, aryl, heterocycle, heteroaryl, quaternary heterocycle, and quaternary heteroaryl,
wherein said aryl, heterocycle, heteroaryl, quatemary heterocycle, and quaternary heteroaryl can be substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle, heteroaryl, arylalkyl, halogen, oxo, OR13, NR13R14, SR13, S(O)R13, SO2R13, SO3R13, NR13OR14, NR13NR14NR15, NO2, CO2R13, CN, OM, SO2OM, SO2NR13R14, C(O)NR13R14, C(O)OM, COR3, P(O)R13R14, P+R13R14R15A−, P(OR13)OR14, S+R13R14A−, and N+R9R11R12A−, 
wherein said alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle and heteroaryl can optionally have one or more carbons replaced by O, NP7, N+R7R8A−, S, SO2, S−R7A−, PR7, P(O)R7, P+R7R8A−, or phenylene, 
wherein said alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle and heteroarycan be further substituted with one or more substituents independently selected from the group consisting of OR7, NR7R8, SR7, S(O)R7, SO2R7, CO2R7, CN, oxo, CONR7R8, N+R7R8R9A−, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycle, beteroaryl, arylalkyl, quaternary heterocycle, quatemary heteroaryl, P(O)R7R8, P+R7R8R9A− and P(O)(OR7)OR8.

7. The pharmaceutical composition of claim 6, wherein R5 or R6 has the formula:


—Ar—(Ry)t 

wherein: 
t is an integer from 0 to 5, 
Ar is selected from the group consisting of phenyl, thiophenyl, pyridyl, piperazinyl, piperonyl, pyrolyl, naphthyl, furanyl, anthracenyl, quinolinyl, isoquinolinyl, quinoxalinyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, pyrimidinyl, thiazolyl, triazolyl, isothiazolyl, indolyl, benzoimidazolyl, benzoxazolyl, benzothiazolyl, and benzoisothiazolyl; and 
one or more Ry are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycle, heteroaryl, quaternary heterocycle, quatemary heteroaryl, OR9, SR9, S(O)R9, SO2R9 and SO3R9, 
wherein said alky, alkenyl, alkynyl, aryl, cycloalkyl, heterocycle, and heteroaryl can be substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle, heteroaryl, arylalkyl, halogen, oxo, OR13, NR13R14, SR13, S(O)R13, SO2R13, SO3R13, NR13OR14, NR13NR14R15, NO2, CO2R13, CN, OM, SO2OM, SO2NR13R14, C(O)NR13R14, C(O)OM, COR13, P(O)R13R14, P+R13R14R15A−, P(OR13)OR14, S+R13R14A−, and N+R9R R A−, wherein said alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle and heteroaryl can be further substituted with one or more substituents independently selected from the group consisting of OR7, NR7R8, SR7, S(O)R7, SO2R7, SO3R7, CO2R7, CN, oxo, CONR7R8, N+R7R8R9A−, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycle, heteroaryl, arylalkyl, quaternary heterocycle, quaternary heteroaryl, P(O)R7R8, P+R7R8R9A−, and P(O)(OR7)OR8; and 
wherein said alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle and heteroaryl can optionally have one or more carbons replaced by O, NR7, N+R7R8A−, S, SO, SO2, S−R7A−, PR7, P(O)R7, P+R7R8A−, or phenylene.

8. The pharmaceutical composition of claim 7 wherein R5 or R6 has the formula (II):

9. A combination therapy method for the treatment or prophylaxis of a hyperlipidemic condition in a patient in need thereof, said method comprising administering to said patient a pharmaceutical composition comprising a first amount of an ileal bile acid transport (IBAT) inhibitor of formula (I), a second amount of an HMG Co-A reductase inhibitor, and a pharmaceutically acceptable carrier,
wherein said formula (I) is represented by: 




wherein: 
q is an integer from 1 to 4; 
n is an integer from 0 to 2; 
R1 and R2 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, haloalkyl, alkylaryl, arylalkyl, alkoxy, alkoxyalkyl, dialkylamino, alkylthio, (polyalkyl)aryl, and cyc:loalkyl, 
wherein alkyl, alkenyl, alkynyl, haloalkyl, alkylaryl, arylalkyl, alkoxy, alkoxyalkyl, dialkylamino, alkyithici, (polyalkyl)aryl, and cycloalkyl optionally are substituted with one or more substituents selected from the group consisting of OR9, NR9R10, N+R9R10RwA−, SR9, S−R9R10A−, P+R9R10R11A−, S(O)R9, SO2R9, SO3R9, CO2R9, CN, halogen, oxo, and CONR9R10, 
wherein alkyl, alkenyl, alkynyl, alkylaryl, alkoxy, alkoxyalkyl, (polyalkyl)aryl, and cycloalkyl optionally have one or more carbons replaced by O, NR9, N+R9R10A−, S, SO, SO2, S+R9A−, P+R9R10A−, or phenylene, 
wherein R9, R10, and Rw are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, acyl, heterocycle, heteroaryl, ammoniumalkyl, arylalkyl, and alkylammoniumalkyl; or 
R1 and R2 taken together with the carbon to which they are attached form G3-C10 cycloalkylidene; 
R3 and R4 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, acyloxy, aryl, heterocycle, heteroaryl, OR9, NR9R10, SR9, S(O)R9, SO2R9, and SO3R9, wherein R9 and R10 are as defined above; or 
R3 and R4 together form ═O, ═NOR11, ═S, ═NNR11R12, ═NR9, or ═CR11R12, wherein R11 and R12 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, arylalkyl, alkenylalkyl, alkynylalkyl, heterocycle, heteroaryl, carboxyalkyl, carboalkoxyalkyl, cycloalkyl, cyanoalkyl, OR9, NR9R10, SR9, S(O)R9, SO2R9, SO3R9, CO2R9, CN, halogen, oxo, and CONR9R10, wherein R9 and R10 are as defined above, provided that both R3 and R4 cannot be OH, NH2, or SH, or 
R11 and R12 together with the nitrogen or carbon atom to which they are attached form a cyclic ring; 
R5 and R6 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycle, heteroaryl, quaternary heterocycle, quarternary heteroaryl, SR9, S(O)R9, SO2R9, and SO3R9, 
wherein alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycle, heteroaryl, quatemary heterocycle, and quatemary heteroaryl can be substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle, heteroaryl, arylalkyl, quaternary heterocycle, quaternary heteroaryl, halogen, oxo, OR13, NR13R14, SR13, S(O)R13, SO2R13, SO3R13, NR13OR14, NR13NR14R15, NO2, CO2R13, CN, OM, SO2OM, SO2NR13R14, C(O)NR13R14, C(O)OM, COR13, P(O)R13R14, P+R13R14R15A−, P(OR13)OR14, S+R13R14A−, and N+R9R11R12A−, 

wherein: 
A− is a pharmaceutically acceptable anion and M is a pharmaceutically acceptable cation, 
said alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle, and heteroaryl can be fiarther substituted with one or more substiruents selected from the group consisting of OR7, NR7R8, SR7, S(O)R7, SO2R7, SO3R7, CO2R7, CN, oxo, CONR7R8, N+R7R8R9A−, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycle, heteroaryl, arylalkyl, quaternary heterocycle, quaternary heteroaryl, P(O)R7R8, P+R7R8R9A−, and P(O)(OR7)OR8 and 
wherein said alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle, and heteroaryl, can optionally have one or more carbons replaced by O, NR7, N+R7R8A−, S, SO, SO2, S+R7A−, PR7, P(O)R7, P+R7R8A−, or phenylene, and R13, R14, and R15 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, polyalkyl, aryl, arylalkyl, cycloalkyl, heterocycle, heteroaryl, quatemary heterocycle, quaternary hereroaryl, and quaternary heteroarylalkyl, 
wherein alkyl, alkenyl, alkynyl, arylalkyl, heterocycle, heteroaryl, and polyalkyl optionally have one or more carbons replaced by O, NR9, N+R9R10A−, S, SO, SO2, S+R9A−, PR9, P+R9R10A−, P(O)R9, phenylene, carbohydrate, amino acid, peptide, or polypeptide, and 
R13, R14 and R15 are optionally substituted with one or more groups selected from the group consisting of sulfoalkyl, heterocycle, heteroaryl, quatemary heterocycle, quaternary heteroaryl, OR9, NR9R10, N+R9R11R12A−, SR9, S(O)R9, SO2R9, SO3R9, oxo, CO2R9, CN, halogen, CONR9R10, SO2OM, SO2NR9R10, PO(OR16)OR17, P+R9R10R11A−, S+R9R10A−, and C(O)OM, 
wherein R16 and R17 are independently selected from the substituents constituting R9 and M; or 
R14 and R15, together with the nitrogen atom to which they are attached, form a cyclic ring; 
R7 and R8 are independently selected from the group consisting of hydrogen and alkyl; and 
one or more Rx are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, polyalkyl, acyloxy, aryl, arylalkyl, halogen, haloalkyl, cycloalkyl, heterocycle, heteroaryl, polyether, quatemary heterocycle, quaternary heteroaryl, OR13, NR13R14, SR13, S(O)R13, S(O)2R13, SO3R13, S+R13R14A−, NR13OR14, NR13NR14R15, NO2, CO2R13, CN, OM, SO2OM, SO2NR13R14, NR14C(O)R13, C(O)NR13R14, NR14C(O)R13, C(O)OM, COR13, OR18, S(O)nNR18, NR13R18, NR18OR14, N+R9R10R12A−, P+R9R11R12A−, amino acid, peptide, polypeptide, and carbohydrate, 
wherein alkyl, alkenyl, alkynyl, cycloalkyl, aryl, polyalkyl, heterocycle, heteroaryl, acyloxy, arylalkyl, haloalkyl, polyether, quatemary heterocycle, and quaternary heteroaryl can be further substituted with OR9, NR9R10, N+R9R11R12A−, SR9, S(O)R9, SO2R9, SO3R9, oxo, CO2R9, CN, halogen, CONR9R10, SO2OM, SO2NR9R10, PO(OR16)OR17, P+R9R11R12A−, S+R9R10A−, or C(O)M, and 
wherein R18 is selected from the group consisting of acyl, arylalkoxycarbonyl, arylalkyl, heterocycle, heteroaryl, alkyl, quatemary heterocycle, and quaternary heteroaryl, wherein acyl, arylalkoxycarbonyl, arylalkyl, heterocycle, heteroaryl, alkyl, quaternary heterocycle, and quatemary heteroaryl optionally are substituted with one or more substituents selected from the group consisting of OR9, NR9R10, N+R9R11R12A−, SR9, S(O)R9, SO2R9, SO3R9, oxo, CO2R9, CN, halogen, CONR9R10, SO3R9, SO2OM, SO2NR9R10, PO(OR16)OR17 and C(O)OM, 
wherein in Rx, one or more carbons are optionally replaced by O, NR13, N+R13R14A−, S, SO, SO2, S+R13A−, PR13, P(O)R13, P+R13R14A−, phenylene, amino acid, peptide, polypeptide, carbohydrate, polyether, or polyalkyl, 
wherein in said polyalkyl, phenylene, amino acid, peptide, polypeptide, and carbohydrate, one or more carbons are optionally replaced by O, NR9, N+R9R10A−, S, SO, SO2, S+R9A−, PR9, P+R9R10A−, or P(O)R9; 
wherein quatemary heterocycle and quatemary heteroaryl are optionally substituted with one or more groups selected from the group consisting of alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle, heteroaryl, arylalkyl, halogen, oxo, OR13, NR13R14, SR13, S(O)R13, SO2R13, SO3R13, NR13OR14, NR13NR14R15, NO2, CO2R13, CN, OM, SO2OM, SO2NR13R14, C(O)NR13R14, C(O)OM, COR13, P(O)R13R14, P+R13R14R15A−, P(OR13)OR14, S+R13R14A−, and N+R9R11R12A−, 
provided that both R5 and R6 cannot be hydrogen, OH, or SH, and R5 is OH, R1, R2, R3, R4, R7, and R8 cannot all be hydrogen; 
provided that when R5 or R6 is phenyl, only one of R1 or R2 is H; 
provided that when q=1 and Rx is styryl, anilido, or anilinocarbonyl, only one of R5 or R6 is alkyl; or 

a pharmaceutically acceptable salt, solvate, or prodrug thereof, 
wherein said first amount is provided in a dosage range from about 0.3 mg/kg bodyweight/day to about 100 mg/kg bodyweightlday and 
wherein said first and second amounts of said inhibitors together comprise an anti-hyperlipidemic condition effective amount.

10. The method of claim 9 wherein said dosage range is from about 1 mg/kg bodyweightlday to about 50 mg/kg bodyweight/day.

11. The method of claim 10 wherein said dosage range is from about 3 mg/kg bodyweightlday to about 10 mg/kg bodyweight/day.

12. The method of claim 9 wherein said dosage range is subdivided into from about 2 to about 6 subdoses/day.

13. The composition of claim 9 wherein said HMG Co-A reductase inhibitor is selected from the group consisting of pitavastatin, rosuvastatin, mevastatin, and cerivastatin.

14. An oral pharmaceutical composition comprising:
a first amount of an ileal bile acid transport (IBAT) inhibitor of formula (I), a second amount of 
an HMG Co-A reductase inhibitor, and a pharmaceutically acceptable carrier, 
wherein said formula (I) is represented by: 




wherein: 
q is an integer trom 1 to 4; 
n is an integer from 0 to 2; 
R1 and R2 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, haloalkyl, alkylaryl, arylalkyl, alkoxy, alkoxyalkyl, dialkylamino, alkylthio, (polyalkyl)aryl, and cycloalkyl, 
wherein alkyl, alkenyl, alkynyl, haloalkyl, alkylaryl, arylalkyl, alkoxy, alkoxyalkyl, dialkylamino, alkyithia, (polyalkyl)aryl, and cycloalkyl optionally are substituted with one or more substiflients selected from the group consisting of OR9, NR9R10, N+R9R10RwA−, SR9, S+R9R10A−, P+R9R10R11A−, S(O)R9, SO2R9, SO3R9, CO2R9, CN, halogen, oxo, and CONR9R10, 
wherein alkyl, alkenyl, aikynyl, alkylaryl, alkoxy, alkoxyalkyl, (polyalkyl)aryl, and cycloalkyl optionally have one or more carbons replaced by O, NR9, N+R9R10A−, S, SO, SO2, S+R9A−, P+R9R10A−, or phenylene, 
wherein R9, R10, and Rw are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, acyl, heterocycle, heteroaryl, ammoniumalkyl, arylalkyl, and alkylammoniumalkyl; or 
R1 and R2 taken together with the carbon to which they are attached form C3-C10 cycloalkylidene; 
R3 and R4 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, acyloxy, aryl, heterocycle, heteroaryl, OR9, NR9R10, SR9, S(O)R9, SO2R9, and SO3R9, wherein R9 and R10 are as defined above; or 
R3 and R4 together fomi ═O, ═NOR11, ═S, ═NNR11R12, ═NR9, or ═CR11R12, wherein R11 and R12 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, arylalkyl, alkenylalkyl, alkynylalkyl, heterocycle, heteroaryl, carboxyalkyl, carboalkoxyalkyl, cycloalkyl, cyanoalkyl, OR9, NR9R10, SR9, S(O)R9, SO2R9, SO3R9, CO2R9, CN, halogen, oxo, and CONR9R10, wherein R9 and R10 are as defined above, provided that both R3 and R4 cannot be OH, NH2, or SH, or 
R11 and R12 together with the nitrogen or carbon atom to which they are attached form a cyclic ring; 
R5 and R6 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycle, heteroaryl, quatemary heterocycle, quartemary heteroaryl, SR9, S(O)R9, SO2R9, and SO3R9, wherein alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycle, heteroaryl, quatemary heterocycle, and quatemary heteroaryl can be substituted with one or more substituent independently selected from the group consisting of alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle, heteroaryl, arylalkyl, quaternary heterocycle, quatemary heteroaryl, halogen, oxo, OR13, NR13R14, SR13, S(O)R13, SO2R13, SO3R13, NR13OR14, NR13NR14R15, NO2, CO2R13, CN, OM, SO2OM, SO2NR13R14, C(O)NR13R14, C(O)OM, COR13, P(O)R13R14, P+R13R14R15A−, P(OR13)OR14, S+R13R14A−, and N+R9R11R12A−, 

wherein: 
A− is a pharmaceutically acceptable anion and M is a pharmaceutically acceptable cation, said alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle, and heteroaryl can be further substituted with one or more substituents selected from the group consisting of OR7, NR7R, SR7, S(O)R7, SO2R7, SO3R7, CO2R7, CN, oxo, CONR7R8, N+R7R8R9A−, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycle, heteroaryl, arylalkyl, quaternary heterocycle, quaternary heteroaryl, P(O)R7R8, P+R7R8R9A−, and P(O)(OR7)OR8 and 
wherein said alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle, and heteroaryl, can optionally have one or more carbons replaced by O, NR7, N+R7R8A−, S, SO, SO2, S+R7A−, PR7, P(O)R7, P+R7R8A−, or phenylene, and R13, R14, and R15 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, polyalkyl, aryl, arylalkyl, cycloalkyl, heterocycle, heteroaryl, quaternary heterocycle, quaternary heteroaryl, and quatemary heteroarylalkyl, 
wherein alkyl, alkenyl, alkynyl, arylalkyl, heterocycle, heteroaryl, and polyalkyl optionally have one or more carbons replaced by O, NR9, N+R9R10A−, S, SO, SO2, S+R9A−, PR9, P+R9R10A−, P(O)R9, phenylene, carbohydrate, amino acid, peptide, or polypeptide, and 
R13, R14, and R15 are optionally substituted with one or more groups selected from the group consisting of sulfoalkyl, heterocycle, heteroaryl, quaternary heterocycle, quatemary heteroaryl, OR9, NR9R10, N+R9R11R12A−, SR9, S(O)R9, SO2R9, SO3R9, oxo, CO2R9, CN, halogen, CONR9R10, SO2OM, SO2NR9R10, PO(OR16)OR17, P+R9R10R11A−, S+R9R10A−, and C(O)OM, 
wherein R16 and R17 are independently selected from the substituents constituting R9 and M; or 
R14 and R15, together with the nitrogen atom to which they are attached, form a cyclic ring; 
R7 and R8 are independently selected from the group consisting of hydrogen and alkyl; and 
one or more Rx are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, polyalkyl, acyloxy, aryl, arylalkyl, halogen, haloalkyl, cycloalkyl, heterocycle, heteroaryl, poiyether, quatemary heterocycle, quaternary heteroaryl, OR13, NR13R14, SR13, S(O)R13, S(O)2R13, SO3R13, S+R13R14A−, NR130R14, NR13NR14R15, NO2, CO2R13, CN, OM, SO2OM, SO2NR13R14, NR14C(O)R13, C(O)NR13R14, NR14C14O)R13, C(O)OM, COR13, OR15, S(O)nNR18, NR13R18, NR18OR14, N+R9R11R12A−, P+R9R11R12A−, amino acid, peptide, polypeptide, and carbohydrate, 
wherein alkyl, alkenyl, alkynyl, cycloalkyl, aryl, polyalkyl, heterocycle, heteroaryl, acyloxy, arylalkyl, haloalkyl, polyether, quaternary heterocycle, and quaternary heteroaryl can be further substituted with OR9, NR9R10, N+R9R11R12A−, SR9, S(O)R9, SO2R9, SO3R9, oxo, CO2R9, CN, halogen, CONR9R10, SO2OM, SO2NR9R10, PO(OR16)OR17, P+R9R11R12A−, S+R9R10A−, or C(O)M, and 
wherein R18 is selected from the group consisting of acyl, arylalkoxycarbonyl, arylalkyl, heterocycle, heteroaryl, alkyl, quaternary heterocycle, and quaternary heteroaryl, wherein acyl, arylalkoxycarbonyl, arylalkyl, heterocycle, heteroaryl, alkyl, quatemary heterocycle, and quaternary heteroaryl optionally are substituted with one or more substituents selected from the group consisting of OR9, NR9R10, N+R9R11R12A−, SR9, S(O)R9, SO2R9, SO3R9, oxo, CO2R9, CN, halogen, CONR9R10, SO3R9, SO2OM, SO2NR9R10, PO(OR16)OR17, and C(O)OM, 
wherein in Rx, one or more carbons are optionally replaced by O, NR13, N+R13R14A−, S, SO, SO2, S+R13A−, PR13, P(O)R13, P+R13R14A−, phenylene, amino acid, peptide, polypeptide, carbohydrate, polyether, or polyalkyl, 
wherein in said polyalkyl, phenylene, amino acid, peptide, polypeptide, and carbohydrate, one or more carbons are optionally replaced by O, NR9, N+R9R10A−, S, SO, SO2, S+R9A−, PR9, P+R9R10N, or P(O)R9; 
wherein quatemary heterocycle and quaternary heteroaryl are optionally substituted with one or more groups selected from the group consisting of alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle, heteroaryl, arylalkyl, halogen, oxo, OR13, NR13R14, SR13, S(O)R13, SO2R13, SO3R13, NR13OR14, NR13NR14R15, NO2, CO2R13, CN, OM, SO2OM, SO2NR13R14, C(O)NR13R14, C(O)OM, COR13, P(O)R13R14, P+R13R14R15A−, P(OR13)OR14, S+R13R14A−, and N+R9R11R12A−, 
provided that both R5 and R6 cannot be hydrogen, OH, or SH, and R5 is OH, R1, R2, R3, R4, R7, and R8 cannot all be hydrogen; 
provided that when R5 or R6 is phenyl, only one of R1 or R2 is H; 
provided that when q=1 and Rx is styryl, anilido, or anilinocarbonyl, only one of R5 or R6 is alkyl; or 

a pharmaceutically acceptable salt, solvate, or prodrug thereof, 
wherein said first and second amounts of said inhibitors together comprise an anti-hyperlipidemic condition effective amount, and 
wherein said oral pharmaceutical composition is suitable for delivery of said anti-hyperlipidemic effective amount to the gastrointestinal tract of a patient by oral administration.

15. The oral pharmaceutical composition of claim 14 wherein said oral pharmaceutical composition is suitable for delivery of said anti-hyperlipidemic effective amount to the small intestine of said patient.

16. The oral pharmaceutical composition of claim 15 wherein said oral pharmaceutical composition is suitable for delivery of said anti-hyperlipidemic effective amount to the ileum of said patient.

17. The oral pharmaceutical composition of claim 14 wherein said oral pharmaceutical composition is in a solid dosage form.

18. The oral pharmaceutical composition of claim 17 wherein said solid dosage form is a slow erosion tablet or capsule.

19. The oral pharmaceutical composition of claim 19 wherein said solid dosage form is a controlled release formulation having an enteric coating.

20. The oral pharmaceutical composition of claim 19 wherein said enteric coating is selected from the group consisting of cellulose acetate phthalate, polyvinylacetate phthalate, hydroxypropylmethylcellulose pbthalate, and an anionic polymer of methacrylic acid and methacrylic acid methyl ester.

21. The oral pharmaceutical composition of claim 14 wherein said oral pharmaceutical composition provides prolonged or sustained release of said anti-hyperlipidemic amount.

22. The oral pharmaceutical composition of claim 21 wherein said oral pharmaceutical composition is a pH sensitive release formulation.

23. The oral pharmaceutical composition of claim 21 wherein said oral pharmaceutical composition is a bioadhesive formulation.

24. The oral pharmaceutical composition of claim 21 wherein said anti-hyperlipidemic effective amount is released by enzymatic action.

25. The oral pharmaceutical composition of claim 14 wherein said HMG Co-A reductase inhibitor is selected from the group consisting of pitavastatin, rosuvastatin, mevastatin, and cerivastatin.

26. The oral pharmaceutical composition of claim 14, wherein R5 and R6 are independently selected from the group consisting of H, aryl, heterocycle, heteroaryl, quaternary heterocycle, and quatemary heteroaryl,
wherein said aryl, heterocycle, heteroaryl, quatemary heterocycle, and quatemary heteroaryl can be substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle, heteroaryl, arylalkyl, halogen, oxo, OR13, NR13R14, SR13, S(O)R13, SO2R13, SO3R13, NR130R14, NR13NR14NR15, NO2, CO2R13, CN, OM, SO2OM, SO2NR13R14, C(O)NR13R14, C(O)OM, CO,R13, P(O)R13R14, P+R13R14R15A−, P(OR13)OR14, S+R13R14A−, and N+R9R11R12A−, 
wherein said alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle and heteroaryl can optionally have one or more carbons replaced by O, NR7, N+R7R8A−, S, SO, SO2, SR7A−, PR7, P(O)R7, P+R7R8A−, or phenylene, 
wherein said alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle and heteroaryl can be further substituted with one or more substituents independently selected from the group consisting of OR7, NR7R8, SR7, S(O)R7, SO2R7, CO2R7, CN, oxo, CONR7R8, N+R7R8R9A−, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycle, heteroaryl, arylalkyl, quaternary heterocycle, quatemary heteroaryl, P(O)R7R8, P+R7R8R9A− and P(O)(OR7)OR8.

27. The oral pharmaceutical composition of claim 26, wherein R5 or R6 has the formula:


—Ar—(Ry)t 


wherein:
t is an integer from 0 to 5, 
Ar is selected from the group consisting of phenyl, thiophenyl, pyridyl, piperazinyl, piperonyl, pyrolyl, naphthyl, furanyl, anthracenyl, quinolinyl, isoquinolinyl, quinoxalinyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, pyrimidinyl, thiazolyl, triazolyl, isothiazolyl, indolyl, benzoimidazolyl, benzoxazolyl, benzothiazolyl, and benzoisothiazolyl; and 
one or more Ry are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycle, heteroaryl, quaternary heterocycle, quaternary heteroaryl, OR9, SR9, S(O)R9, SO2R9 and SO3R9, 
wherein said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycle, and heteroaryl can be substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle, heteroaryl, arylalkyl, halogen, oxo, OR13, NR13R14, SR13, S(O)R13, SO2R13, SO3R13, NR130R14, NR13NR14R15, NO2, CO2R13, CN, OM, SO2OM, SO2NR13R14, C(O)NR13R14, C(O)OM, COR13, P(O)R13R14, P+R13R14R15A−, P(OR13)OR14, S+R13R14A−, and N+R19R11R12A−, wherein said alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle and heteroaryl can be further substituted with one or more substituents independently selected from the group consisting of OR7, NR7R8, SR7, S(O)R7, SO2R7, SO3R7, CO2R7, CN, oxo, CONR7R8, N+R7R8R9A−, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycle, heteroaryl, arylalkyl, quaternary heterocycle, quaternary heteroaryl, P(O)R7R8, P+R7R8R9A−, and P(O) (OR7)OR8; and 
wherein said alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, beterocycle and heteroaryl can optionally have one or more carbons replaced by O, NR7, N+R7R8A−, S, SO, SO2, SR7A−, PR7, P(O)R7, P+R7R8A−, or phenylene.

28. The oral pharmaceutical composition of claim 27, wherein R5 or R6 has the formula (II):

29. A combination therapy method for the treatment or prophylaxis of a hyperlipidemic condition in a patient in need thereof, said method comprising orally administering to said patient a pharmaceutical composition comprising a first amount of an ileal bile acid transport (IBAT) inhibitor of formula (I), a second amount of an HMG Co-A reductase inhibitor, and a pharmaceutically acceptable carrier,
wherein said formula (I) is represented by: 




wherein: 
q is an integer from 1 to 4; 
n is an integer from 0 to 2; 
R1 and R2 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, haloalkyl, alkylaryl, arylalkyl, alkoxy, alkoxyalkyl, dialkylamino, alkylthio, (polyalkyl)aryl, and cycloalkyl, 
wherein alkyl, alkenyl, alkynyl, haloalkyl, alkylaryl, arylalkyl, alkoxy, alkoxyalkyl, dialkylamino, alkylthio, (polyalkyl)aryl, and cycloalkyl optionally are substituted with one or more substituents selected from the group consisting of OR9, NR9R10, N+R9R10RwA−, SR9, S+R9R10A−, P+R9R10R11A−, S(O)R9, SO2R9, SO3R9, CO2R9, CN, halogen, oxo, and CONR9R10, 
wherein alkyl, alkenyl, alkynyl, alkylaryl, alkoxy, alkoxyalkyl, (polyalkyl)aryl, and cycloalkyl optionally have one or more carbons replaced by O, NR9, N+R9R10A−, S, SO, SO2, S+R9A−, P+R9R10A−, or phenylene, 
wherein R9, R10, and Rw are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, acyl, heterocycle, heteroaryl, ammoniumalkyl, arylalkyl, and alkylammoniumalkyl; or 
R1 and R2 taken together with the carbon to which they are attached form C3-C10 cycloalkylidene; 
R3 and R4 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, acyloxy, aryl, heterocycle, heteroaryl, OR9, NR9R10, SR9, S(O)R9, SO2R9, and SO3R9, wherein R9 and R10 are as defined above; or 
R3 and R4 together form ═O, ═NOR11, S, ═NNR11R12, ═NR9, or ═CR11R12, wherein R11 and R12 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, arylalkyl, alkenylalkyl, alkynylalkyl, heterocycle, heteroaryl, carboxyalkyl, carboalkoxyalkyl, cycloalkyl, cyanoalkyl, OR9, NR9R10 SR9, S(O)R9, SO2R9, SO3R9, CO2R9, CN, halogen, oxo, and CONR9R10, wherein R9 and R10 are as defined above, provided that both R3 and R4 cannot be OH, NH2, or SH, or 
R11 and R12 together with the nitrogen or carbon atom to which they are attached form a cyclic ring; 
R5 and R6 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycle, heteroaryl, quatemary heterocycle, quartemary heteroaryl, SR9, S(O)R9, SO2R9, and SO3R9, 
wherein alkyl, alkenyl, aikynyl, aryl, cycloalkyl, heterocycle, heteroaryl, quatemary heterocycle, and quaternary heteroaryl can be substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle, heteroaryl, arylalkyl, quaternary heterocycle, quatemary heteroaryl, halogen, oxo, OR13, NR13R14, SR13, S(O)R13, SO2R13, SO3R13, NR13OR14, NR13NR14R15, NO2, CO2R13, CN, OM, SO2OM, SO2NR13R14, C(O)NR13R14, C(O)OM, COR13, P(O)R13R14, P+R13R14R15A−, P(OR13)OR14 , S+R13R14A−, and N+R9R11R12A−, 

wherein: 
A− is a phannaceutically acceptable anion and M is a pharmaceutically acceptable cation, said alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle, and heteroaryl can be fi,irther substituted with one or more substituents selected from the group consisting of OR7, NR7R8, SR7, S(O)R7, SO2R7, SO3R7, CO2R7, CN, oxo, CONR7R8, N+R7R8R9A−, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycle, heteroaryl, arylalkyl, quatemary heterocycle, quaternary heteroaryl, P(O)R7R8, P+R7R8R9A−, and P(O)(OR7)OR8 and 
wherein said alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle, and heteroaryl, can optionally have one or more carbons replaced by O, NR7, N+R7R8A−, S, SO, SO2, S+R7A−, PR7, P(O)R7, P+R7R8A−, or phenylene, and R13, R14, and R15 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, polyalkyl, aryl, arylalkyl, cycloalkyl, heterocycle, heteroaryl, quatemary heterocycle, quaternary heteroaryl, and quatemary heteroarylalkyl, 
wherein alkyl, alkenyl, alkynyl, arylalkyl, heterocycle, heteroaryl, and polyalkyl optionally have one or more carbons replaced by O, NR9, N+R9R10A−, S, SO, SO2, S+R9A−, PR9, P+R9R10A−, P(O)R9, phenylene, carbohydrate, amino acid, peptide, or polypeptide, and 
R13, R14, and R15 are optionally substituted with one or more groups selected from the group consisting of sulfoalkyl, heterocycle, heteroaryl, quatemary heterocycle, quaternary heteroaryl, OR9, NR9R10, N+R9R11R12A−, SR9, S(O)R9, SO2R9, SO3R9, oxo, CO2R9, CN, halogen, CONR9R10, SO2OM, SO2NR9R10, PO(OR16)OR17, P+R9R10R11A−, S+R9R10A−, and C(O)OM, 
wherein R16 and R17 are independently selected from the substituents constituting R9 and M; or 
R14 and R15, together with the nitrogen atom to which they are attached, form a cyclic ring; 
R7 and R8 are independently selected from the group consisting of hydrogen and alkyl; and 
one or more Rx are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, polyalkyl, acyloxy, aryl, arylalkyl, halogen, haloalkyl, cycloalkyl, heterocycle, heteroaryl, polyether, quaternary heterocycle, quatemary heteroaryl, OR13, NR13R14, SR13, S(O)R13, S(O)2R13, SO3R13, S+R13R14A−, NR13OR14, NR13NR14R15, NO2, CO2R13, CN, OM, SO2OM, SO2NR13R14, NR14C(O)R13, C(O)NR13R14, NR14C(O)R13, C(O)OM, COR13, OR18, S(O)nNR18, NR13R18, NR18OR14, N+R9R11R12A−, P+R9R11R12A−, amino acid, peptide, polypeptide, and carbohydrate, 
wherein alkyl, alkenyl, aikynyl, cycloalkyl, aryl, polyalkyl, heterocycle, heteroaryl, acyloxy, arylalkyl, haloalkyl, polyether, quatemary heterocycle, and quatemary heteroaryl can be further substituted with OR9, NR9R10, N+R9R11R12A−, SR9, S(O)R9, SO2R9, SO3R9, oxo, CO2R9, CN, halogen, CONR9R10, SO2OM, SO2NR9R10, PO(OR16)OR17, P+R9R11R12A−, S+R9R10A−, or G(O)M, and 
wherein R18 is selected from the group consisting of acyl, arylalkoxycarbonyl, arylalkyl, heterocycle, heteroaryl, alkyl, quaternary heterocycle, and quatemary heteroaryl, wherein acyl, arylalkoxycarbonyl, arylalkyl, heterocycle, heteroaryl, alkyl, quaternary heterocycle, and quaternary heteroaryl optionally are substituted with one or more substituents selected from the group consisting of OR9, NR9R10, N+R9R11R12A−, SR9, S(O)R9, SO2R9, SO3R9, oxo, CO2R9, CN, halogen, CONR9R10, SO3R9, SO2OM, SO2NR9R10, PO(OR16)OR17, and C(O)OM, 
wherein in Rx, one or more carbons are optionally replaced by O, NR13, N+R13R14A−, S, SO, SO2, S+R13A−, PR13, P(O)R13, P+R13R14A−, phenylene, amino acid, peptide, polypeptide, carbohydrate, polyether, or polyalkyl, 
wherein in said polyalkyl, phenylene, amino acid, peptide, polypeptide, and carbohydrate, one or more carbons are optionally replaced by O, NR9, N+R9R10A−, S, SO, SO2, S+R9A−, PR9, P+R9R10A−, or P(O)R9; 
wherein quatemary heterocycle and quaternary heteroaryl are optionally substituted with one or more groups selected from the group consisting of alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle, heteroaryl, arylalkyl, halogen, oxo, OR13, NR13R14, SR13, S(O)R13, SO2R13, SO3R13, NR13OR14, NR13NR14R15, NO2, CO2R13, CN, OM, SO2OM, SO2NR13R14, C(O)NR13R14, C(O)OM, COR13, P(O)R13R14, P+R13R14R15A−, P(OR13)OR14, S+R13R14A−, and N+R9R11R12A−, 
provided that both R5 and R6 cannot be hydrogen, OH, or SH, and R5 is OH, R1, R2, R3, R4, R7, and R8 cannot all be hydrogen; 
provided that when R5 or R6 is phenyl, only one of R1 or R2 is H; 
provided that when q═1 and Rx is styryl anilido or anilinocarbonyl only one of R5 or R6 is alkyl; or 

a pharmaceutically acceptable salt, solvate, or prodrug thereof, 
wherein said first and second amounts of said inhibitors together comprise an anti-hyperlipidemic condition effective amount, and 
wherein said pharmaceutical composition is suitable for delivery of said anti-hyperlipidemic effective amount to the gastrointestinal tract of said patient by oral administration.

30. The method of claim 29 wherein said pharmaceutical composition is suitable for delivery of said anti-hyperlipidemic effective amount to the small intestine of said patient.

31. The method of claim 30 wherein said pharmaceutical composition is suitable for delivery of said anti-hyperlipidemic effective amount to the ileum of said patient.

32. The method of claim 29 wherein said pharmaceutical composition is in a solid dosage form.

33. The method of claim 32 wherein said solid dosage form is a slow erosion tablet or capsule.

34. The method of claim 32 wherein said solid dosage form is a controlled release formulation having an enteric coating.

35. The method of claim 34 wherein said enteric coating is selected from the group consisting of cellulose acetate phthalate, polyvinylacetate phthalate, hydroxypropylmethylcellulose phthalate, and an anionic polymer of methacrylic acid and methacrylic acid methyl ester.

36. The method of claim 29 wherein said pharmaceutical composition provides prolonged or sustained release of said anti-hyperlipidemic amount.

37. The method of claim 36 wherein said pharmaceutical composition is a pH sensitive release formulation.

38. The method of claim 36 wherein said pharmaceutical composition is a bioadhesive formulation.

39. The method of claim 36 wherein said anti-hyperlipidemic effective amount is released by enzymatic action.

40. The method claim 29 wherein said HMG Co-A reductase inhibitor is selected from the group consisting of pitavastatin, rosuvastatin, mevastatin, and cerivastatin.